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Abbreviation 
AIRE  Auto-Immune Regulator  
AP-1  Activator Protein-1  
AP-3  Adaptor Protein 3  
APC  Antigen presenting cell 
aPKC  atypical PKC 
Arp 2/3  Actin-related protein-2/3  
Bcl-2 B cell leukemia/lymphoma 2 
B-EBV  Epstein Barr transformed B lymphocyte 
CAR Chimeric Antigen Receptors 
CatB Cathepsin B 
CCE  Capacitative calcium entry 
CD  Cluster of differentiation  
CDR  Complementary determining region  
CHS  Chediak-Higashi syndrome  
CMA Concanamycin A 
cPKC  Conventional or Classical PKC 
CR Complete Response 
CRAC  Calcium Release Activated calcium chanel  
CRIB  Cdc-42/Rac interactive binding  
Csk  C terminal Src Kinase  
CTL  Cytotoxic T lymphocyte  
CTLA-4  Cytotoxic T lymphocyte associated protein-4  
DAG  1,2 Diacylglycerol  
DC  Dendritic cell  
DIA-1  Diaphanous-1  
DN  Double Negative  
DNA  Desoxyribonuclic Acid 
DP  Double Positive  
ECM Extracellular matrix 
ER Endoplasmic Reticulum 
Erk  Extra-cellular signal-Regulated protein Kinases  
ERM  Ezrine-Radixine-Moesine  
FACS  Fluorescence Activated Cell Sorting  
FAMM Familial atypical multiple mole melanoma syndrome 
FHL  Familial hemophagocytic lymphohistiocytosis  
FLIP FLICE like inhibitory protein 
Foxp3  Forkhead box P3  
FRET  Fluorescence resonance energy transfer  
GAP  GTPase-activating proteins  
GEF  Guanine nucleotide Exchange Factor  
GFP  Green fluorescent protein  
GLUT-1 Glucose Transporter-1 
GM-CSF  Granulo-Monocytes-Colony Stimulating Factor  
GrzB Granzyme B 
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GTP  Guanosine 5′-triphosphate  
GvHD graft versus host disease 
Her2/neu Human Epidermal Growth Factor Receptor 2 
HIF1a Hypoxia-inducible factor -1 alpha 
HLA  Human Leukocyte Antigen  
HPS2  Hermansky-Pudlak syndrome de type 2  
HS1  Haematopoietic-cell-specific protein-1  
ICAM-1 Intercellular Adhesion Molecule 1 
IDO Indoleamine 2,3-dioxygenase 
IFN  Interferon  
Ig  Immunoglobulin 
Ik  I kappa B kinase  
IL  Interleukin 
IP3  Inositol 1,4,5 trisphosphate  
IQGAP1  IQ-motif-containing GTPase activating protein-1  
IS Immunological synapse 
ITAM Immunoreceptor Tyrosine-based Activation Motif 
JNK-c Jun NH2-terminal Kinases 
LAMP Lysosome Associated Membrane Protein 
LAT  Linker for Activation of T cells 
LCK Lymphocyte Cell-specific tyrosine Kinase 
LFA-1 Lymphocyte function-associated antigen-1 
LG Lytic granule 
LLE Late lysosome endosome 
LMP Low Molecular mass Proteins 
LS Lytic synapse 
MAPK Mitogen activated protein kinase 
MC Microclusters 
MCA Methylcholanthrene 
mDC Myeloid dendtitic cells 
MEK Mitogen-activated or extracellular signal-regulated 
protein kinase 
MHC  Major Histocompatibility Complex 
MIP-1 Macrophage Inflammatory Protein-1 
Mo-DC Monocytes drived DC 
MTOC Microtubule organizing center 
NFAT Nuclear Factor of activated T cells 
NFB Nuclear factor-kappa B 
NK Natural killer cells 
NKT Natural killer T cells 
NOS2 Nitric Oxide Synthase 2 
PBMC Peripheral blood mononucleous cells 
PD Progressive Disease 
PD-1 Programmed Cell Death 
pDC Plasmoctoide dendritic cells 
PDK-1 Phosphoinositide-dependent protein kinase-1 
 5 
 
PD-L1 PD-1 ligand 
PI propidiom iodide 
PI3K Phosphatidylinositol-3-OH kinase 
PiP2 Phosphatidylinositol -4,5-biphosphate 
PIP3 Phosphatidylinositol-3,4,5-trisphosphate 
PKC Protein kinase C 
PLCγ1 Phospholipase Cγ1 
pMHC peptide MHC 
PR Partial Response 
pRb Retinoblastoma protein 
Prf Perforin 
PTEN phosphatase and tensin homolog 
RAG Recombinaition Activating Genes 
Ras Rous avian sarcoma 
RECIST Response Evaluation Criteria In Solid Tumors  
ROS Reactive Oxygen Species 
RSS Recombinaition Signal Sequence 
SAg Super antigen 
SH2 Src homology 2 
SLP-76 SH2-domain-containing leucocyte protein of 76 kDa 
SMAC Supra Molecular Activation Cluster 
Smurf-1 Smad ubiquitination regulatory factor-1 
SNARE Soluble N-ethylmaleimide±sensitive factor Accessory 
Protein Receptors 
TAP Transporter associated with antigen processing 
TCR T Cell Receptor 
TGF Transforming Growth Factor 
Th T helper 
TIL Tumor infiltrating lymphocytes 
TIRF Total Internal Reflection Fluorescence  
TLR Toll Like Receptors 
TNF Tumor Necrosis Factor 
Tyrp1 Tyrosinase Related Protein 1 
VEGF Vascular Endothelial Growth Factor 
 
  
 6 
 
List of Figures 
Figure I-1. Development of cells of the immune system.  
Figure I-2. B cell receptor structure. 
Figure I-3. Schematic representation of T cell activation and differentiation in response to  
APC stimulation.  
Figure I-4.  T cell receptor structure.  
Figure I-5. Gene re-arrangement for coding TCR.  
Figure I-6. Structure of MHC molecules.  
Figure I-7. MHC molecules interaction with TCR.  
Figure I-8. Kinetic proofreading model.  
Figure I-9. TCR serial engagement model. 
Figure I-10. T cell receptor (TCR) signal transduction Pathways. Adapted from Brownlie 
2013 
Figure I-11. Calcium signaling pathway in immune cells.  
Figure I-12. PKC  signaling pathway 
Figure I-13. An illustration of the phases of interaction between a T cell and an APC.  
Figure I-14. Five types of molecular arrangements at the immunological synapse.  
Figure I-15.Organization of receptors at the immunological synapse.  
Figure I-17. TCR Signalling can occur both at the pSMAC and the cSMAC.  
Figure I-18. Mechanism of lytic granule polarization.  
Figure I-19. Genetic diseases giving rise to familial hemophagocytic lymphohistiocytosis 
(FHL).  
Figure I-20. Lytic granule exocytosis.  
Figure I-21.  Perforin mediated granzyme B penetration.  
 7 
 
Figure I-22. Apoptotic induction by Granzyme B.  
Figure I-23. Progression of melanocytes to malignant melanoma.  
Figure I-24. Model of the membrane traffic to melanosomes and lysosomes in melanocytes. 
  
 8 
 
Résumé 
Roxana Khazen 
Etude du mécanisme précoce de la résistance des cellules du 
mélanome à l’attaque des lymphocytes T cytotoxique. 
 
Directeur de Thèse: Dr. Salvatore Valitutti              
Soutenance de Thèse: 29 Jan 2016, Toulouse France 
Les cellules de mélanome humain expriment différents antigènes tumoraux qui sont reconnus 
par les lymphocytes T cytotoxiques CD8 + (CTL) induisant des réponses spécifiques de la 
tumeur in vivo.  
Cependant, chez les patients atteints de mélanome l’efficacité de la réponse naturelle des CTL 
ou stimulée par thérapie est limitée. Les mécanismes sous-jacents de l'échec de la phase 
effectrice des CTL contre les mélanomes sont encore largement méconnus.  
Notre hypothèse est que l'efficacité limitée des CTL dans leur combat contre les tumeurs est le 
résultat d'une balance défavorable entre la capacité des CTL à tuer les tumeurs et une résistance 
tumorale intrinsèque à l'activité cytolytique des CTL. 
Au cours de ma thèse je me suis concentrée sur la dynamique moléculaire qui se produit à la 
synapse lytique afin de pouvoir identifier un mécanisme précoce mis en place par les cellules 
de mélanome face à l’attaque des CTL. 
En combinant l’utilisation d’approches de microscopie de pointe et des outils moléculaires, j'ai 
pu montrer que, lors de l’interaction avec les CTL, les cellules de mélanome humain subissent 
une activation de leur trafic vésiculaire endosomal et lysosomal, lequel est intensifié à la 
synapse lytique et corrèle avec la dégradation par la cathepsine de la perforine et un défaut de 
pénétration d’entrée du granzyme B. De plus, j’ai démontré que le blocage du trafic lysosomal 
dépendant de SNAP23, la modification du pH (intra-vésiculaire) et l’inhibition de l’activité 
lysosomale protéotlytique  des cellules de mélanome permet de restaurer leur sensibilité à 
l’attaque des CTL. 
Nos résultats révèlent une stratégie sans précédent d’ " auto-défense " des cellules de mélanome 
à la synapse immunologique basée sur une sécrétion lysosomale massive et sur la dégradation 
de la perforine sécrétée par les CTL. Ainsi pouvoir interférer avec cette stratégie synaptique 
d’auto-défense des cellules de mélanome pourrait contribuer à potentialiser les réponses des 
CTL et les immunothérapies chez les patients atteints de mélanome. 
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Abstract 
Roxana Khazen 
Dissecting early mechanism of melanoma cell resistance to 
cytotoxic T lymphocyte attack 
Thesis Director: Dr. Salvatore Valitutti              
Thesis defense: 29 Jan 2016, Toulouse France 
Human melanoma cells express various tumor antigens that are recognized by CD8+ cytotoxic 
T lymphocytes (CTL) and elicit tumor-specific responses in vivo. However, natural and 
therapeutically enhanced CTL responses in melanoma patients are of limited efficacy. The 
mechanisms underlying the failure of CTL effector phase against melanomas are still largely 
elusive. Our hypothesis is that the limited efficacy of CTL in their fight against tumors is the 
result of an unfavorable balance between CTL ability to kill tumors and an intrinsic tumor 
resistance to CTL cytolytic activity.  
During my thesis I focused on the molecular dynamics occurring at the lytic synapse in order to 
identify possible “early response-mechanism” of melanoma cells to CTL attack. 
Using a combination of cutting edge microscopy approaches and molecular tools, I showed that 
upon conjugation with CTL, human melanoma cells undergo an exacerbated late 
endosome/lysosome trafficking, which is intensified at the lytic synapse and is paralleled by 
cathepsin-mediated perforin degradation and deficient granzyme B penetration. Abortion of 
SNAP-23-dependent lysosomal trafficking, pH perturbation or impairment of lysosomal 
proteolytic activity restores susceptibility to CTL attack.  
Our results reveal an unprecedented strategy of melanoma cell “self-defense” at the 
immunologic synapse based on a lysosome secretory burst and perforin degradation at the lytic 
synapse. Interfering with this synaptic self-defense strategy might be instrumental to potentiate 
CTL-mediated therapies in melanoma patients.  
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I- Introduction 
General View of the Immune system: 
Human immune response is based on an interactive network of lymphoid organs, cells, humoral 
factors1, and cytokines that has evolved to simultaneously facilitate peaceful cohabitation with 
beneficial microorganisms that constitute the microbiota, to provide host defense against 
infectious agents, to eliminate cancerous cells and to initiate repair and remodeling processes 
that restore and maintain tissue homeostasis 2. Groundbreaking studies over the past decades 
formally characterize immune system in to two main axes: innate immunity and adaptive 
immunity. Although, these two components of the immune response mainly differ in terms of 
specificity, rapidity, duration and effector functions, yet they are complementary as there is 
essential communication linking the cells of the innate and adaptive immune response. 
Development of immune system starts from a common pluripotent hematopoietic precursor cell 
that differentiates into more specialized progenitor cells in the bone marrow to form a 
heterogeneous group of immune cells called leukocytes, or white blood cells (Figure -1). 
  
Innate immunity plays an essential role in body's immediate defense allowing recognition of 
self/nonself by a system consisting of soluble proteins and relatively invariant cellular 
receptors. It involves a large number of cells such as inflammatory resident cells (mast cells, 
macrophages), endothelial cells, monocytes, dendritic cells, natural killer cells (NK), as well as 
subpopulations of lymphocytes (B-1, NKT cells and T cells), basophils and eosinophils.  
Adaptive immunity is characterized by expansion and differentiation of specific lymphocytes 
for a given antigen. This type of immunity takes longer to get involved and constitutes the 
second line of body's defense. In contrast to innate response that is rapid but sometimes harmful 
to normal tissues due to lack of specificity, adoptive immunity requires several days or weeks 
to develop and finally allows efficient and specific elimination of antigens, infected cells and 
cancerous cells. It is noteworthy that adaptive response is capable of generating memory so that 
subsequent exposure to pathogens would lead to a more vigorous and rapid response and 
provide a long-lasting protection. 
The adaptive response has two components: the cellular response, based on the action of T 
lymphocytes that coordinate the action of immune cells and destroy infected or cancerous cells, 
and the humoral response, based on the production of immunoglobulins by plasma cells.   
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Figure I-1. Development of cells of the immune system. This development starts from a common pluripotent hematopoietic precursor cell that 
differentiates into more specialized progenitor cells in the bone marrow to form a heterogeneous group of immune cells called leukocytes, or 
white blood cells. Neutrophils, monocytes, macrophages and immature dendritic cells (DC) originate from common myeloid precursor cells, 
whereas B and T lymphocytes and natural killer (NK) cells arise from common lymphoid progenitors. These differentiated leukocytes circulate 
in the bloodstream or reside in peripheral tissues to scan the environment for danger or respond to danger through different effector 
mechanisms. (Adapted from eBiosciences). 
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The innate immune response 
When epithelial barriers fail to block microorganism, pathogen entrance and replication 
activates innate immune system. The first line of defense is composed of tissue macrophages 
that mediate microorganism engulfment and destruction through recognition of pathogen 
associated patterns via their receptors. This pathogen clearance is either mediated through the 
fusion of the phagosome with lysosomes that contain antimicrobial compounds or through the 
generation of a “respiratory burst”. Activated macrophages are also capable of secreting 
cytokines and chemokines, causing inflammation and recruitment of other immune cells. Such 
inflammatory responses increase the local blood flow, reduce blood flow velocity and induce 
up-regulation of adhesion molecules on activated endothelial cells with consequent 
extravasation of circulating leukocytes into the infected tissues. Neutrophils and monocytes are 
the first to arrive to the site of infection3. Monocytes differentiation will lead to the generation 
of additional macrophages in innate response. During viral or intracellular infection, NK cells 
play an important role in providing a primary defense by releasing lytic molecules when 
contacting target cells. Inflammatory responses also increase the flow of antigens from infected 
tissues to draining lymph nodes, a mechanism that will help mounting an adaptive immune 
response. Moreover complement system is activated by microbial products contributing to 
create an inflammatory environment.  At this stage, innate immunity might succeed in infection 
removal. Alternatively, infection might be kept under control to prevent dissemination, while 
adaptive immune response develops to provide a stronger level of defense.  
More recently, innate lymphoid cells (ILC) have been identified. They exhibit a broad range 
functions. The ILC are a family of innate effector cells characterized by a specific cytokine 
production repertoire. These cells share functional similarities with T cells but differ from T 
cells by the absence of TCR expression and of clonal deletion during their development in the 
bone marrow4. The ILCs are therefore defined as cells at the interface between innate and 
adaptive immunity and play a key role in the development of effective immune responses. They 
are implicated in immune responses to viruses, intracellular bacteria, parasites, and fungi (LC1s 
and ILC3) and in the induction of type 2 inflammation required for immunity to some 
extracellular parasites (ILC2)2. 
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The adaptive immune response 
The main feature of an adaptive immune response is the usage of antigen specific receptors 
expressed by T and B lymphocytes. The recognition of antigenic determinants by T or B 
lymphocytes leads to their activation, priming, and differentiation. These steps will result in the 
generation of an effector adaptive immune response that is composed of antibody secretion by 
plasma cells into blood and tissue fluids and by a T cell mediated cellular immune response.  
 
 Overview of B lymphocyte activation and function 
Specific antigen recognition by B lymphocytes is mediated by BCRs or membrane bound 
immunoglobulins. The BCR recognizes unprocessed antigens in soluble form or bound to cell 
surface (Figure-2). BCRs can internalize antigens allowing B cells to process captured 
antigens within their lysosomal/late endosomal compartments and to express on their surface 
antigenic peptides bound to MHC molecules for antigen presentation to T cells. After 
activation, B-cells develop into plasma cells that release secretory forms of antibodies.  BCRs 
do not possess an intrinsic signaling function. On B cell surface each BCR is associated with a 
heterodimer of protein belonging to the immunoglobulin superfamily: Ig and Ig. These 
proteins bear a cytoplasmic tail containing the ITAM motifs (Immunoreceptor Tyrosine-based 
Activation Motifs, YxxL (X)6-8YxxL) that are responsible for signal transduction. 
BCR/Antigen interaction causes BCR internalization and establishes a cascade of 
phosphorylation processes leading to the activation of B cells. 
                                                                                             
Figure I-2. B cell receptor structure. BCRs are composed of two identical light chains and two identical heavy chains. Each of these chains is 
composed of a variable region, determining the specificity of the receptor for the antigen, and of a constant region, defining the functional 
properties of the immunoglobulin. On B cell surface, each BCR is associated with a heterodimer of immunoglobulin superfamily proteins: Igα 
and Igβ.  Adapted from Murphy immunobiology 20125. 
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 Overview of T lymphocyte activation and function 
T lymphocytes comprise another type of adaptive immune cells. Among them T cells 
constitute the majority of T lymphocytes. As result of gene rearrangements during 
development, most individual T lymphocytes express a unique TCR, responding to a specific 
Ag-derived peptide. T lymphocytes are characterized by simultaneous expression of CD3 
lineage marker in combination with CD4 or CD8, molecules that are intimately tied to target 
recognition.  
T lymphocytes are divided into several groups including: CD8+ cytotoxic T lymphocytes, 
CD4+
 
Th1 and CD4+ Th2 cells, Th17 cells, follicular Th cells and a heterogeneous group of 
regulatory T cells. In addition subsets of T lymphocytes that exhibit a limited diversity of their 
TCR repertoire also exist, such as  T cells, and invariant NKT cells. They somehow 
comprise an intermediary population at the interface between innate and adaptive immunity. 
The current picture of T cell biology postulates that T cells are a very diverse family of cell 
subsets that display some level of differentiation plasticity and carry either effector or 
regulatory functions depending on time and location during an immune response. Figure-3 
summarizes some phenotypic and functional characteristics of these cell subsets. 
 
 15 
 
 
Figure I-3. Schematic representation of T cell activation and differentiation in response to APC stimulation. TCR stimulation by 
recognition of pMHC complexes in combination with costimulatory signals and cytokines provided by APC, triggers the activation and 
differentiation of naïve CD4+ and CD8+ T cells. CD4+ T cells can differentiate into conventional Th1, Th2, Th17 and Tfh or regulatory T cells, 
depending on the cytokine milieu in which activation occurs. After activation and differentiation, effector T cells undergo clonal expansion to 
assure host defense. Adapted from Dee Meester J 2011 thesis 6 
 
T lymphocyte/antigen presenting cells interaction: 
1) Antigen Recognition 
 TCR gene organization: 
Organization and expression of genes encoding TCR chains are perfectly suited to their 
particular receptor function. A part of some exception7, each T lymphocyte expresses a unique 
TCR type on its surface, with single antigen specificity, i.e. it is able to recognize a unique 
peptide-MHC complex type. In order to recognize the immense diversity of peptidic antigens, 
evolution has developed a system which permits formation of a large number of different TCR. 
This process randomly generates specificity of TCR for antigenic peptides. It takes place during 
thymic development and involves a process of gene recombination very similar to that used for 
rearrangements of the heavy and light chains of the Ig during B lymphopoiesis. 
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In its germline configuration, the locus encoding the α chain of the TCR is composed of 
numerous segments V for Variable and J for Joining and a C for Constant domain. In addition, 
two D domains for diversity are present in the locus encoding  chain of TCR. C domain 
encodes the constant, hinge, transmembrane region and cytoplasmic tail of TCR chains. Once 
rearranged the VJ and VDJ segments code variable regions of TCR chains. 
These gene rearrangements are governed by RSS (Recombination Signal Sequence) sequences. 
These are palindromic sequences, heptameric and nonameric, separated by 12 or 23 pairs of 
bases and are serving as anchors to the corresponding machinery of RAG-1/RAG-1 
recombinase8,9. The  chain genes rearrange first during thymic selection. First, there is the 
association of one of the two D segments with a J segment, and then a V segment will be added 
to previously obtained DJ segment producing a VDJ segment. At this point, all segments of 
genes located in the V-D-J complex intervals are eliminated and the synthesized primary 
transcript has the constant segment (V-D-J-C).  Introns are eliminated and translation of 
messenger RNA generates TCR β-chain. This protein is then associated with a substitute of  
chain of TCR to form pre-TCR and is expressed on the surface of the DN thymocytes 
(thymocytes expressing neither CD4 nor CD8 molecules on their surface). If rearrangement of 
TCR  chain is functional cells proliferate and subsequently, the rearrangement of genes 
encoding  chain takes place. A V segment will rearrange with a J segment and then, upon 
transcription and translation,  chain of TCR is expressed. It has been estimated that via such 
processes of somatic recombination more than 1015 TCR can be theoretically generated during 
thymic development. However a large number of thymocytes expressing a given TCR are 
eliminated during positive and negative thymic selection of developing T cells. Accordingly it 
has been estimated that the TCR repertoire of human T lymphocytes is of about 2 x 107 
different TCR in the periphery10. 
 TCR Structure 
 T lymphocytes recognize antigenic peptides in the context of MHC molecules via their 
TCR. The αβ TCR consists of two transmembrane glycosylated polypeptide chains α and β that 
are linked through a disulfide bond11,12 (Figure -4). These glycoproteins belong to the 
immunoglobulin (Ig) superfamily. They consist of an amino-terminal extracellular domain 
containing a variable region (V), a constant region (C) and a short hinge region with a cysteine 
residue necessary for the formation of disulfide bonds (for TCR generation refer to Figure -5). 
These two chains contain also a short intracytoplasmic tail of 4 to 12 amino acids and a 
hydrophobic transmembrane domain composed of 20 positively charged amino acids allowing 
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TCR to stably associate with the CD3 molecules (endowed with a negatively charged 
transmembrane domain) (Figure -4) 12-14. 
While C domain is invariant for each chain of TCR independently of the T lymphocyte on 
which it is expressed, V domain varies considerably from one individual T cell to another. This 
variability mainly resides in 3 zones known as hyper-variable regions or CDR15. 
Crystallographic Studies have shown that CDR regions are projected outside of V domain to 
bind pMHC complexes. In TCR the variable regions of α and β chains are disposed side by side 
to form a unique site for antigen recognition by TCR. The CDR1 and CDR2 regions mainly 
bind to MHC molecules, while CDR3 (where most of TCR variability is concentrated) binds 
preferentially the antigenic peptide16,17. 
All three proteins of CD3,  are encoded by adjacent genes belonging to the same region. 
They each have an extracellular domain that contains an Ig type domain, followed by a 
transmembrane region and a cytoplasmic domain of approximately 40 amino acids. CD3 chain 
has a very short extracellular domain thus it does not contain an Ig domain. On the other hand, 
it has the most important cytoplasmic region with 113 amino acids (Figure -4). 
 
The association of TCR with these six CD3 chains seems to have two main functions: 
Firstly, since TCR lacks an intracellular domain, in order to initiate signal transduction, CD3 
chains and  dimer are requested for signal transduction via ITAM phosphorylation. Each CD3 
complex consisting of 6 chains containing 10 ITAM motifs: 3 on each chain, and 1 on each of 
the , , and chains.  dimer has 6 ITAM motifs (Figure -4). Secondly, TCR/CD3 
interaction allows stabilization of TCR expression on surface of T lymphocytes18-21. 
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Figure I-4.  T cell receptor structure. TCR consists of two chains, α and β, and forms a complex with the CD3 signaling molecules that are 
composed of a andcomplex, a  and  and complex and a -complex CD3γε, CD3δε, ζζ)These CD3 chains contain one or more ITAM 
motif of 14 to 16 amino acids in their cytoplasmic region, while each chain that plays a central role in TCR signal transduction contains three 
ITAM motifs    Adapted from J. Gascoigne NR Nat Rev 200822. 
                              
Figure I-5. Gene re-arrangement for coding TCR. The  chain genes rearrange first during thymic selection. First, there is association of one 
of the two D segments with a J segment, and then a V segment will be added to previously obtained DJ segment producing a VDJ segment. At 
this point, all segments of genes located in the V-D-J complex intervals are eliminated and the synthesized primary transcript has the constant 
segment (V-D-J-C).  Introns are eliminated and translation of messenger RNA generates TCR β-chain. This protein is then associated with 
a substitute of  chain of TCR to form pre-TCR and is expressed on the surface of the DN thymocytes (Double Negative : thymocytes 
expressing neither CD4 nor CD8 molecules on their surface). If the rearrangement of TCR  chain is functional cells proliferate and 
subsequently, the rearrangement of genes encoding  chain takes place. A V segment will rearrange with a J segment and then, upon 
transcription and translation,  chain of TCR is expressed. Adapted from Murphy immunobiology 20125. 
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 Antigen presentation to lymphocytes 
In T lymphocytes, the recognition of antigen fragments requires antigen processing and 
presentation by antigen presenting cells (APCs).  Antigens are presented to T cells on the 
surface of the APCs in the form of peptides bound to the major histocompatibility complex 
(MHC) molecules. CD4 or CD8 co-receptors are also involved in recognition of these peptide 
MHC (pMHC) complexes. Whereas CD4+ T lymphocytes recognize antigenic peptides 
associated with MHC Class  molecules, CD8+ T lymphocytes recognize those associated with 
class molecules. 
Most of the cells are able to present antigen to CD8+ T lymphocytes in the context of their 
MHC  molecules. Conversely, only cells expressing MHC- can present antigens to the CD4+ 
T cells, they are named professional APCs. Among these cells there are dendritic cells (DC), B 
lymphocytes and macrophages. There are also additional cells that can express MHC- 
molecules and serve as unconventional APC for CD4+ T cells such as IFN- primed mast 
cells23, endothelial or epithelial cells 24 and basophils25-27. 
 MHC genes 
The MHC or HLA (Human Leukocyte Antigens) system in humans is a set of more than 200 
genes, located on chromosome 6 and organized into regions encoding three classes of 
molecules: classes 1, 2 and 3. Class 3 codes for different proteins involved for instance in the 
complement cascade or cytokines expression such as TNF, and have no direct function in the 
antigenic presentation. Here we focus on the first two classes, involved in antigen presentation 
to T lymphocytes. 
The molecules of MHC genes have three basic characteristics: polygenicity, co-dominance and 
the polymorphism. There are three classic genes encoding  chain of the MHC-in humans. 
They are named HLA-A,-B and–C. There are also three genes encoding for human MHC-. 
They are called DP, DQ and DR (polygenicity). The co-dominance refers to the expression of 
two alleles of a certain gene in a single cell. This property allows individual cells to express a 
higher number of MHC molecules with different ranges of specificity of bonded peptide.  
In addition, MHC molecule genes are polymorphic genes referring to the presence of many 
alleles of each gene in the whole population. This feature supports recognition of a larger 
pattern of pathogens since different antigenic peptides are bound by different MHC alleles.  
Even though molecules of MHC Class  and Class  all have the common property of binding 
to antigenic peptides, they differ in many other aspects: 
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 a) The MHC Class  molecules are present on the surface of all nucleated cells in the body. The 
presentation of endogenous peptides by MHC Class molecules leads to specific activation of 
CD8+ T cells. These peptides are products of enzymatic degradation by proteasome inside the 
cell and are constituted of 8-10 amino acids28 (Figure -6 and -7).  
b) The MHC Class  molecules are present only on the surface of professional APCs. The 
association of the domains with domains of and chains forms a groove that can 
accommodates 12 to 24 amino acid long peptides to be presented to CD4+ T lymphocytes29. 
These peptides are derived from degradation of extracellular proteins internalized via 
endocytosis (Figure -6 and -7).  
 
                                                              
Figure I-6. Structure of MHC molecules. A) MHC class I are composed of a 45 kDa chain with three domain (α1, α2 and α3similar to those 
of immunoglobulins) associated to the β2-microglobulin. 1 and 2 domains form a pocket, which is the site where peptide antigens bind to 
MHC molecules and where the polymorphism of the molecule is mostly represented. B) MHC class II are heterodimeric molecules, composed 
of two transmembrane glycoproteins: a 30-32kDa  chain that is non-covalently associated to a 27-29 kDa  chain. The peptide binding pocket 
is formed by the 1 domain of the  chain and the 1 domain of the chain. Adapted from Murphy immunobiology 20125. 
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Figure I-7. MHC molecules interaction with TCR. The peptide complexed in the pocket of MHC interacts with CDR (Complementarity 
Determining Region) regions of the TCR and these interactions are stabilized through association of CD8 or CD4 co-receptor with MHC Class 
I and MHC Class II molecules respectively. Adapted from Murphy immunobiology 20125. 
 
2) Molecular steps of T Lymphocytes and Antigen presenting cell interaction  
 
 TCR/pMHC interaction 
TCRs display remarkable ability to specifically recognize a wide array of structurally and 
chemically diverse antigens. Understanding of the molecular basis of TCR interactions with 
peptide-MHC has been greatly advanced by a number of studies that elucidated the interface 
sites, key contacts, and binding modes of several of these complexes. 
Two important aspects of such interaction are mentioned here: 
 
Affinity of contact: 
Several cellular studies demonstrated that a full activation of T cells requires a su30stained 
signaling31,32. However, this concept was difficult to reconcile with several molecular studies 
aiming at dissecting pMHC/TCR interactions. These studies based on the measurement of 
TCR/pMHC binding parameters in solution revealed a low affinity of TCR/pMHC binding (Kd 
approximately between 1–100 μM) as well as a very short dwell-time of binding(seconds)33,34.  
This was a paradoxal finding considering the specificity and efficacy of TCR in recognition of 
as few as a single foreign antigen among a sea of self-pMHC complexes. The high specificity 
of TCR binding is also shown by the fact, that while a given pMHC may act as a strong agonist 
capable of triggering full activation of T cell through TCR engagement, other related peptides 
will be considered weak or null agonist and may have no or at best partial effects on T cell 
activation. Moreover, substitution of a single amino acid in the sequence of the antigenic 
peptide presented by MHC can render T cells unresponsive to subsequent stimulation with the 
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immunogenic peptide35. Moreover, using single-molecule microscopy and fluorescence 
resonance energy transfer (FRET) between fluorescently tagged TCRs and their cognate pMHC 
ligands for measuring kinetics of TCR-pMHC binding in situ, Huppa et al. reported that 
compared to solution measurements association and dissociation were even faster36. 
Complementary results were obtained using a different approach by J. Huang et al. 37. Together 
these results underline the extreme rapidity of TCR/pMHC binding within the IS confines and 
that, for sustained signaling in T cells, multiple rounds of TCR/pMHC binding are required36,37 
. 
Force of contact: 
More recently, Zhu C. et al. introduce a new concept in TCR/pMHC interactions in which TCR 
uses mechanical contact (the forces involved in their binding to the antigens) for decision 
making. In this context, interactions between TCR and agonist pMHC form catch bonds that 
are strengthen with the application of additional force to initiate intracellular signaling. Less 
active MHC complexes form slip bonds that weaken with force and do not initiate signaling. 
Overall, they described how the signaling outcome of TCR/pMHC interaction depends on the 
magnitude, duration, frequency and timing of the force application, such that agonist peptides 
form catch bonds that trigger the T cell digitally, whereas antagonists form slip bonds that fail 
to activate38.  
Probability of interaction: 
Interaction of TCR and its ligand has major constraints. First, even if a T cell expresses a 
significant number of TCR with the same affinity for a specific antigen on its surface, the APC 
will only present a few number of MHC molecules on their surface presenting the specific 
antigen for which those TCR are specific. In fact most of the pMHC express on an APC surface 
are self antigens, produced by processing intra and extracellular proteins. Demotz et al in 1990 
measured that T cells are activated by APCs that display on their surface no more than 0.03% 
of specific pMHC complexes binding the specific peptide. Therefore, the probability of 
presence of specific pMHC complexes at the contact zone between two cells is rare. The 
second parameter that yet reduces the probability of TCR/pMHC interaction is the length of 
extracellular domains of TCR and their ligand comparing to other membrane molecules. Each 
of these two molecules is approximately 7.5 nm long. This length requires that the membrane 
of T cell and APC cells would be at a ~14 nm distance to allow productive TCR engagement, 
this scenario is difficult to envisage because of the expression on the surface of cells of a large 
number of glycosylated large proteins that might prevent such proximity.  
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In spite of those compelling factors, TCR/pMHC interaction is extremely sensitive. Recent 
studies, demonstrated that as few as single pMHC is able to induce a transient [Ca2+]i increase 
in both mouse CD4+ and CD8+ T cells and that by maintaining a sustained [Ca2+]i increase in T 
cells, TCR recognition of only 10-15 pMHC complexes is strong enough to induce T cell 
activation39,40. Likewise, CTLs were capable of killing target cells expressing 1-10 pMHC 
complexes on their surface41,42 . 
In the last decades many studies tried to investigate such intriguing paradox. Two models have 
been proposed for explaining the mechanism regulating antigen recognition by T cells: the 
kinetic proof reading model and the serial TCR engagement model. 
Kinetic proofreading model:  
In 1995 McKeithan et al. proposed the kinetic proofreading model in which a prolonged time 
of interaction of TCR with pMHC is considered as a crucial element for full activation of T 
cells. According to this model there is a lapse of time between initial TCR/MHC interaction and 
transduction of signal.  The model proposes that TCR-coupled signaling is composed of a series 
of intermediate reversible steps leading to full activation of the signaling cascade (Figure -8). 
The original model proposed three hypotheses; first, the inactive primary TCR/pMHC 
undergoes a sequence of N modifications leading to an activated state via a series of 
intermediaries. Even though these modifications haven't been described in details, it can 
include: phosphorylation or dephosphorylation in tyrosine within the receptor complex, 
conformational changes of proteins, generation of secondary messengers or even recruitment of 
scaffolding components to the receptor. Second, dissociation of the interaction leads to 
reversion of these modifications and, third, upon interaction of non-specific TCR/pMHC 
complexes the rate of dissociation is sufficiently high to avoid formation of productive 
interactions leading to reversion of such modifications and to a destructive signal. This model 
explains how T cells discriminate between ligands based on kinetic differences of intermediary 
interactions. In this manner, the modifications induced during TCR-pMHC interaction 
supposedly will be amplified in order to maximize minor differences and thus explaining the 
high specificity of such interaction.  
The above theory revolves around the concept that short-term TCR engagement will induce 
proximal signaling events but not later T cell responses, due to the reversibility of early 
activation steps. Indirect support for these models has been obtained by the demonstration that 
there is a rough correlation between the duration of TCR/ligand contact and the biologic 
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efficacy of this interaction43-45 but the mechanism by which these kinetic differences alter T cell 
responses is less clear. 
                         
Figure I-8. Kinetic proofreading model. The kinetic proofreading model suggests that binding of a TCR to a pMHC to form a TCR–pMHC 
complex initiates a sequence of signaling events with intermediates (C1, C2 …). These culminate in the formation of the final signaling product 
(CN), which signals to the cell. However, if the TCR–pMHC complex dissociates before the formation of CN, then the signaling fails. The 
association (k1) and dissociation (k−1) rate constants for the TCR–pMHC interaction are shown, as are the rate constants of the intermediate 
pathway (kp, is assumed to be the same for every step). Adapted from George AJ Trends in immunology 2005 30 
 
Serial TCR engagement: 
Even though the kinetic proof reading model can explain the high specificity of T cell 
activation induced by TCR/pMHC interactions, it doesn't provide a model to describe the high 
sensitivity of such interactions with small number of specific pMHC. In other words, how such 
short interactions of TCR/pMHC permits T cells to recognize a very low number of specific 
pMHC complexes presented on the surface of APCs? It has been previously shown that a 
prolonged and uninterrupted TCR engagement with its pMHC ligand is required for a sustained 
signaling in T cells46. Considering the fact that TCRs have a low affinity of binding with their 
ligands, how these TCR remain engaged with the same individual pMHCs for such long time? 
In 1995 S.Valitutti et al. proposed the serial engagement model in order to explain sustained 
TCR/pMHC interaction. They used TCR internalization as a parameter of TCR/pMHC binding 
and observed that a very few specific pMHC complexes can lead to high level of TCR 
internalization. They indeed estimated that on pMHC could engage trigger and internalize ~180 
TCR, meaning that a very few pMHC complexes can trigger a considerable number of TCRs. 
The model proposes that low affinity TCRs by interacting in series with a small number of 
specific pMHC can lead to a sustained and amplified signaling. This model thus provides a 
plausible explanation of how a T cell can sensitively detect a limited number of pMHC through 
“sequential” high TCR occupancy (Figure -9). 
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Recent publications reporting extremely fast TCR/pMHC binding on-rate and off-rates as well 
as other experimental and computational studies support serial triggering model for an optimal 
T cell responsiveness, however other observations do not support the model (reviewed in47 
Dushek O and van der Merwee PA Nat Rev 2011) 
Kinetic proof reading and serial engagement models might be not mutually exclusive. In fact, 
on one hand the kinetic proof reading, mostly explains the specificity of interactions at the 
molecular level. On the other hand, serial engagement mostly explains the sensitivity of T cell 
for antigen stimulation at the cellular level. It is conceivable that in physiological conditions 
where the density of specific pMHC complexes on APC surface is low, in order to activate T 
cell, the half life of TCR/pMHC interactions should be long enough to allow signaling 
proofreading and short enough to allow a single pMHC complex to engage in a series multiple 
TCR. 
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 Early steps of signal transduction in T cells: 
TCR engagement: 
Activation of T lymphocyte is a general term which includes signaling events leading to cell 
survival, proliferation, rearrangement of the cytoskeleton, metabolism increase and variation 
of gene expression profile.   In naive T cells, activation requires the accomplishment of two 
distinct and synergistic signals: the TCR and the co-stimulatory molecule engagement.  
TCR early signaling events can be divided into 4 steps (Figure -10): 
1) Rapid recruitment of Src family tyrosine kinases: LCK (major role player) and Fyn. 
Engagement of TCR will cause its translocation into membrane micro-domains, rich in 
cholesterol and sphingolipids, known as DRMs (detergent-resistant membranes), which 
facilitates phosphorylation of ITAMs motifs48-50. Following TCR/co-receptor/pMHC 
interaction, LCK is recruited into close proximity of ITAM motifs via its association with CD4 
and CD8 co-receptors 51,52.  Early recruitment of CD45 facilitates LCK activity53. ITAM 
phosphorylation will cause recruitment of a set of enzymes (protein kinases, GTPases, 
phosphatases) and adaptor molecules in DRMs to forms a “TCR signalosome”54,55 . 
2) Phosphorylation of ITAM motifs present in the cytoplasmic domains of CD3 complex/ 
dimer in their tyrosine residues by LCK and Fyn. 
3) Recruitment of protein ZAP-70 (ζ-chain-associated protein kinase 70 kDa) to the 
phosphorylated ITAMs via its two SH2 (Src homology 2) domains and its activation by Src 
kinases-mediated phosphorylation in a regulatory tyrosine.  
4) Activation of LAT protein (Linker for Activation of T cells) through phosphorylation by 
ZAP-70. LAT is associated with membrane micro-domains and becomes a platform for 
binding of additional signaling proteins. 
In fact, another important substrate of ZAP-70 activity is SLP-76 (SH2-domain-containing 
leucocyte protein of 76 kDa) which is an adaptor protein implicated in signal transduction. 
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                       Figure I-10. T cell receptor (TCR) signal transduction Pathways. Adapted from Brownlie 201356 
 
Co-stimulatory molecules engagement: 
As mentioned earlier, the second activation signal is generated by the engagement of several T 
cell's accessory molecules with their ligands on APCs including: co-stimulatory molecules such 
as CD28, CD4 and CD8 co-receptors and the adhesion molecules like LFA-1 and CD2. Such 
interactions not only influence and regulate the strength of TCR/pMHC binding, but also affect 
the magnitude and the quality of T cell signaling. We will briefly review some features these 
molecules and their contribution to downstream events of the TCR signaling process. 
a) Role of CD80-CD86/CTLA-4 – CD28 interaction 
The two member of B7 family the CD80 (B7-1) and CD86 (B7-2) can bind two receptors: 
CD28 and CTLA-457,58. CD80 and CD86 are the monomeric proteins with two Ig-like 
extracellular domains and are expressed specifically by activated professional APCs59,60. These 
two molecules have particular kinetic of expression and affinity. While CD86 is expressed 
constitutively on APCs and is up-regulated upon interaction with CD28, expression of CD80 is 
only induced after APCs activation and is stable for a longer time frame of 4-5 days (compared 
to CD86 with a maximum of 48 hours)61. 
The CD28 molecule belongs to Ig family and is expressed constitutively on the surface of T 
cells. In contrast, CTLA-4 has a more complex kinetic of expression; in resting T cells, this 
transmembrane protein is present in intracellular vesicles and following TCR activation it 
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translocates to the immunological synapse. Moreover CD28 recycling rate is slower than that of 
the CTLA-4 whose membrane expression half-life is about 2 hours61. 
Differences in the expression of the two co-stimulatory molecules have been observed that 
could support a model where CD80 might be considered a preferential (but not exclusive) 
inhibitory ligand for CTLA-460. Since CD86 and CD28 membrane expression is constitutive, 
their binding is more plausible as soon as T cell contacts APC.  This interaction generates a 
positive signal to naive T cells for their activation and induces T cell proliferation, cytokine 
production while tolerance induction is inhibited62,63. On the other hand, interaction of CD80 
and CTLA-4 is favored later, given the kinetic of expression of these two molecules and the 
higher affinity of CTLA-4 for CD80/CD86 molecules compared to CD28. This later binding 
generates a negative signal and is implicated in the termination of signaling and in anergy 
induction64,65.  
b) Role of CD40/CD40L interaction: 
CD40 is a transmembrane receptor belonging to TNF family of receptors. Interaction of CD40 
with its ligand CD40L is largely involved in T cell and DC dialogues as it induces many 
reciprocal effects in T cells and DCs66,67. CD40 engagement enhances DCs survival via up-
regulating of Bcl-2 expression and results in DC maturation68. In addition, following CD40 
engagement, DC increase expression of MHC class II molecules, of co-stimulatory molecules 
CD80 and CD86 and are activated to production of cytokines such as TNF-, IL-8 and MIP-
1.  CD40 binding also induces production of IL-6 and IL-12 in response to IFN-.  
 
 Signal transduction to the nucleus: 
TCR signaling leads the activation of multiple intracellular effectors signaling pathways 
involved in expression of many genes: 
1) Calcium pathway 
2) Protein kinase C pathway 
3) MAP Kinases pathway 
All these pathways converge on the nucleus to regulate the expression of genes involved in 
cellular responses of T lymphocytes such as the proliferation, production of interleukins and 
differentiation. 
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Calcium Pathway: 
Following TCR/pMHC interaction there is a rapid increase in [Ca2+]i concentration in T 
lymphocytes 72. M.Davis and co-workers showed that as early as 6 seconds after specific 
TCR/pMHC engagement an elevation of [Ca2 +]i can be detected41. Calcium signaling pathway 
and its role in inducing calcineurin dependent translocation of the transcription factor NFAT 
into the T cell nucleus is illustrated in Figure -11.  
In addition to its well described role in regulating T cell activation to cytokine production, 
[Ca2+]i increase appears to have an impact on the 'stop signal' of T cells. Indeed, while scanning 
the APC surface for antigen recognition, T cells are highly mobile cells with an elongated 
shape. T lymphocyte/APC interaction leads to an arrest and rounding of T cells known as 'stop 
signal’. T cell arrest is preceded by an increase in [Ca2+]i. The artificial decrease in the intensity 
of calcium [Ca2+]i increase induced an inhibition of the 'stop signal’73. This T cell arrest 
requires activation of calpain, a calcium-dependent protease that frees LFA-1 from its 
cytoskeletal anchoring form thus permitting mobile LFA-1 to cluster at the cell-cell contact 
zone. Such LFA-1 clustering is fundamental for strengthening and stabilization of the 
intercellular contact74,75.  
 
 
 
Figure I-11. Calcium signaling pathway in immune cells. Antigen recognition through the TCR results in the activation of protein tyrosine 
kinases, such as LCK and ZAP70, which initiate phosphorylation events of adaptor proteins, such as SLP76 and LAT. This leads to the 
recruitment and activation of the TEC kinase ITK (interleukin-2-inducible T-cell kinase) and phospholipase C1 (PLC1). Similarly, binding of 
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G-protein-coupled chemokine receptors results in the activation of PLC. PLC and PLC1 catalyse the hydrolysis of the membrane 
phospholipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to inositol-1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG). InsP3 
binds to and opens InsP3 receptors (InsP3Rs) in the membrane of the ER, resulting in the release of Ca2+ from intracellular Ca2+ stores. A 
decrease in the Ca2+ content of the ER is 'sensed' by stromal interaction molecule 1 (STIM1), which in turn activates calcium-release-activated 
calcium (CRAC) channels in the plasma membrane. Ca2+ influx though CRAC channels and elevated intracellular Ca2+ concentration activate 
Ca2+-dependent enzymes, such as calcineurin, and thereby transcription factors, such as NFAT (nuclear factor of activated T cells), NF-B 
(nuclear factor-B) and CREB (cyclic-AMP-responsive-element-binding protein). cADPR, cyclic ADP ribose; CaMK, calmodulin-dependent 
kinase; GADS, growth-factor-receptor-bound-protein-2-related adaptor protein; IKK, inhibitor of NF-B kinase; RYR3, ryanodine receptor 3. 
Adapted from Feske S Nat Rev 200776 
 
Moreover, A.Quintana et al. showed that mitochondria and ORAI channels are brought into 
close proximity (200 nm) and PMCA (plasma membrane Ca2+-ATPase) are re-organized into 
discrete regions of the plasma membrane where they are co-localized with mitochondria at the 
IS. This redistribution helps mitochondria to rapidly take up the inflowing Ca2+, thereby 
avoiding high Ca2+ microdomains close to ORAI channels, thus preventing Ca2+-dependent 
channel inactivation and reducing local Ca2+-dependent PMCA modulation. This optimizes net 
Ca2+ influx at the IS. By slowly exporting Ca2+ further away from the PM, mitochondria sustain 
an elevated global Ca2+ signal that enhances the translocation of NFAT into the nucleus and the 
subsequent activation of Th cells77,78.    
   
PKC pathway: 
A. Kupfer and co-workers, in their first description of an immunological synapse, showed that 
the PKC- is recruited very rapidly to the T cell/APC immunological synapse in an antigen 
specific manner79. TCR stimulation activates PLC1 that hydrolyses PIP2 into DAG and InsP3. 
DAG will recruit PKC- to the plasma membrane. GLK kinase phosphorylates PKC- on its 
catalytic site (Thr538) and activates it. Activated-PKC-will lead to the formation of a 
CARMA1/MALT/BCL10 complex and initiate a cascade of phosphorylation events, CARMA1 
complex phosphorylation of IB will result in its proteosomal degradation and release of the 
active form of NF-B thatcan translocateto the nucleus and induce gene expression. This 
signaling pathway is important in Th1/Th2 differentiation process. Indeed, while absence of 
PKC- prevents development of Th2 lymphocytes differentiation, it does not influence Th1 
phenotype80 (Figure -12). 
The PKC family includes 10 structurally and functionally related isoforms that are grouped into 
three subfamilies based on the composition of their regulatory domains and their respective 
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cofactor requirements81. They are referred to as: conventional PKCs (cPKC: , , ), novel 
PKCs (including: nPKC: δ, ε, η, θ) and atypical PKCs (aPKC: ζ, λ/ι). Novel PKCs are DAG-
dependent, but Ca2+ and phospholipid independent for their activity82. Six of the PKC isoforms, 
including PKC α, δ, ε, η, θ, and ζ are expressed at varying amounts in T cells83 and it has been 
shown that distinct PKC isoforms are required for different aspects of the activation and 
effector functions of T cells. PKC θ is one of the most well-known proteins recruited to the IS 
and accumulates at cSMAC upon TCR engagement in a CD28 dependent manner66,79. Recently, 
work from Hivroz’ s lab and from Valitutti’ lab identified atypical PKC ζ as a key molecular 
guide for Th cell polarization toward DC 84 85. 
                                              
Figure I-12. PKC  signaling pathway. TCR stimulation activates PLC1 that will hydrolyze PIP2 into DAG and InsP3. DAG will recruit 
PKC- to the plasma membrane. GLK kinase phosphorylates PKC- on its catalytic site (Thr538) and activates it. Activated-PKC-will lead 
to the formation of a CARMA1/MALT/BCL10 complex and initiate a cascade of phosphorylation events, CARMA1 complex phosphorylation 
of IB will result in its proteosomal degradation and release of the active form of NF-B thatcan translocateto the nucleus and induce gene 
expression. C1, DAG-binding domains of PKC; C2, calcium- and phosphatidylserine-binding domain; PP, polyproline motif; CNH, citron 
homology domain; YYY, Tyr-Tyr-Tyr; CARD, caspase-recruitment domain; PDZ, postsynaptic density 65–discs large–zonula occludens 1 
domain; GUK; guanlylate kinase domain; DD, death domain; Ig, immunoglobulin domain; IKK, inhibitor of NF-κB kinase (γ, α, β are 
subtypes); KIN, kinase domain (tyrosine or serine-threonine) Adapted from Dustin ML Nat Rev 2011 86. 
 
MAP kinases pathway: 
The MAPK signaling pathway (mitogen activated protein kinase) is highly conserved in 
evolution and used ubiquitously. There are three groups of MAPK in mammals:  
1) Erk 1 and 2 (Extra-cellular signal-Regulated protein Kinases)  
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2) p38 MAPK  
3) JNK (c-Jun NH2-terminal kinase)  
Each MAPK is activated by different upstream MAPK kinases (MEKs) and MAPK kinase 
kinases (MEKKs). MAPK are activated by dual phosphorylation on tyrosine and threonine 
residues. MAPK activation results in phosphorylation and activation of distinct downstream 
transcription factors, depending on the group of MAPK activated. Thus, ERK activates Elk-1 
and c-Myc87, p38 activates c-Fos88 and ATF-289, and JNK activates c-Jun and ATF-290. The 
phosphorylation and activation of these transcription factors permits the MAPK family to 
regulate gene expression and hence, cellular fate and effector function.  
3) Cellular contacts in adaptive immune response:  
T cell and APC cognate interaction is a crucial step in defining T cell destiny and thus a key 
element of initiation of an adaptive immune response. Depending on the type of presented 
antigen, duration and molecular organization of the T cell/APC interaction, T cells can be 
turned on or off.  
These interactions contribute to several process of T cell biology including T cell 
differentiation, maturation, proliferation, the acquisition of effector or memory function. 
Alternatively these interactions can have tolerogenic effects leading to T cell anergy91,92. 
T cell/APC interaction can be schematically divided into 3 phases 93 (Figure -13):  
1 - Initiation of contact or searching for antigen 
2 - Duration and stability of contact 
3 – T cell detachment after a few minutes or a few hours followed by migration resumption.    
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Figure I-13. A schema of the phases of interaction between a T cell and an APC. Contact acquisition is followed by initial scanning, 
contact, contact resolution (through detachment) and migration away from the APC. The interaction supports apposition of the membranes of 
the interacting cells and signaling, but stable and dynamic phases vary considerably in different experimental settings. T cells in which signal 
transduction is occurring are depicted in green. Adapted from Friedl P 200593 
 
 
 Initiation of contact or searching for antigen  
First step in interaction between T cells and APC is their physical contact that may take place in 
lymph node for naive T cells or in tissues for effector T cells. however most studies performed 
using two-photon microscopy to monitor T cell/APC interaction in live tissues were performed 
in mouse lymph nodes94. This step is initially independent of the presence of antigen and of the 
type of the lately formed immunological synapse such random encounters are driven by T cell 
motility and by DC probing of the intercellular milieu using their highly motile dendrites. T cell 
scanning of the APC surface is a requisite element for detecting presence of an antigen and is 
finely controlled. Both CD4+ and CD8+ T lymphocytes migrate to T cell zone of amoeboid 
lymph nodes in a rapid fashion. Their average speed is approximately 10 µm/min with peaks of 
more than 25 µm/min95-97. APC, such as B cells or DC, are less mobile98 and their average 
speed of migration is 6µm/min95 96. High migration capacity of T cells in vivo allows them to 
serially scan a large number of APC. Studies conducted by the team of M.Cahalan 
demonstrated that, in absence of antigen, approximately 5000 CD4+ T cells per hour will 
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encounter a same DC99 while E.Robey and co-workers estimated that about 500 CD8+ T cells 
can scan a single DC in one hour96, such rapid frequency of contact enables recognition of rare 
antigens by the pool of T cells in a lymph node within a reasonable timeframe. In addition there 
are other factors hastening antigen detection process. In vivo two-photon microscopy 
visualization of mice lymph nodes harboring florescent DCs revealed existence of a DC 
network (at sites of homing within high endothelial venules) within which mature DCs were 
more motile than steady-state DCs, facilitating their interaction with migrating T cells arriving 
in the lymph node. Moreover, chemokine release or the formation of tunneling nanotubes by 
mature DCs has also been proposed not only to globally optimize of antigen detecting process 
(guided priming)100 but also to allow finding rare antigens. Proof of such highly effective 
organization is that less than 100 DCs in a lymph node are sufficient to initiate a response with 
very rare naive antigen-specific T cells101. 
During this first phase, LT are therefore highly mobile and move from one APC to another. The 
binding of their TCR with pMHC complexes initiates a process of activation and begins the 
second phase of specific interaction102.    
 
 The stability and duration of contact: 
Single vs successive encounter models  
T cell response establishment requires signal integration via T cell-APC interaction, two 
models have been proposed. 
The first model defined as: “single encounter model” emerged from the initial observation of 
firm interaction of T cells and APCs in early 1990s. This model describes T cell stop feature as 
a consequence of TCR engagement and a subsequent stabilization provided by adhesion 
molecules, such stable interaction forms an immunological synapse that may last for hours103-
105. In this context several studies reported the necessity of prolonged T cell-APC contacts for T 
cell activation, indicating that full activation and initiation of proliferation requires stimulation 
over several hours (from 6-30 hours) depending on the strength of signal provided by APC46,106 
. 
Real time monitoring of T cell movements in 3D collagen during interaction with DCs 
provided support for a second model. This model proposed by P. Friedl and co-workers, is 
based on the observation that several successive transient interactions of about 3-20 minutes are 
formed between motile T cells and their cognate DCs. Even though these interactions were 
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rather dynamic, short lived and sequential, they have been shown to effectively induced T cell 
activation. Integration of signals from multiple contacts suggests existence of a short-memory 
that allows T cells to accumulate signals over few minutes93. The capacity of the T cells to add 
interrupted signals has been confirmed by S.Valitutti and coworkers107 and has been recently 
well characterized in vivo by P.Bousso and Colleagues108. All in all, these observations leaded 
to a more precise description of the immunological synapse in which kinapses are referred as 
more dynamic synapses while synapses are T cell/APC junction of more stabilized 
interactions109. 
Given the difference of signaling and functionality in different types of synapses, the functional 
destiny of T cell depends on which kind of synapses are formed and on how these synapses 
contribute to T cell activation. Moreover, the quality of collected signals within individual 
contacts and signal sum up from serial encounters dictates the destiny of an activated T cell. In 
other words, it is tempting to speculate that there are 3 scenarios during T cells interaction with 
cognate APCs. First, APCs are presenting high affinity antigen that provides a STOP signal for 
T cells and prompt formation of synapses, in this context the T cells collect enough signal for 
full activation. Second, low affinity antigens will lead to formation of kinapses due to weak 
signal transmission and failure in T cell activation. Third, in conditions in which the strength of 
antigenic stimulation is intermediate, the signal accumulating capacity of T cells come in to 
account and depends on the density of APCs. In this condition, several kinapse formation and 
sum up of signals in the presence of high density of APCs can cause T cell activation. 
In 2004 a 3-stage model of successive T cell-DC interaction was proposed based on two-photon 
microscope study of naive T cell dynamics in lymph node (LN). This study showed that newly 
arrived T cells in LN form transit interactions with DCs that last for about 3-11 minutes and 
results in up regulation of the activation marker CD69 on T cells. A second stage take place few 
hours later, when upon a progressive decrease of motility, contacts of longer duration (around 
12-14h) are formed and T cells start to secrete IFN-and IL-2 and form dense clusters with 
DCs. Later on T cells recover their rapid migratory capacity and in parallel to proliferation T 
cells make transient interactions with DCs. This is referred to as 3rd stage. Several studies 
investigated formation and duration of such interactions in vivo, reporting somewhat 
controversial results most probably due to the variety of the utilized systems 110-112. However, 
together these reports point out the influence of APC differentiation status as well as the 
quantity and quality of presented antigen in the control of the different stages of T cell/APC 
interaction. Such interaction will eventually determine T cell fate. Fully mature DCs with high 
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levels of adhesive and co stimulatory molecules more likely induce T cell arrest and priming, 
accordingly high affinity pMHC can more easily induce T cell arrest leading to formation of a 
productive immunological synapse, while low potency complexes ends up with T cell anergy 
and their retention in LN113.  
All in all, T cell/DC interaction can be described by both single and successive encounters 
depending of several factors including antigen presentation and environmental elements such as 
quantity and quality (potency) of antigens113, nature and activation state of the APC114, T cell 
phenotype and presence of bystander competitor115, presence of Tregs116,117 and even presence 
or absence of chemokine118-121.  
 
 Termination of cell interaction: 
This final phase corresponds to dissolution of synapse, T cell detachment from its APC and its 
return to a migratory phenotype. This step is for the moment the less studied and, therefore, it is 
not fully understood. In particular, it is still not determined if termination of synapse is a 
consequence or a prerequisite for cell detachment93. Several mechanisms appear to be involved 
in this phenomenon such as: internalization and degradation of TCR122 and adhesion molecules 
such as LFA-1123, increasing of expression and recruitment of inhibitory receptors such as 
CTLA-4 at the synapse124,125 or induction of the expression of chemokines and their receptors 
that can favor a migratory phenotype. 
 
Dynamics of LT/APC interaction and synapse formation  
As discussed earlier,  T cells are activated through engagement of their TCR with the 
cognate peptide-MHC complex expressed on the surface of their APC. This TCR/pMHC 
engagement in cooperation with duration of contact and recruitment of specific co-stimulatory 
molecules at the cell-cell interface provokes a complex of signaling cascade in T cells that 
dictates type and amount of information that is going to be exchanged between T cells and 
APCs. Such interactions between the two cells leads to the formation of a specialized signaling 
area referred as immunological synapse (IS), a term that was initially derived from neuronal 
synapses due to the analogy between T cell/APC contacts and neuronal contacts. This first 
observation of IS dates back to 1980 when microscopy-based studies revealed formation of a 
contact site between CD4+, CD8+ or NK cells with the APCs that was accompanied by the 
polarization of actin and microtubule cytoskeleton, the microtubule organizing center (MTOC) 
and the Golgi apparatus towards the contact site126-129. IS formation also results in the transport 
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of intracellular vesicles and cell-surface receptors (including TCRs and co-stimulatory 
molecules) to the contact zone130. All these rearrangements support the concept of formation of 
synapses for intercellular information exchange among immune cells. The main difference of 
IS and neuronal synapses, is the short duration of cell-cell contact of IS when compared to the 
ones of neurons or epithelial cells that can last for years131. This short interaction requires a 
very well organized dynamics of formation. 
It was only twenty years after the term immunological synapse was coined that the 
development of lipid bilayers and advancement in microscopy, allowed the definition of 
molecular compartments of IS. In its original definition, the mature IS was described as a 
specialized signaling domain formed at the contact site between T cells and APCs, 
characterized by large-scale molecular segregation of surface receptors and signaling 
components132. Furthermore research lead to an expansion of this term, where the IS comprises 
a multitude of structures, with a common feature of having mediators of intercellular 
communication75.  
 
It is now well established that different types of contacts between immune cells and the 
subsequent type and amount of signal that is generated is determined by several factors:  
1. Contact duration (short vs long termed interactions) 
2. Physical dynamics (dynamic vs stable) 
3. Strength of signals transmitted (weak vs strong) 
4. Presence vs absence of secretion 
5. Activation state of both T cell and the APC 
6. Type of environment in which the interaction is taking place 
 
 
1) Immunological synapse structure: 
In a review published in 2004, P. Friedl's 133 team classified the different types of IS into 5 
groups (Figure -14): mono-centric (stable), secretory, multi-centric, non-segregated and 
dynamic synapse. Even if a specific type of synapse is observed in certain conditions, it is 
important to note that the kinetic observation of living cells points out variable molecular 
rearrangement that can result into different or incomplete structures.  
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 a. mono-centric or mature synapse: “bull eye” 
 Spatial organization: 
Since 1990's, T. Springer et al. proposed that molecular complexes of various sizes can be 
segregated into different domains located at the interface between T cell and APC. They 
proposed a model in which the contact site is enriched with TCR/pMHC complexes and 
CD2/CD58, while bigger size molecules, such as LFA-1 and CD45, are aggregating at their 
periphery134. Thanks to advances in microscopy studies, tri-dimensional molecular organization 
of the synapse has been revised through the detailed study of protein spatial segregation 
between CD4 T cell and antigen loaded B cells 132. Obtained images confirmed and deepened T. 
Spriger’s hypothesis. In its original description IS was composed of distinct areas called SMAC 
(Supra Molecular Activation Cluster). cSMAC (central SMAC) is synapse's heart, and 
correspond to TCR aggregation. Molecules known to be recruited to cSMAC, at least 
temporarily, includes: CD28135, CD2136, CD4 (transient)137, CD45 (transient)138 and CTLA-4125. 
CD28 co-stimulation molecule enrichment at cSMAC permits to facilitate its synergistic action 
with TCR. pSMAC (peripheral SMAC) is the area that directly surrounds the cSMAC. It is 
composed of accessory proteins, such as LFA-1 and talin (actin binding protein). Later, a third 
structure called dSMAC (distal SMAC) was described. It is the most peripheral area composing 
the synapse. It contains long and highly glycosylated molecules, that are excluded from the 
synapse core, such as the CD45 and CD148 phosphatase, and the CD43 molecules known to 
interact with actin cytoskeleton through ERM molecules (ezrin, radixin, moesin) 139,140 141. In 
vivo observation of T cells in lymph nodes showed TCR aggregation and CD43 exclusion from 
the IS142 102 (Figure -15). 
This surface protein segregation, is paralleled with an intracellular reorganization of 
intracellular signaling components. Molecules such as PKC-, LCK or Fyn, are aggregated at 
cSMAC level132,143. However, cSMAC formation is not required for productive TCR 
engagement, since TCR-mediated signal transduction precedes the formation of mature IS143. 
 
Mono-centric immunological synapse serves as a reference since it was the first synapse that 
was described. “Immunological synapse” and “immunological mature or mono-centric 
synapse” terms are often mixed up, however considering the following two facts may help 
avoiding confusions. First, if a mature synapse is possibly formed, preceding structure is also a 
synapse where information between two cells is already exchanged. Second, most synapses 
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rarely adopt a concentric structure, and rather form multifocal ones with several TCR 
aggregates75. 
                                                          
Figure I-15. Immunological synapse. Cartoon summary of the organization of receptors showing the relative positions of the cSMAC, 
pSMAC, dSMAC, centrioles, actin and microtubule cytoskeletons, and secretory lysosomes at the immunological synapse in cross section and 
across the area of cell contact. Adapted from  Griffiths GM J Cell Biol 2010144. 
 
IS Formation dynamics: 
Since 1999, the use of pMHC embedded into lipidic bilayers allowed the analysis of IS 
formation dynamics. During the first 30 seconds, the T cell stops its migration, and then a wide 
central area composed of ICAM-1 aggregation appears.  At the same time, the engagement of 
pMHC and TCR is detected only in peripheral contact area104. This organization is therefore the 
inverse of the one previously described as mature immunologic synapse132. However, this 
engagement is clearly functional because an increase of [Ca+2]i is detected. Moreover, in 2002, 
J.Lee et al. observed ZAP-70 and LCK phosphorylation at the IS periphery before cSMAC 
formation143. During the following five minutes, engaged-TCRs in periphery migrate to the 
center of the contact area, while ICAM-1 moves to the periphery104,143. This spatial 
organization remains stable for hours. During this IS construction phase, several other receptors 
are submitted to dynamic changes between different areas of IS. For example, CD4 co-receptor 
rapidly aggregates at cSMAC just after cell-cell interaction, then relocates in the pSMAC after 
5 to 10 minutes of interaction137. Same behavior is described for CD45 phosphatase138,139. 
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Initial central enrichment of CD45 could explain how CD45 can activate LCK through its 
dephosphorylation before being exclude from the TCR signaling area53. TIRF microscopy 
provided new information on a smaller scale about molecular remodeling at the IS structure. In 
T cell interacting with lipid bilayer containing MHC and ICAM-1, the TCR and its associated 
molecules gather at the level of microclusters (MC) 145,146. The number of detectable MC by T 
cell is between 100 and 300 and this number increases with the increase of antigen 
concentration146,147. TCR microclusters (MC) represent the main place of initiation and 
maintenance of TCR-induced signaling147,148. Indeed, in parallel with TCR signaling, ZAP-70, 
LAT molecules, Grb2 or SLP-76 MC are also forming149. These MC migrate from the 
periphery of the IS to the cSMAC, allowing the accumulation of TCR into the synaptic center. 
It is important to note that even after the formation of the cSMAC, MC continue to form on the 
peripheral area148 and that they are the privileged place of the TCR signaling. 
 
 b. secretory synapse  
It has been described that the mono-centric IS is adapted to the secretion of soluble factors 
required for specific function of effector lymphocyte93. In this type of synapse, pSMAC is 
composed of LFA-1 and talin, which forms a ring of adhesion molecules, whereas cSMAC is 
divided into two parts: a TCR enrichment part and a secretory domain co-localizing with T cell 
secretion machinery150,151. This area is devoid of actin and it forms, a sort of gap between the 
two membranes152. The secretory synapse is therefore adapted to CTL intercellular granules 
release. 
Th lymphocytes secrete vesicles containing cytokines such as IL-2, IL-4, IL-5 and IFN- 
towards the APC in a polarized fashion,142,144,153-155. Similarly, CTL and NK cells polarize their 
lytic granules, containing perforin and granzymes, to their target cell144. 
The definition of secretory synapse as a specialized mature synapse is controversial because 
several teams have shown that CTL cytotoxicity does not require formation of a mature IS40,156 
157. In particular the team of S.Valitutti put forth the notion that CTL interacting with cognate 
target cells exhibit a dual activation threshold reflecting the formation of two distinct IS: the 
lytic synapse and the stimulatory synapse. The term lytic synapse was coined to refer to the 
polarization of the lytic machinery detectable both at low and at high antigen concentrations. 
The term stimulatory synapse was coined to refer to the large scale molecular segregation of 
surface molecules and signaling components characteristic of a mature IS and occurring only 
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with target cells providing the strong antigenic stimuli required for activation of cytokine 
production107,156. The team also demonstrated that the IS formed by CTL are endowed with a 
high degree of plasticity. Indeed CTL form multiple synapses with different target cells 
encountered simultaneously. Although CTL establish preferential “liaisons” with target cells 
offering a strong antigenic stimulus (stimulatory synapses) they simultaneously kill target cells 
offering a low antigenic stimulus (lytic synapses158). More recently, the team also showed that 
lethal hit deliver by CTL can occur extremely rapidly (within 30-40 seconds after CTL/target 
cell conjugate formation) thus it can precede mature IS formation and MTOC repolarization 
towards the target cell (both events requiring a few minutes to be accomplished,159). Yet, this 
work was done in CD8+ T cells and does not exclude that control of cytokine release might be different 
in CD4+ T cells. 
 c. multi-centric synapse 
During antigen recognition, there may be an interruption in the molecular mechanism leading 
to the formation of the mono-centric IS, resulting in the generation of a so-called immature or 
multi-centric IS. This synapse is characterized by formation of several aggregates of TCR/CD3 
complexes next to area enriched with LFA-1. These molecular clusters are dynamic and can 
merge or split during the interaction. It would be simplistic to think that this multi-centric 
synapse results from a failure of a mono-centric synapse formation. In fact, it has been reported 
that concentric mature IS is not the prototypical structure; T cell even during prolonged contact 
with APC can establish synapses with a non-concentric structure. For instance, a multi-centric 
structure is observed at contact site between thymocytes and thymic epithelial cells160,161 during 
thymic selection. A multi-centric IS also forms during the interaction between naive T cells and 
DC162. 
 d. non segregating synapse 
In the case of immunological non segregating synapse, TCR and signaling molecules are 
enriched at contact zone but exhibit a diffuse pattern. This synapse is observed at least under 4 
different physiological situations. First, this structure is formed when a T cell interacts with an 
APC displaying on its surface no specific antigens (for instance, T cell scanning of APC within 
a secondary lymphoid organ)163. This non-specific synapses have short-term and long-term 
consequences. They induce a moderate increase in tyrosine phosphorylation as well as a small 
increase in intracellular calcium concentration, that then turn into a modest proliferation and 
significantly prolonged survival. This phenomenon could therefore have an important role in 
the maintenance of naive T cells stock in vivo. The non-segregating IS is also observed during 
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the initial phase of contact before formation of segregating IS102. Thirdly, naive CD8+ T cells 
can be activated and then proliferate after generation of a non-segregating synapse164. Finally, 
IS forming between naive T and DC can also be categorized in this type of synapse163,165.  
 e. Dynamic synapse or kinapse 
In some cases, T cells are capable of forming dynamic synapses, i.e. to integrating activation 
signals while migrating (refer to page 32-34 109) 
Cell destinies related to type of formed-synapse have been summarized in Figure -16.   
 
Figure I-16. T cell/APC interaction define T cell destiny. The interactions of T cells with different antigen-presenting cells (APCs) in the 
thymus (a), secondary lymphoid organs (b–f) and peripheral tissues (g) lead to T-cell development, maintenance, activation, and helper and 
effector function. The particular outcome depends on the contact mode and signal intensity. Stable interactions result from long-lived one-to-
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one conjugation of a T cell and an APC, whereas short-lived contacts allow T cells to transit between different APCs. a) Different strengths of 
peptide–MHC–T-cell-receptor (TCR) binding might determine a range of stable and dynamic binding during positive selection (right panel), 
and mostly stable binding during negative selection (left panel). b) Serial encounters support T-cell homeostasis in the absence of agonist 
peptide. c) Serial encounters support the initial activation of naive T cells by agonist-peptide–MHC complexes. d) For initially activated T-cell 
blasts, contact stabilization supports cytokine release from the APC and maturation of T cells to effector T cells. e) Serial engagement that does 
not result in a stable phase has been implicated in tolerance induction. f) T helper (TH) cells establish a stable immunological synapse with 
activated B cells and release cytokines that promote the differentiation of B cells into plasma cells. g) Cytotoxic T lymphocytes (CTLs) that 
receive a strong signal bind stably to target cells and induce target-cell killing by releasing the contents of lytic granules. T cells in which signal 
transduction is occurring are depicted in green. IL, interleukin. Adapted from Friedl P 200593 
 
2) Immunological synapse biological function 
Since its discovery, mature immunological synapse and its various components (cSMAC, 
pSMAC and dSMAC) have been proposed to be involved in several biological processes.    
 Role of immunological synapse in initiating T cell signaling 
Microclusters, each composed of minimum 11 to 17 TCR molecules, are the smallest signaling 
unit known to date148.  Interestingly, based on several studies it has been suggested that TCR 
microcluster formation do not necessarily require antigen recognition. High resolution 
microscopy techniques further enabled visualization of TCR pre aggregation at the surface of 
unstimulated effector cells166-168 and of naive T cells169. Antigen stimulation did not change the 
size of the MCs and the number of TCR molecules present per MC. Moreover TCR MC at the 
surface of the T cell has been reported to slightly vary in terms of composition, independently 
of antigenic stimulation. While both non-phosphorylated form of GRB2 (growth factor receptor 
band 2) and LAT adapter molecules are present in preexisting TCR MCs, upon TCR 
engagement the number of GRB2 molecules, unlike LAT, increases in MC.  
The above reported results indicate that the smaller signaling unit observed at the moment in T 
cells preexist signaling. Taken together with result discussed in page 38 (IS formation) in which 
I reported the observation by Lee et al. that signaling starts at the periphery synapses before 
molecular segregation143, these results strongly suggest that molecular segregation at the IS is 
rather a consequence  than the cause of TCR signaling. 
 Role of immunological synapse in tuning T cell signaling 
The proposed role of cSMAC in sustaining TCR-mediated signaling has been a controversial 
issue for prolonged time. Recently a model has been proposed suggesting that cSMAC 
formation can serve as a controller of T cell signaling by amplifying weak signals and by 
attenuating strong ones. Cemerski et al 170reported that both signaling and TCR degradation can 
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take place in cSMAC and the balance between the two depends on the strength of antigenic 
stimulation and on antigen quality 170-172 (Figure -17). 
                                               
Figure I-17. TCR Signaling can occur both at the pSMAC and the cSMAC. After T cell-APC conjugation, signaling (shown as tyrosine 
phosphorylation, green) initiates in the periphery of the IS both at high and at low antigenic stimulation. TCRs are internalized and degraded in 
the IS center (red). With high antigen stimulation, signaling continues throughout the IS. Because TCR degradation rate in the cSMAC is high, 
tyrosine phosphorylations are not easily detected. However, signaling does occur in the cSMAC as detected by PI3K activation (see text). At 
low antigen densities, sustained tyrosine-phosphorylation events are more pronounced in the cSMAC where they coexist with a moderate rate 
of TCR degradation. Adapted from Valittuti S 2008 172. 
 
 Role of immunological synapse in the termination of T cell signaling 
Involvement of cSMAC in extinguishing signal has been confirmed by the use of lipid bilayers. 
Inserting physical barriers in these lipid bilayers generates spatially mutated synapses where 
cSMAC formation is inhibited173. T lymphocytes are forced to form multifocal synapses with 
TCR microclusters associated with patches of molecules phosphorylated in tyrosine. In these T 
cells, calcium signaling is significantly higher confirming the hypothesis that cSMAC is 
involved in inhibition of signaling via TCR.   
 Role of immunological synapse in privileged intracellular dialogues. 
It has been proposed that IS creates a sort of physical barrier that can prevent dispersion of 
secreted molecules in a polarized manner and would therefore participate in privileged 
intercellular communication by limiting the effect of these soluble factors on adjacent cells109. 
Accordingly, there is an inward movement of actin filaments towards cSMAC that guides 
molecules such as TCR and LFA-1 into the center of synapse174. Such a dynamic flux thus, 
could allow the entry of molecules more in the center of the synapse rather than the 
periphery109. The presence of sort of synaptic baskets avoiding the leakage of lytic molecules 
outside of the IS has been also reported at CTL/target cell lytic synapses175. 
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3) Immunological synapse and secretory machinery 
 Microtubule organization center 
The discovery of T cell MTOC polarization towards APC occurred in the 1980s. First 
observations were made in CTL; it was shown that target cell killing by CTLs is a very specific 
and unidirectional phenomenon. G. Berke’s team hypothesized that the unidirectional killing 
activity is at least partially related to the specific polarized re-arrangement of cytoskeleton. 
Their results suggested that CTL interact with their target cells via the membrane region close 
to the MTOC127 CTL plasma membrane proximal to the MTOC is particularly active in 
forming stable intercellular contacts, resulting in CTL-target conjugation, and that subsequent 
modulation of the microtubular system of the CTL may be related to the cytolytic response and 
to detachment of the effector cell127. 
Two years later, A.Kupfer published a first of a long series of articles on the phenomenon of 
polarization of T lymphocytes. They demonstrated that T cells polarization is an active 
mechanism: the MTOC and the Golgi apparatus of CTLs and murine NK cells re-orient 
following specific contact with a target cell126,128,176. Two years later, the same team showed 
that CD4+ T cells can, also, polarize their secretory machinery towards APC in an antigen-
specific manner129. This phenomenon has then been widely confirmed in human T cells177. 
More recently, the study by J.Kuhn et al. showed that once located at the synapse, MTOC is not 
static but oscillates laterally over a distance not exceeding 2 µm. These oscillations may be 
caused by opposing forces and is probably generated by molecular motors anchored at pSMAC, 
such as dynein178.  
One major characteristic of MTOC polarization is its rapidity as it occurs as early as about 2-3 
minutes after contact with APC and before formation of the synapse41,179. Therefore, IS 
formation is not necessary to this polarization. In fact, CD4+ T lymphocytes are able to polarize 
their Golgi apparatus under conditions where the synapse formation is inhibited by anti-CD2 
blocking antibodies180. In addition, this process is highly dynamic and selective allowing Th 
cells to polarize selectively towards the APC offering the strongest antigenic stimulation179. 
 Lytic granules 
The polarized secretion of lytic granules by CTL was first observed during the investigation of 
their MTOC polarization176. This process of lytic granule polarization is highly dynamic158. The 
multi-polarization of the lytic granules to different targets was also observed in vivo in a mouse 
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model, during an interaction between CTLs and neurons181. This phenomenon of "multiple 
killing" is however questioned by other studies as discussed later. 
There are major difference between secretion of lytic granules and secretion of cytokines 
because of their time kinetics. In fact, CTLs release their lytic granules as early as few minutes 
or seconds after interaction with the target cells159. The CTL can therefore undergo several 
cycles of antigenic recognition, polarization and cytotoxicity. In addition, a recent study 
showed that CTL can rapidly synthesize new stocks of perforin182 and consequently kill several 
targets. For this reason CTLs are called serial killers. In contrast, cytokines are released a few 
hours after antigenic stimulation as their production requires, most often, gene transcription46.  
Lytic granules biogenesis: 
Granules biogenesis process was unveiled in part through the study of two genetic diseases: 
Hermansky-Pudlak syndrome type 2 (HPS2) and Chediak-Higashi syndrome (CHS); patients 
with these diseases are mutated in the gene encoding AP-3 (adaptor protein 3) and in the gene 
encoding LYST respectively. LYST is a cytoplasmic protein that regulates the lysosomal 
trafficking and AP-3 is necessary for the transport of proteins from the trans-Golgi to 
lysosomes or endosomes. The CTL of these patients have a defect in polarization of granules to 
IS. Lytic granules are also larger than in normal183. Moreover, the deficient AP-3 T cell granules 
seem unable to migrate along microtubules184. This suggests that AP-3 may be required for the 
expression of one or more proteins involved in the dynamics of the granules along 
microtubules. LYST and AP-3 proteins are therefore involved in the early stages of the 
formation and transport of lytic granules. 
During their biogenesis, lytic granules are loaded with lethal molecules namely perforin and 
granzymes. It has been suggested that the distal end of the C-terminal region of perforin 
encodes a highly efficient ER export motif that is required for protein delivery from the ER to 
the granules 185. Deletion of the last 12 amino acids or even a mutation of the last C-terminal 
residue, tryptophan, results in the retention of functional and stable perforin in the ER and in 
the death of CTL owing to perforin pore-forming activity 185. This notion is further supported 
by the observation that CTL that express an inactive perforin variant, which cannot properly 
bind to Ca2+ (required for perforin function) are protected from the toxic effects of mutations of 
the C-terminal region 185. Accordingly, an explanation for cell survival during perforin 
synthesis is that it is rapidly exported from the ER, thus minimizing the concentration of active 
perforin in the ER at any given time186. Furthermore, it is notable that N-linked glycans are 
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essential to enable the delivery of perforin from the Golgi to secretory granules. The exact 
carrier (or carriers) of nascent perforin are unknown185; however, this process may involve 
members of the constitutive protein trafficking machinery (such as lysosome-associated 
membrane glycoprotein 1 (LAMP1)187  or the mannose 6-phosphate receptor) 188.  
Mechanism of lytic granule polarization: 
Upon CTL/target cell interaction, the CTL quickly polarizes its MTOC and its Golgi 
apparatus127,189 as well as its lytic granules towards the target cells (Figure -18)176. Lytic 
granules contain proteins such as perforin, granzyme and Fas-L. This polarized granule 
secretion consists of several steps: polarization towards the synapse, followed by their 
anchorage and fusion with the plasma membrane allowing the release of the contents of the 
granules within the synaptic cleft. 
                                      
Figure I-18. Mechanism of lytic granule polarization. Recognition of the target MHC class I molecules bound to peptide antigen occurs via 
the TCR. Once the TCR is engaged, the most proximal signaling molecule to be recruited is LCK (shown in green). The centrosome (γ-tubulin, 
yellow), which is normally perinuclear, polarizes towards the synapse and docks at the plasma membrane. The granules (LAMP-1, red) migrate 
towards the centrosome, where they dock and fuse with the plasma membrane, releasing their contents into the synaptic cleft, causing target 
cell destruction. Adapted from Griffiths and Jenkins 2014190. 
 
MTOC and LG parallel polarization: 
It is generally accepted that MTOC polarization governs granules secretion by CTL. 
Accordingly it was reported that, nocodazole-treated CTL (inducer of microtubules 
depolymerization) were unable to polarize and exhibited a reduced cytotoxicity126. Granules 
transit along the microtubules towards the negative end191, to be released in the center of the 
synapse formed with target cells192. Thus according to this model, centrosome plasma 
membrane contact seems required191. 
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Two ways of lytic granules secretion in a MTOC-dependent fashion have been reported: a fast 
way and a slow one. Both are regulated according to signaling kinetics. Strong signaling leads 
to a rapid enrichment of granules at MTOC location followed by a rapid MTOC re-positioning 
and granule secretion while weak signals induce a slow recruitment of granules via their 
migration along the microtubules from the periphery to the IS175. Recently, G. Griffiths’s team 
has shown that polarization of the centrosome and lytic granules may be dissociated193. Indeed, 
through the use of OT-1 mouse and antigenic ligands of varying functional avidity for TCR, 
they showed that low and high avidity interactions induce polarization of the centrosome while 
only high avidity interactions allow the polarization of the lytic granules. 
However, this one-way vision of the polarization of the lytic granules disagrees with studies 
showing that the CTL can simultaneously kill several cells target158,181. 
The study by J.Kuhn et al. provided a first explanation for this phenomenon of “multiple 
killing” 178. They showed by time-lapse microscopy, that when a CD8+ LT is in contact with 
two targets, its MTOC can oscillate from one cell to the other thus inducing lysis of both. 
However, recently S. Valitutti Lab clearly showed that lytic granules can be secreted 
independently of MTOC polarization.  In a first approach by using TIRF microscopy, they have 
shown spatio-temporally dissociation of MTOC and lytic granules in CTLs stimulated with 
immobilized pMHC. This result was confirmed by studying by time lapse microscopy 
CTL/target cell conjugates in which lytic granule secretion preceded microtubule polarization 
and was detected during the first minutes or even second after initial cell-cell contact. 
Surprisingly, inhibition of microtubule organizing center and centrosome polarization impaired 
neither lytic granule release at the CTL synapse nor killing efficiency159. This MTOC-
independent secretion of lytic granules of CD8+ T lymphocytes is compatible with the 
multidirectionally secretion of cytokines (TNF and MIP-1) exhibited by CD4+ T cells as 
described by M.Huse et al.154. It is tempting to speculate that CD8+ T cells are endowed of a 
first mechanism that allows them to secrete granules in a polarized manner towards the synapse 
and another allowing them to secrete to a second target cell without forming equally and 
simultaneously a stimulatory synapse with it. In this context, it is interesting to note that 
cytotoxic molecules such as perforin may also be secreted by a granule independent pathway182 
194. 
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Lytic granules anchorage: 
In eukaryotic cells, vesicular trafficking towards specific cellular locations is handled by 
families of protein highly conserved during evolution. In the center of this process are the 
SNARE proteins (soluble N-ethylmaleimide-sensitive factor accessory protein receptors). 
Typically, one R-SNARE protein residing on the vesicular membrane and three Q-SNAREs 
(Qa, Qb, and Qc) proteins residing on the target membrane can span the distance between two 
membranes, forming a parallel four-helical bundle that catalyzes membrane fusion195. When 
forming a SNARE complex, SNARE proteins demonstrate remarkable specificity for their 
cognate SNARE partners, resulting in highly specific combinations of SNAREs at different 
steps of vesicle fusion196,197. Different R and Q-SNARE have distinct cellular locations and 
their interactions are regulated by various accessory proteins that add a higher level of 
specificity. Many studies reported involvement of SNARE proteins in the mechanism of lytic 
granules fusion with the plasma membrane at synapse198. However, lytic proteins such as 
perforin, granzymes A and B and Fas-L, whose expression can be induced by TCR engagement 
can be also secreted directly from the Golgi apparatus at the IS182making it difficult to study the 
proteins involved in the vesicular pathway194 . 
Proteins involved in polarized granules trafficking into the IS and in secretion process have 
been discovered primarily in melanocytes due to genetic diseases causing immunodeficiency 
associated with an albinism188,199,200. However, it is now clear that even though there is a 
similar pattern of secretory gene expression shared among LT and melanocytes, the relative 
importance of each molecule is different within two cell types. Among other possibilities, these 
differences can be explained, by the fact that secretion occurs in opposite directions. In 
melanocytes, the MTOC is in the center of the cell and it is the positive ends extremity of 
microtubules that are connecting vesicles to the membrane via actin. In this case, the vesicles 
migrate to the positive end of microtubules. On the other hand, in T cells, the MTOC is 
polarized to the membrane and vesicles move towards the negative ends of microtubules. 
Melanocyte secretory machinery will be more detailed in page 68 (melanocyte vesicular 
trafficking). 
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Lytic granule Fusion: 
Two studies have identified the PKC requirement for polarization and lytic granule exocytosis. 
PKC  deficient murine CTLs have a defect in these 2 processes despite a correct MTOC 
polarization. This defect in lytic granules polarization results in a loss of the cytotoxic capacity 
of these CTLs201,202. The PKC kinase activity is therefore involved in the early steps of the 
lytic granule release. 
Most of our knowledge on lytic granule trafficking came from the study of genetic diseases 
causing FHL (Figure -19). Rab27 deficient CTLs can polarize their granules with the MTOC 
towards the synaptic zone but they cannot be anchored and fused to the plasma membrane 150 . 
Moreover, Rab27a is not constitutively associated with the lytic granules in human cytotoxic 
lymphocytes, but is recruited to them in response to T cell stimulation. Over-expression of 
Rab27a-GFP in CTLs did not show colocalization of Rab27a and perforin, until immediately 
before degranulation203. Rab27a may therefore be required for the dissociation of lytic granules 
from microtubules as was described for melanocytes 200. While the function of Rab27a in CTLs 
appears to be mainly related to vesicle docking at the plasma membrane, the GTPase activity is 
also involved in the regulation of vesicle movement at the plasma membrane204. Decreased 
expression of Rab27a via siRNA treatment resulted in increased motility of granules in the 
cytoplasm of NK cells, and fewer and less mobile lytic granules reaching the plasma 
membrane, indicating that Rab27a is required for retention and cytoskeleton-dependent 
directional movement of lytic granules at the plasma membrane. Two studies show that the 
proteins Slp1 and Slp2 (synaptotagmin-like proteins) interact with Rab27a allowing granules to 
anchor to the membrane205,206. Rab27a complex with Kinesin1 and slp3 also mediates the 
terminal transport of lytic granules to the IS 207. 
Protein Rab27a interacts with Munc13-4 protein that is known to regulate initial fusion steps. 
Munc13-4 deficient CTLs are indeed able to polarize their lytic granules and to anchor them to 
plasma membrane at IS but cannot fulfill fusion step208. Munc13-4 maintains the docking 
SNARE in an open conformation; without this molecule the fusion is impossible. Syntaxin 11 
defect does not prevent polarization but the exocytosis of the granules. It can be 
counterbalanced by stimulation via IL-2 suggesting that this stimulation may induce the 
synthesis of proteins that overcome the defect, explaining thus the lesser severity of this form 
of deficiency209. It is assumed that Munc13-4 permits the conversion of syntaxine11 into its 
open conformation. Munc18-2 is the main partner of Syntaxin 11 (Stx11) in CTL. Complexes 
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Munc18-2/Syntaxin 11 at IS, probably regulated anchoring and formation of the SNARE 
complex required for the fusion step.  
The vesicle-associated membrane protein (VAMP) family typically mediates fusion of vesicles 
with cognate, membrane-associated SNARE complexes. It is yet unclear how distinct VAMPs 
regulate cytotoxic granule trafficking and fusion for target cell killing. Accordingly, it has been 
reported that VAMP2 colocalizes with cytotoxic granules and that VAMP2 knockout mice 
display defective cytotoxic granule exocytosis210. VAMP4, and VAMP7 also co-localize with 
cytotoxic granule proteins and their siRNA-mediated knockdown in a human natural killer cell 
line resulted into deficit of perforin-mediated cytotoxicity211. Furthermore, in mice, VAMP8, 
an R-SNARE associated with exocytosis of secretory vesicles in multiple immune cell types, 
colocalized with granzyme B. Vamp8 knockout mouse CTLs display reduced granule 
exocytosis and impaired target cell killing212 213. Recently, a study on human primary 
lymphocyte using SIM (Structured illumination microscopy) and TIRF microscopy, showed 
that VAMP8 is associated with recycling endosome compartments rather than with cytotoxic 
granules214. In addition the authors observed a rapid accumulation and fusion of recycling 
endosomes then fused at IS preceding lytic granule arrival. Inhibition of VAMP8 expression 
compromised both recycling endosome and cytotoxic granule fusion, revealing a VAMP8-
dependent fusion step between recycling endosomes and the plasma membrane that brings 
Stx11 close to the immune synapse for cytotoxic granule exocytosis.  
G. de Saint Basile proposed a model to describe lytic granules exocytosis at IS by gathering all 
the data acquired through the study of genetic diseases and the neuronal synapse (Figure -
20)188 . 
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Figure I-19. Genetic diseases giving rise to familial hemophagocytic lymphohistiocytosis (FHL). At the IS, secretory lysosomes dock, 
prime, and undergo fusion at the plasma membrane into a small secretory cleft. Perforin (blue) forms a pore in the target cell allowing entry of 
granzymes (brown), which trigger apoptosis. Loss of perforin leads to FHL2. Rab27a (deficiency causes Griscelli syndrome 215) and Munc13-4 
(deficiency causes FHL3 209) associate with granules and are required for docking and priming, respectively. Syntaxin 11 (deficiency causes 
FHL4 216,217) and Munc18-2 (deficiency causes FHL5) are thought to be required for fusion by assisting formation of the final SNARE 
complex. Adapted from Lieberman J 2013 218. 
 
 
Figure I-20. Lytic granule exocytosis. Following antigen recognition and proximal signaling events, cytotoxic granules are polarized towards 
the CTL–target cell contact site where the immunological synapse forms. Actin filaments are cleared away from the site of secretion. Mature 
cytotoxic granules dock at the plasma membrane through the interaction of RAB27a with SLP1 or SLP2. In addition, cytotoxic granules 
interact with a docking complex formed of MUNC18-2 and Syntaxin 11 in the closed conformation. Docked vesicles are then primed by 
MUNC13-4, which probably triggers the switch of Syntaxin 11 from a closed to an open conformation. A SNARE complex then forms between 
a vesicle membrane SNARE, possibly VAMP7 and/or VAMP8, on one side and the target membrane SNAREs Syntaxin 11 and SNAP23 on the 
other side. Completion of the fusion reaction occurs when MUNC18-2 clasps across the zippering four-helix SNARE complex bundle. 
Formation of the SNARE complex precedes membrane fusion.  Adapted from de Saint basil and Fischer Nat Rev188 
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 Vesicular recycling at immunological synapse 
In addition to the polarization of lytic granules, cytokine containing vesicles and other types of 
vesicles such as recycling endosomal vesicles are also translocated to the IS. This pathway 
allows the internalization of proteins and their re-orientation to plasma membrane or to 
lysosomes in order to induce their degradation.  
In 2004, M.Alonso et al. showed a polarization of transferring receptor and of recycling vesicle 
at the IS219. During the same year, A. Alcover’s team demonstrated that TCR accumulation in 
cSMAC occurs through polarization of recycling endosomes containing TCR and that this 
phenomenon is guided by the polarization of the MTOC. Thus, colchicine treatment of T cells 
that induced inhibition of the polarization of recycling vesicles resulted in a defect in the 
accumulation of the TCR at the synapse. Proteins Rab35 and EP164C (a Rab GTPase activating 
protein (GAP) that activates Rab35) co-located with TCR in recycling endosomes and were 
involved in polarization of these vesicles at IS. Their inhibition induced alteration in IS 
formation220. 
As discussed earlier, CTL/target cell interaction induces lytic granule synaptic polarization. 
CTL degranulating is visualized through appearance of lysosomal associated membrane 
protein-1 (LAMP-1) at the cell surface. Study conducted by Liu et al. in 2009 using TIRF 
microscopy revealed that Lamp-1 is accumulated in a large and spatially stable cluster that 
overlapped with a site of membrane internalization. Perforin-containing granules were 
juxtaposed to an intracellular compartment where exocytosed LAMP-1 was retrieved. The 
authors thus, concluded that cytotoxic immune synapses include a central region of 
bidirectional vesicular traffic, which is controlled by integrin signaling221.  
Interestingly, in 2002, Henkart lab provided evidence that lysosomal exocytosis at the synaptic 
area is accompanied by the exposure of Cathepsin B (a cystein protease) that confers protection 
to CTL from their own-secreted perforin. This notion was later questioned by Baran et al in 
2006222. These authors claimed that Cathepsin B deficient mice did not reveal a lack of 
protection of their CTLs upon target cell killing and that perforin is a poor substrate of 
Cathepsin B223,224). 
Finally such a polarized lysosomal trafficking associated to MTOC re-polarization has been 
also described in B cell synapses during antigen extraction and processing. It depends on the 
function of small GTPase Cdc42 and aPKC .  These polarized secreted lysosomes create an 
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acidic extracellular microenvironment at the cell interface facilitating antigen extraction by 
lysosomal proteases225 .  
 
 
Cytotoxic T cells 
1) Activation and Differentiation of Naïve CD8+ T cells into CTLs 
Naive CD8+ T cells that have not previously seen antigen do express neither granule effector 
molecules or nor receptors, and are incapable of cell-mediated cytotoxicity. The activation 
process of the CD8+ T cells starts when naive T cells recognize their specific antigen presented 
by an APC in the context of MHC class I molecules in the secondary lymphoid organs. This 
recognition stimulates the TCR and provides the first signal of activation process and gives 
specificity to the response. The second signal is provided by the engagement of co-stimulatory 
molecules of CD8+ T cells with their ligand molecules on APCs. Contrary to the first signal, 
this signal is nonspecific but is crucial to the development of an effective CD8+ T cell mediated 
immune response. Absence of such interactions may lead to T cell anergy or death.  
Moreover, there is evidence supporting the idea that CD8+ T cell proliferation and 
differentiation, for establishment of an optimal response, can be influenced by the environment 
(third signal). The 3rd signal provided by inflammatory cytokines, act as a ‘switch’ that 
determines whether Ag and co-stimulatory signals lead to tolerance (deletion/anergy), or in 
their presence, to a productive response leading to strong effector function, CD8+ T cell 
survival and memory T cell generation226. This signal is induced by exogenous inflammatory 
and antiviral cytokine227 provides a means for a CD8+ T cell that encounters Ag to determine if 
there is ‘danger’ present, and to respond accordingly. For instance in vitro and in vivo 
experiments identified IL-12 and IFN / as predominant sources of signal 3 for CD8+ T cells 
responses to a variety of stimuli 226.  
Combination of these 3 signals causes clonal expansion of a specific CD8+ T cell population 
(up to 1000 fold increase) and induces their differentiation into cytotoxic T cells (CTL).  While 
this clonal expansion guarantees presence of sufficient amount of antigen specific T cells for 
eradication of the invading pathogens or the cancerous cell, It is also controlled by a 
contraction phase during which the number of cells declines and only 5-10% of these antigen 
specific cells remains in order into develop the memory cells. These memory cells 
downregulate expression of cytotoxic effector proteins, but the kinetics of downregulation 
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varies with the molecule and depend on of the immunostimulatory environment227. Memory 
phase consist of long-lived antigen specific cells that are ready to respond in a faster and 
stronger manner upon second encounter with the same pathogen. 
 
 
2) Effector functions of CTLs: 
Upon activation, within about 5 days CD8+ T cells differentiate into effector CTLs equipped 
with effector molecules. During this time period, they also down-regulated the expression of 
adhesive molecules and chemokine receptors (such as CD62L and CCR7) that retain them in 
the LN and in the mean time they acquire receptors that allow their traffic towards site of 
infection or of tumor invasion. For instance CD8+ T cells that are activated within the skin-
draining inguinal lymph nodes preferentially up-regulate functional E-selectin and P-selectin 
ligands as well as CCR4 and/or CCR10, which are associated with homing to skin228. 
CTLs are one of the most effective players of immune system in controlling the threats of 
intracellular infection and cellular transformation by destroying infected or cancerous cells. 
This elimination is targeted through contact dependent and independent pathways. 
The main axis of CTL cytotoxicity is mediated by perforin/granzyme pathway and to lesser 
extent the Fas-FasL mediated pathway. These mechanisms are highly specific and require an 
intimate cell-cell contact.  
 Contact dependent target cell destruction: 
Granzyme and perforin-mediated cytotoxicity  
Lytic granules are specialized late endosome/lysosome, containing multiple proteins:  
o Membrane-perturbing proteins: Pore-forming molecule “perforin” and “granulysin”. 
o Granule serine proteases: in humans 5 “granzymes” have been identified: granzyme A, 
B, H, M and K.  
o Proteoglycan matrix: serglycin 
o Perforin-inhibitor: calreticulin 
o Lysosomal enzymes or Cathepsin with roles in granzyme processing (Cathepsin C) and 
protecting CTLs against perforin (Cathepsin B)  
o Stored T effector molecules: Fas Ligand  
Upon CD8+ T cell activation, the transcription of the genes encoding perforin and granzymes 
starts. De novo synthesized proteins are non-functional and need to undergo post-translational 
modifications in order to acquire their biological active form. Once modified, these molecules 
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are assembled in lytic granules. Lytic granules have a low pH (estimated around 5.5-6), that 
allows to keep granzymes in an inactive state and contain lysosomal-associated membrane 
glycoproteins (LAMPs) 1, 2 and 3229. These molecules are up-regulated upon CD8+ T cell 
activation and are associated with exocytosis of lytic granules230.  
 
The perforin/granzyme dependent pathway is also shared by NK cells and is calcium dependent 
since perforin needs to be in a calcium-containing milieu to function186. Since lytic granules are 
among the lysosome related organelles190, they are expressing CD107a and CD63 (LAMP-1 
and LAMP-3 respectively); it has been shown that lytic granules upon opening towards the 
extracellular medium,  will expose CD107a molecule on the surface of the T cells, this process 
is now being widely used as a readout of CTL granule release159,231. 
 
Perforin: 
A clear indication of the role of perforin in anti-cancer response and in the clearance of 
intracellular pathogens has been shown in mice harboring a mutated form of perforin or 
perforin knock-out. The mice developed spontaneous lymphomas in paralleled with 
abolishment of granule-dependent target cell death232-234. Moreover, congenital perforin 
deficiency in fatal hyper inflammatory (FHL) patients, having inherited a mutated form of the 
perforin gene result in inefficient immune response against intracellular pathogens188. 
Structural studies performed using electron microscopy, have shown that perforin has a marked 
homology with pore-forming proteins such as the C9 protein of the complement complex235,236. 
Based on such observation, it has been suggested that perforin is capable of making pores (at 
neutral pH and in the presence of Ca+2) on the surface of the target cells. Further detailed 
studies of perforin structure and pore formation revealed that perforin-formed pores have an 
internal diameter of 16-22nm237-239. 
Even though perforin mode of function has been widely investigated, so far there are 3 not fully 
agreeing models of perforin mediated cytotoxicity that are summarized below (Figure -21): 
1) The first model postulates that following Ca2+-mediated interaction of perforin monomers 
with phosphorylcholine (specific Ca2+-dependent receptor molecule for perforin240) on 
target cell membrane, perforin monomers assembles and produce pores that permits the 
entry of granzymes into the cytosol of the target cells, leading to initiation of the apoptotic 
process241,242.  
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2) This model was later challenged by the view postulating that perforin and granzymes can 
be endocytosed within the endosomes in the target cells and it is within such endosomes 
that perforin monomers polymerization cause endosome lysis permitting granzyme access 
to cytosol. This hypothesis was also supported by the fact that granzyme B can be 
endocytosed by the cells in the absence of perforin243-245. However, perforin function 
requires neutral pH and high calcium concentration, given the acidic pH and low Ca+2 
concentration of endosomal lumen 246, this way of perforin/granzyme uptake is rather 
unlikely238,247,248. 
3) Finally, there are studies in support of granzyme endocytosis via a process mediated by  
Mannose-6-phosphate receptors, heparin sulfates or even electrostatic forces. However, 
these mechanisms are less characterized249,250.  
                                 
Figure I-21.  Perforin mediated granzyme B penetration. On interaction of a CTL with a target cell, there is a directed exocytosis of the CTL 
granules into the extracellular space between the two cells. a) The original view was that perforin polymerized to form a pore in the target-cell 
membrane through which granzymes could pass. b) More recently, the discovery of a receptor for granzyme B has indicated that granzymes 
might be taken up by receptor-mediated endocytosis and that perforin acts to release granzymes that are sequestered in endosomes into the 
cytosol of the target cell. c) In addition, granzymes might bind to the cell surface such that granzyme uptake is stimulated by perforin-mediated 
damage to the membrane. Adapted from Bleackley and Barry Nat Rev 2002251 
 
It has been previously described that any physical, chemical and biological damage to the 
membrane of the cells cause the re-localization of intracellular vesicles towards the damaged 
zone so that, by donation of a part of their membrane the integrity of the cell is preserved252 253. 
In this context, Keefe et al in 2005 tried to explore more in detail the step by step mechanism of 
 60 
 
perforin mediated apoptosis using recombinant and purified mouse perforin and granzyme B. 
They have shown that indeed polymerized perforin forms small pores on the plasma membrane 
that initially cause a calcium influx in target cells. This calcium influx is followed up by 
triggering the membrane repair mechanism based on the recruitment of endosomes that are 
EEA+ and CD107a- . Endosomes uptake perforin and granzymes; fusion of such early 
endosomes results in the formation of gigantosomes that according to the authors is the 
organelle where perforin pores form channel large enough for granzyme B passage into the 
cytosol 227,245,254 . 
More recently, Lopez JA. et al have developed a system by which perforin function can be 
visualized in real time by using propidium iodide as a read out. In fact, diffusion of solute 
through a pore is proportional to its concentration and radius, hence at high concentration of 
between 100 µM-200 µM, PI free diffusion inside the cells can be detected as PI will not only 
bind to the DNA but also to the cytosolic RNA by forming stable PI/RNA complexes, 
consequently any early pore formation activity can be followed using time-lapse microscopy. 
The authors showed that, within 60-80 seconds after [Ca+2]i increase  in CTL (a read-out of 
degranulation), PI entry was detected, starting from the immunological synapse and moving 
towards to the distal area of the target cell, indicating that perforin acts by forming pores on the 
membrane. Rapidly after (within 30seconds) membrane repair mechanism are triggered to 
prevent osmotic lysis238,247. 
Granzymes: 
Other important lethal molecules of CTLs’ arsenal are granzymes, which are serine proteases 
implicated in the induction of target cell apoptosis. Once internalized via mechanisms described 
earlier, granzymes rapidly induce the cascade of apoptosis in target cells255. There are several 
granzymes in humans among them granzyme A and B are more important in CTL effector 
function.  
 
Granzyme A: 
Granzyme A is capable of inducing apoptosis process independently of caspases cascade256. 
This granzyme was the first discovered of its family and is the most widely expressed. Cells 
treated with granzyme A and perforin die rapidly within minutes, revealing typical apoptotic 
signs such as membrane blebbing, mitochondrial dysfunction, phosphatidyl serine 
externalization and nuclear fragmentation257. Human granzyme A has however, minimal 
 61 
 
cytotoxicity even at high concentrations, reflecting evolutionary development of a customized 
range of granzymes that can initiate cell death pathways in infected or tumor cells. 
Granzyme A functions through various mechanisms such as induction of cellular DNA break, 
interference with DNA repair mechanism or even by opening up the chromatin through 
cleaving the linker protein histone H1. Granzyme A function is mainly based on interfering 
with normal functions of SET complex (a complex associated to the reticulo-endothelial 
system.) by cleaving it.  
 
 
Granzyme B: 
Granzyme B is the most potent pro-apoptotic granzymes and its unique feature is that it cleaves 
after aspartic residues, like the caspases. Granzyme B functions through cleavage of Bid (a 
member of the pro-apoptotic molecules family). The truncated form of the Bid (t-Bid) will 
induce cytochrome c release from the mitochondria that will stimulate the activation of caspase 
signaling cascade for DNA fragmentation. Moreover, granzyme B can directly function on 
caspase-3 and caspase-8, inducing DNA fragmentation (Figure -22)258-263 . 
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Figure I-22.  Apoptosis induction by Granzyme B. Once released into the cytoplasm, granzyme B can initiate apoptotic cell death through the 
direct cleavage of pro-caspase-3 or, indirectly, through caspase-8. In addition, cleavage of BID results in its translocation, with other members 
of the pro-apoptotic BCL2-family such as BAX, to the mitochondria. This prompts cytochrome c release and the activation of caspase-9 
through interaction with the adaptor molecule apoptotic protease-activating factor 1 (APAF1). Alternatively, mitochondrial dysfunction can 
lead to necrotic death and the release of factors such as apoptosis-inducing factor (AIF) and endonuclease G (EndoG), which mediate caspase-
independent cell death. Finally, studies have shown a direct activation of DFF40/CAD (DNA fragmentation 40/caspase-activated 
deoxynuclease) — which damages DNA and leads to cell death — by granzyme-B-mediated proteolysis of the inhibitor ICAD.  Adapted from 
Bleackley and Barry Nat Rev 2002251 
 
There are other types of granzymes in humans called orphan granzymes such as granzyme K, H 
and M. The mechanisms of function of these granzymes are yet to be understood, for instance 
granzyme K is a protease that can induce a Bid-dependent apoptosis264, while granzyme M 
induce cell death via Ezrins (family of molecules linking proteins to plasma membrane) and a-
tubulin cleavage265. It’s noteworthy that although many of these granzymes are able to induce 
cell death their delivery via immunological synapse to the target cells hasn’t been detected, thus 
it remained unclear whether other granzymes in addition to granzyme A and B have generic 
cytotoxic activity.  
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Once the “apoptotic switch” has been triggered the dying cell undergoes typical morphological 
transformation, characterized by: 
o cell shrinkage and rounding because of the breakdown of the cytoskeleton by caspases  
o dense cytoplasm with tightly packed organelles  
o chromatin condensation (pyknosis) and fragmentation (karyorrhexis)  
o the nucleus breaks into several nucleosomal units due to DNA degradation  
o the cell membrane displays “ blebbing”  
o and finally the cell breaks apart into apoptotic bodies, which are then cleared by 
phagocytes  
 
Granulysin: 
Human cytotoxic granules also contain another effector molecule: granulysin which is a 
membrane perturbing saponin-like molecule 266. This protein is expressed 3-5 days after T cell 
activation coincides with the expression and storage of other effector molecules in naïve T 
cells. Granulysin is synthesized and secreted by CTLs as a 15kDa protein that is later processed 
to 9KDa to be stored in lytic granules; the latter is only released during cytotoxic attack267. 
Main activity of granulysin is disruption of bacterial membrane but it has been shown in vitro 
that at high concentration granulysin can have anti-tumor activity268. Additional studies 
demonstrated the chemoattractant effect of secreted granulysin on dendritic cells and the 
induction in dendritic cells of the production pro-inflammatory cytokines269. Similar to 
granzymes, granulysin requires perforin pore to be delivered into the infected cell cytosol270 
271). 
A second contact-dependent mechanism of CTL to eliminate their cognate target cells involves 
ligation of death receptors expressed on the surface of target cells. 
Death receptor Pathways 
CTLS can trigger their target cell apoptosis by ligation and signaling via cell surface tumor 
necrosis factor (TNF) receptor family members containing cytoplasmic death domains. Among 
those  is the Fas-FasL pathway (CD95-CD95L)272. FasL is a death receptor belonging to the 
super-family of TNF receptors273. This molecule is either expressed on the surface of the T cells 
or is secreted upon cleavage by matrilysine (a member of the zinc-dependent metallo-
proteinase family)274. Interaction of Fas receptors expressed on the target cell surface with their 
ligand triggers an apoptosis cascade in target cell275. The FasL is expressed minimally on the 
surface of CTLs in resting conditions, however a few hours after TCR stimulation, FasL is 
upregulated on CTLs’ surface. Initially it has been proposed that FasL is expressed and stored 
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in CTL and is delivered to target cells upon lytic granule release in parallel to perforin and 
granzyme, thus inducing cell death. However, as mentioned earlier, basal FasL expression in 
CTL is low, thus minimizing the effect of this pathway in inducing rapid cell death, since FAS-
mediated cytotoxicity requires de novo synthesis of the protein. Fas-FasL is not only involved 
in cell-mediated cytotoxicity but is also involved in T cell homeostasis 276. Defective Fas-
mediated apoptosis could allow prolonged survival of lymphocytes, which could then become 
targets of transforming events, suggesting a role for Fas-FasL the control leukemia/lymphoma 
development276. Fas-FasL interactions are also implicated in graft versus host disease (GVDH) 
and autoimmune diseases277. Indeed, Fas-FasL-mediated killing would play a role in the 
elimination of cells chronically exposed to self-antigens, either by fratricide or by cell suicide 
processes 278,279.  
 
 
 
 Contact independent target cell destruction: 
Following their activation, CTLs secrete cytokines that can also contribute to their cytotoxicity 
function. In particular, they secrete IFN- and TNF- two cytokines that can have both local 
and systemic effects. 
Role of IFN- production 
IFN- is produced predominantly by NK cells, NKT cells, CD4+ Th1 cells and CD8+ CTL. 
Defective production and/or secretion of IFN- lead to occurrence of tumors, inflammatory-and 
autoimmune phenomena, indicating its critical role in immunity. IFN- can directly inhibit viral 
replication and has antitumoral, immunostimulatory and immunomodulatory properties. 
Combined presence of IFN- and TNF- leads to macrophage activation and recruitment to the 
site of infection. It is also noteworthy that IFN- induce MHC class I expression on cells, 
improving the possibility of target cell recognition by CTLs as well as up-regulation of 
adhesion and binding molecules required for leukocyte migration, NK cell activity and Th1 
differentiation (by up-regulating the transcription factor Tbet)(reviewed in Schoenborn et al 
2007280 and Schroder et al 2004281) .  
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Role of TNF- production: 
TNF- is an important regulator of the immune response and is also able to induce apoptotic 
cell death and inflammation, as well as inhibiting tumorigenesis and viral replication. TNF- is 
produced mainly by macrophages, but also by other immune cells, in particular, T lymphocytes.  
Upon secretion, TNF- binds to its receptor TNF-R presented on the surface of target cells. 
This receptor containing the death domain will recruit adapter molecules, Fas-associated death 
domain (FADD) that serves as a platform for recruiting signaling complexes. FADD recruits 
the apical caspases 8 and/or 10 to form the death-induced signaling complex (DISC) at the cell 
membrane. Within the DISC, these caspases are self-cleaved and activated. These activated 
caspases are then released into the cytosol to cleave the Bcl-2 family member Bid in order to 
activate mitochondrial damage and also cleave and activate the executioner caspases (3, 6, and 
7) that ends up with cell death236 282. TNF-induced cell death plays only a minor role283 
compared to its overwhelming functions in the inflammatory process. 
 
3) CTL effector function in vivo 
Weninger and co-workers using multiphoton microscopy analyzed the behavior of tumor-
infiltrating CTLs in vivo in an experimental context in which the CTLs efficiently rejected 
tumor cells, under these conditions, they observed a random migration of tumor-specific CTLs 
within the tumor microenvironment, and that sustained migration was dependent on specific 
antigen recognition by CTLs18. Following contact with tumor cells some CTLs physically 
engage long-lasting interactions (lasting longer than 30 min), while others established short-
term and sequential contacts. Although reasons for such behavior haven’t yet been nailed down, 
it is likely that lytic granules delivery possibly occurs only during long-lasting interactions.  
Similarly, in another study conducted by S.Amigorena and co-workers  CTLs accumulated 
initially in tumor periphery and then infiltrated towards the center284. Peripheral CTLs with 
typically high velocities were arrested on tumor cells as soon as recognizing their cognate 
antigen presented by tumor cell. CTL migration was observed typically in regions where 
neighboring tumor cells had been killed, this re-gaining migratory phenotype by CTLs were 
presumably in search of new tumor cells. The authors also observed that CTL infiltration in the 
center of the tumor required presence of cognate antigen. This is in agreement with previous 
studies in melanoma patients in which the authors, by using pMHC tetramers, showed that a 
substantial fraction of total CD8 T cells infiltrating the tumor was identified to be specific 
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individual melanoma antigens285,286. An additional recent in vivo imaging study confirmed that 
CTLs reach the center of the tumor (and control tumor growth) only when tumor cells express 
the cognate antigen287. 
P. Bousso’s lab further investigated the kinetics of CTL cytotoxicity in vivo using a 
multiphoton microscopy-based real-time single-cell killing assay288. They utilized genetically 
modified tumor cell lines that expressed CFP and YFP molecules linked by a DEVD motif. 
Tumor cell apoptosis activates caspase 3, which cleaves DEVD and results in disruption of 
Forster resonance energy transfer (FRET) between the two fluorescent moieties. FRET can be 
measures by multiphoton-intravital microscopy (MP-IVM) in real-time and in individual cells. 
They reported that non-CTL-contacted tumor cells remained alive, whereas stable engagement 
of nearly all tumor cells with at least one CTL caused their apoptosis. They estimated that on 
average one CTL requires 6 hours to kill one tumor cell. In fact, CTLs often remained attached 
to apoptotic tumor cells for several hours; thus on average above 6 h was estimated for a CTL 
to get ready to attack a second target. In addition to such long procedure of in vivo killing, 
tumor cells killing by human CTLs has been also observed in vitro for highly resistant 
melanoma cells231. In addition, it has been reported that CTLs in lymph nodes can kill antigen-
pulsed target cells and subsequently detach from them in only 15 min, and typically in <1 h 32. 
The relatively low pace at which CTLs kill tumor cells may be influenced by several factors 
such as evolution of self defense mechanism, Treg inhibitory cytokines, etc that will be 
discussed in page 74-75 (tumor escape mechanism).  
 
It is now known that CTLs are capable of killing multiple targets289-291, either simultaneously or 
serially by bouncing from one target cell to another158. Although the underlying mechanism of 
such serial cytotoxicity is not yet elucidated, it has been proposed that target cell annihilation 
by CTLs may require exocytosis of small quanta of lytic molecules144,156. In parallel another 
series of experiment from Griffiths’s lab proposed that de novo synthesis of lytic molecules is 
an event stimulated by specific TCR/pMHC engagement that will either refill the lytic granules 
or will be secreted directly via constitutive secretory pathway thus arming CTL for several 
rounds of cytotoxicity194.  
In addition, several studies currently revealed that both at polyclonal and intraclonal levels 
CTLs respond in a heterogeneous manner in terms of expansion and differentiation 292. In line 
with these findings Vasconcelos et al recently established an assay to measure kinetics of target 
cell annihilation by individual human CTLs belonging to the same T cell clone specific for 
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single antigenic peptide. Using this experimental set up they described a heterogeneous killing 
capacity among individual cells belonging to the same T cell clones based on the onset of 
killing during sustained CTL target cell interaction of super-killer CTL killing target cells at 
high rate293.  
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Cancer Biology and Tumor Immunology 
1) Cancer development 
Cancer is a complex process based on malignant transformation of a single cell that is initiated 
by a wide variety of events, mainly mutagenic such as ultraviolet (UV) or -irradiation or DNA 
intercalating agents. In other words, cancer is a multi step process of fatal deregulation of 
various cellular processes such as DNA repair, cell survival, proliferation and motility. These 
deregulations are often caused by accumulation of various genetic and epigenetic mutations. 
During oncogenesis, controlled cell proliferation is disrupted due to accumulation of mutations 
that results in formation of a tumor mass from which tumor cells can disseminate to form 
metastasis at distant sites in the body. The metastatic state is often fatal for the patient because 
it targets many organs of the body and complicates treatment strategies. 
Tumorigenic mutations are typically sub-classified into driver and passenger mutations. Driver 
genes are mainly involved in cell fate, cell survival and genome maintenance processes, and 
impairment of any gene of this type cause loss of growth control. On the other hand, passenger 
mutations do not intrinsically confer cell proliferation advantages. Whole genome sequencing 
of the DNA of cancer patients estimate that a typical tumor contains 2-8 driver mutations 
accompanied by approximately 30-60 passenger mutations. This finding points out the 
complexity of malignant transformation. It has been shown that melanoma, is an extreme case 
in this context harboring approximately 200 mutations per tumor. It’s noteworthy that every 
tumor accumulates unique mutations patterns and consequently will acquire distinctive 
immunogenicity294. 
Many tumorigenic mutations concern so-called oncogenes and tumor-suppressor genes. During 
tumorigenesis chronic activation of oncogenes and deactivation of tumor suppressors induce 
cancerous process in the given cell. Some prototypical oncogenes are myc, Her2/neu (human 
epidermal growth factor receptor 2) and Ras whereas typical tumor-suppressor genes are: pRb 
(retinoblastoma protein), p53 or PTEN (phosphatase and tensin homolog). As mentioned 
earlier, although tumors can comprise independent identities, many tumor entities share similar 
mutation patterns providing them with similar features which led to the classification of the 
hallmarks of cancer. For instance, mutation of a certain protein at various sites of several 
cancers indicates its importance in tumorigenesis. 
Genetic instability acquisition by neoplastic cells grants ultimate tumor cell abnormal growth 
and disseminating behavior. D.Hanahan and RA.Weiberg in 2000295 proposed an organizing 
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principle codifying the six traits that all cancers have in common, which was revised in 2011 by 
addition of emerging hallmarks295,296. 
 Hallmarks of cancer  
1) Enabling replicative immortality  
One characteristic of tumor cells is their immortalized state. In healthy cells, after many rounds 
of cell division, telomeres of the chromosomes get overly truncated and aggregate. This will 
cause cell death. Contrariwise, tumor cells continue to express a functional telomerase that 
constantly adds nucleotide repeats to the end of the chromosomes in tumor cells, avoiding cell 
death297-299.  
2) Activating invasion and metastases  
Upon acquisition of certain mutation, primary tumors often initiate a sequence of certain steps, 
the invasion-metastasis cascade, leading to the dissemination of single tumor cells. These are 
transported via lymphatic or blood vessels to distant organs which they colonize. This process 
involves the de-regulation of adhesion molecules such as E-cadherin but also tumor-infiltrating 
bone-marrow derived cells like macrophages that can supply matrix-degrading enzymes can 
facilitate metastasis300,301.  
3) Inducing angiogenesis  
Cancer cells are metabolically highly active needing proper nutrition with various metabolites 
as well as a well established gas exchange. Sustaining tumor growth requires establishment of 
an extensive blood vessel system. Generation of such blood vessels is called angiogenesis or 
neo-angiogenesis. In tumors the angiogenic switch is mainly triggered by vascular endothelial 
growth factor (VEGF)301. 
4) Resisting cell death  
In healthy cells a sustained proliferative signaling will induce cell death. In order to keep 
malignancy, tumor cells often up-regulate or activate key elements of cell death signaling 
process. This is often achieved via: loss of p53302,303, over-expression of anti-apoptotic factors 
such as B-cell leukaemia/lymphoma 2 (Bcl-2)304 or down-regulation of pro-apoptotic factors 
such as Bax or Bim.  
 
 
 5) Sustaining proliferative signaling  
In the process of oncogenic transformation, tumor cells constantly require receiving growth 
and/or survival signals. This is conveyed in large by autocrine stimulation with growth factors 
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or constant signaling of growth factor receptors (independent of ligand)305. One example is B-
Raf mutation yielding a constitutively active version of the protein that can be detected in 
around 40% of melanoma samples304. 
 
6) Evading growth suppressors  
In line with the sustained proliferative signaling, tumor cells should evade growth suppressing 
signaling. As genetic mutations are accumulating, control proteins (which can drive cells into 
senescence or apoptosis when DNA damage is overwhelming) need to be kept in check. 
Accordingly, p53 is one of the most frequently mutated control proteins in cancer showing 
point mutations in about 50% of all sequenced tumors295,303.  
 
Although during tumorigenesis the acquisition of these six important hallmarks is crucial, 
individual cancer cell may acquire them in varying orders or with different timings using 
distinct mechanisms. In addition, an important concept of tumorigenesis is the enabling 
characteristics that do not necessarily cause cancer but assist cells in a transition from normal to 
oncogenic state (see below). 
 Enabling characteristics 
1) Genome instability and mutation  
Genetic instability enables cells or cancer cells to acquire mutations in a random fashion. The 
tumor promoting mutations are selected and support uncontrolled tumor proliferation. This 
selection gives rise to the most successful or tumorigenic sub-clones that dominate in the local 
tissue environment. To enhance the probability of clonal expansion and survival, cancer cells 
normally increase the rate of their mutations by either increased sensitivity towards mutagenic 
agents or by circumventing cell surveillance systems monitoring genomic integrity. These 
mutations may include protein coding regions of the genome or may affect the expression of 
regulatory elements. 
 
2) Tumor-promoting inflammation  
Various immune cell infiltrate in cancer microenvironment at different densities has been 
shown in many types of cancer. However, the effect of immune cell presense on tumor 
progression is a controversial issue. 
In addition to the fact that many of these immune cells can help tumor evasion, tumor-
associated inflammation may enhance tumorigenesis and tumor progression, helping incipient 
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neoplasias to acquire hallmark capabilities. In this context, inflammation can supply bioactive 
molecules to the tumor microenvironment such as growth, survival and pro-angiogenic factors. 
It can also modify the extracellular matrix (ECM) that may facilitate angiogenesis 306,307, 
invasion, and metastasis. Finally inflammation can release chemicals like reactive oxygen 
species (ROS) that are actively mutagenic for nearby cancer cells, inflammation has been 
shown to be able to promote tumorigenesis308. 
More recently thank to the immense research efforts in oncology another concept has been put 
forth that takes in consideration the influence of two new emerging hallmarks in tumor 
development and progression. 
 
 
 Emerging hallmarks: 
1) Deregulating cellular energetic  
Tumor cells require many nutrients to fuel their excessive growth. Yet, the tumor 
microenvironment is often hypoxic, thus disabling the usage of the citric acid cycle that 
critically depends on normal oxygenation. O.Warburg first described this phenomenon in 
1930s. Since then it became increasingly clear that hypoxia via Ras signaling can 
independently increase the hypoxia-inducible factor 1 alpha (HIF1α) which subsequently up-
regulates glycolysis. Together with the over-expression of glucose transporters like the glucose 
transporter-1 (GLUT-1) this process provide enough energy to drive the uncontrolled 
proliferation of tumor cells in hypoxic tissues 309,310.  
2) Avoiding immune destruction  
It has been shown successfully in models of adoptive transfer and/or lymphocyte depletion that 
among other actors of the immune response, cytotoxic T lymphocytes (CTL) and NK cells can 
control tumor growth in vivo 311. In line with this observation it has been shown that immune-
suppressed individuals, for example organ recipients, also display a higher risk for developing 
cancer. Also, several studies reported that usually the level of infiltration of tumor tissue by T 
and/or NK cells correlated with better prognosis312,313. These data led to the addition of the 
hallmark “immune evasion” to the existing list of tumor progression arms.   
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2) Melanoma a prototype immunogenic solid tumor 
 Melanoma development and risk factors 
Melanocytes, originally derived from the neural crest, are situated just above the basal 
membrane between dermis and epidermis314. They are responsible for pigmentation in the skin. 
Common acquired melanocytic nevi are neoplasms arising mostly during the first 3 decades of 
life, whereas congenital nevi are present from birth315. Melanoma is the malignant 
transformation of melanocytic cells that express a large range of tumor associated antigens 
(TAA) and is considered a highly immunogenic tumor316. Morphological studies indicate that 
cutaneous melanomas are commonly pigmented and are recognized clinically as asymmetric 
lesions with irregular borders and variegated pigmentation as well as by the size and evolution 
over time of the lesion314.  
Four stages of melanoma have been described based on the spreading of the tumor to regional 
lymph nodes or distant site. At early stages of the disease melanoma cell proliferation takes 
place at its location which is between dermis and epidermis, while at later stages melanoma cell 
uncontrolled proliferation establish a radial growth and by reaching the blood vessels or 
lymphatics malignant cells start to metastasize throughout the body. This stage is termed stage 
IV of the disease (Figure -23). Lung and liver are the common sites of melanoma metastasis. 
In fact, when compared to other skin cancers, melanoma has a high tendency of metastasis, 
even from small primary tumors. 
                      
Figure I-23. Progression of melanocytes to malignant melanoma. There are 4 distinct states of melanocyte progression where each 
melanocyte clone gains advantage over surrounding tissue. Early benign nevus becomes dysplastic with morphologically atypical melanocytes. 
This is followed by a radial-growth-phase and a secondary vertical growth phase which is the first stage to have malignant potential. In the final 
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stage of malignant melanoma the tumor cells have infiltrated vascular and lymphatic systems and spread to distant organs. Adapted from Gray-
Schopfer et al, Nature 2007314 
Although melanoma is representing approximately 2% of skin cancer, the incidence of 
melanoma is increasing comparing to other common cancers, particularly in young generations 
317. Historically melanoma more commonly affected women than men, but the gender 
imbalance has recently leveled and melanoma is now the 6th most common cancer diagnosed 
for each sex. In Europe the highest cancer rate is found in France with 385 men and 267.7 
women per 100,000 inhabitants diagnosed in 2012 (WCRF website, accessed 25/09/2015).  
Chance of melanoma risk, slightly increases in cases with a family history of melanoma 
incidence, although familiarity contributes to less than 10% of reported cases (Olsen et al., 
2010). The most common familial syndrome is familial atypical multiple mole-melanoma 
syndrome (FAMM), other syndroms such as xeroderma pigmentosum and albinism can also 
lead to melanoma318,319.  
Although early-stage melanomas are commonly cured by surgical excision, locally advanced or 
metastatic melanoma has a dismal prognosis. The survival of patients with melanoma varies 
from 97% at five years for patients with small, easily resected tumors, through to 33% at one 
year for patients with the most advanced metastatic disease320.  
Furthermore, although the lifetime risk of developing cutaneous malignant melanoma (when 
compared to other tumors) is comparably low, melanoma incidence rate increases faster than 
for any other malignancy.  
As already introduced, melanoma cells harbor usually more mutations than other cancer 
entities. This is due to the fact that melanocytes are frequently exposed to mutating UV 
irradiation which is part of the spectrum of sunlight. In fact, prominent mutations in melanoma 
samples are among critical genes controlling a range of important cellular processes that results 
in the proliferation and dissemination of melanoma throughout the body and are directly in line 
with issues that were discussed under “cancer development” chapter. As mentioned above the 
proto-oncogene B-Raf is mutated in about 40% of melanoma samples but also N-Ras, Bcl-2, 
PTEN or nuclear factor-κB (NF-κB) frequently exhibit mutations providing progenitors of 
melanoma cells with growth advantages leading to oncogenic transformation.  
One of the reasons why, despite increasing incidence the melanoma-related death rate is 
virtually stable is that it is more often detected in its early stages where it can be removed with 
surgery. However, as melanocytes are derived from highly motile neural-crest progenitors they 
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are very prone of initiating metastatic spread either locally to lymph nodes or distally to other 
organs (preferentially lung321, liver or brain322,323). Upon metastasis, surgical excision becomes 
problematic and survival rates are dramatically reduced, with a median life expectancy of 6 
months and only 5% of patients surviving beyond 5 years. Also, melanoma cells are often 
refractory to most existing treatment strategies and can exhibit a pronounced apoptosis-
resistance in vitro and in vivo. Thus, novel strategies targeting melanoma are desperately 
needed. 
The high mortality rate of melanoma is essentially due to the lack of effective treatments, 
particularly for late stage or disseminated disease. For several decades researchers and 
clinicians have trialed several immunotherapeutic approaches in the treatment of melanoma, 
but without ever reliably improving on the existing standard of care except than during the last 
few years in which novel therapeutic strategies are under development. Improvements to 
existing therapies or the development of novel drug strategies are required in order to increase 
overall survival in patients with metastatic melanoma. 
 
 Vesicular trafficking in melanocytes 
Melanocytes contain two kinds of lysosome-related organelles: lysosomes (similar to those 
contained in many cells) and melanosomes (melanocytes specific organelles). These 
compartments have many common features such as presence of both soluble and 
transmembrane lysosomal proteins, an acidic luminal environment, accessibility by endocytic 
tracers, and the ability to fuse with phagosomes  324. It has been suggested that melanosomes 
are specialized lysosomes325. Melanosomes and lysosomes provide different contribution to the 
cell homeostasis; melanosomes are involved in pigmentation and lysosomes are involved in 
degradation, therefore each compartment is equipped with specific protein sorting and transport 
systems while sharing some key elements.  
 
A melanosome biogenesis model proposes that the membrane of melanosomes originates from 
smooth ER, and that this compartment receives melanin-synthesizing enzymes from the TGN-
derived vesicles326. Immature melanosomes gradually mature into heavily melanized 
melanosomes (stage I-IV) and are finally transferred to adjacent cells, keratinocytes, by 
potentially one of the following mechanisms: cytophagocytosis, membrane fusion or shedding-
phagocytosis or exo/endocytosis327. 
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Melanosomes (vesicular) trafficking in melanocytes is accomplished by a combination activity 
of two cytoskeletal components: microtubules and actin filaments328-330, before anchoring to the 
plasma membrane. These vesicles adhere to microtubules via kinesin or dynein molecules 
which move the melanosomes in an anterograde/retro grade direction respectively331,332. These 
motor proteins consume ATP to ‘walk’ along the microtubules 333 and are composed of globular 
domain with two heavy chain subunits for attaching to the microtubules, as well as several light 
chains for holding the vesicles332. Kinesin molecules perform the transfer of vesicles from 
perinuclear area to cell periphery where melanosomes are taken by actin filaments for vesicular 
distribution334. Actin filaments capture vesicles through a complex of proteins composing of 
several SNARE machinery and Rab-GTPase proteins. SNARE machinery composed of 
VAMP7 on vesicles and syntaxin-3 and SNAP23 on plasma membrane regulates this 
trafficking. 
Several combinations of such vesicular trafficking molecules have been proposed to perform in 
melanocyte. For instance: a Rab27A–Slac2-a/melanophilin–myosinVa complex in actin-
dependent melanosome transport328, and a melanoregulin (or Rab36)–RILP–dynein motor 
complex in microtubule-dependent retrograde melanosome transport329,330. 
More recently, Yatsu and his colleagues335 proposed that syntaxin-3 is a mediator of fusion 
between TRP-1 (tyrosinase-related protein 1)-containing vesicles and their target organelles by 
forming a complex with VAMP7 and SNAP23. In this manner, when the TRP-1-containing 
vesicles reach their target organelle, i.e., stage II/III melanosomes, VAMP7 is released from 
Varp (VPS9-ankyrin-repeat protein, a Rab32/38 effector) by an unknown mechanism, and a 
SNARE complex is formed between VAMP7 (on the TRP-1-containing vesicle) and two t-
SNAREs, syntaxin-3 and SNAP23 (on the melanosome), leading to fusion between the two 
membranes. As a result, TRP-1 protein is transported to the melanosome, thereby enabling 
successful melanin synthesis (i.e., the formation of a stage IV melanosome). 
Moreover, VAMP7 has at least two functions in melanocytes: regulation of LAMP-1 transport 
independently of syntaxin-3 and SNAP23, and regulation of TRP-1 transport in concert with 
syntaxin-3 and SNAP23335,336. In addition it has been shown that Syntaxin-13 regulates 
melanosomal cargo transport and biogenesis through its cycling between recycling endosomal 
domains and melanosomes in a mutual regulation with VAMP7 337. 
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Rab27a provides the direct linkage between melanosomes and the transport complex 
(VAMP7/Syt3/SNAP23), and is independent of melanophilin and myosinVa 338. Melanophilin 
is recruited to the complex by Rab27a-GTP, and binds to Rab27a by its N terminal domain and 
to actin via its C terminus. Interaction between melanophilin and myosinVa is via a coiled coil 
domain339. MyosinVa co-localizes with actin and is thought to be crucial for capturing the 
vesicles at the cell periphery327,334.  
These evidences suggest that both melanosomes and lysosomes utilize the same mechanism for 
membrane transport; however, there are specific features in melanosomes, melanin-
synthesizing enzymes, and matrix filaments that can help us distinguish these two 
compartments.  
More recently, it has been revealed by Immunofluorescence analysis that TRP--1 does not co-
localize with lysosomal membrane proteins CD107a and LGP85 in melanocytes. In the same 
article the authors proposed a late sorting mechanism based on AP-3 complex function for 
targeting specific membrane proteins into melanosomes and lysosomes340  (Figure -24).  
                           
Figure I-24. Model of the membrane traffic to melanosomes and lysosomes in melanocytes. In biosynthetic pathways, the traffic route of 
melanosome membrane protein (tyrosinase-related protein 1: TRP-1) partially overlaps but is distinct from that of the endo/lysosomal one 
(LAMP1, LGP85). The melanosome pathway is separated from the lysosome one after the AP-3-dependent sorting steps, probably at late 
endosomes and/or PLC (prelysosmal compartment). Melanosomes gradually maturate into heavily melanised melanosomes (from stage I to 
stage II–IV) with the accumulation of melanin inside the membrane. In the presence of wortmannin, there is membrane retrieval from the 
lysosomes or immature melanosomes, but not from the heavily melanised melanosomes. The melanosome pathway is also segregated from the 
endocytic pathway (TR-dextran). Adapted from Fujita H 2001340 
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Table1. Characteristic differences between lysosome related organelles (LRO) 
 
 
 
3) Tumor /Immune system interface  
 Development of an anticancer immune response 
Besides fighting pathogenic invaders, the immune system also evolved to recognize altered self 
as target structures and to mount an immune reaction against transformed cells. However, the 
immune system effector cells and molecules are not always exerting beneficial effects, 
rendering tumor immunity a double-edged sword.  
Paul Ehrlich has first predicted the concept of tumor suppression by immune cells more than 
100 years ago. He was followed by F.M. Burnet who believed developing cancer would be 
eliminated by an effective immunologic reaction provoked via tumor cell-specific neo-antigens. 
Alternatively, L.Thomas theorized that there should be a barrier of protection against neoplastic 
diseases similar to that mediating homograft rejection. The results from studies in inbred mouse 
models strongly suggested the existence of tumor associated antigens and formed the 
renaissance of modern tumor immunology introducing “cancer immune surveillance 
hypothesis” which stated that thymus-dependent cells of the body constantly surveyed host 
tissues for recently transformed cells. 
Characteristic Lysosome Melanosome Lytic granule 
Cell type Most Melanocytes CTL, NK 
Luminal pH 4.5–5.0 <5 5.1–5.4 
Lysosome hydrolases + + + 
CD107a/LAMP-1 + − + 
LAMP-2 + + + 
CD63/LAMP-3 + + + 
MPRs − − − 
Accessibility to endocytic tracers + + + 
TRP--1 - + - 
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Yet, the similarity of tumor cells to healthy cells made the advancement of tumor immunology 
complicated, since danger signals like bacterial LPS for instance were recognized to be clearly 
missing in a tumor context. Also data were differing in various groups. The very first clear-cut 
result in favor of anti-tumor immune surveillance was achieved in the 1990s when IFN--/- or 
IFN- receptor (IFN-R)-/- mice were shown to exhibit defective tumor rejection compared to 
wild type (wt) mice upon carcinogen challenge or injection of tumor cell lines. Several 
important findings on this topic comprehensively reviewed by Vesely et al. and ultimately led 
to the general appreciation of tumor immune-surveillance341. More importantly, clinical results 
also support immune surveillance hypothesis. Immune-suppressed patients show higher 
incidence of tumors (both spontaneous tumors or virally induced). Moreover abundant 
lymphocytes infiltrate in some tumors correlates with a longer survival in cancer patients342,343. 
The most comprehensive of these studies were in colorectal cancer341.  
Moreover, several lines of evidence indicate that, although tumors at least induce transient 
immune responses, cancer still develops344. As discussed earlier, immune mediated recognition 
of tumors not only enhance tumor eradication but also cause a selective pressure favoring 
growth of less immunogenic tumor clones, that point out a continuous “sculpturing” of tumor 
phenotype by immune system in its environment. This comprehensive concept of immune 
surveillance was revised later by Schreiber and his colleagues and termed “immunoediting”. 
The concept postulates three phases that describe tumor evolution in light of its interaction with 
the immune system: elimination, equilibrium and escape. 
Elimination  
Elimination phase refers to successful eradication of developing tumors who had escaped from 
intrinsic tumor suppressor mechanisms. Ideally, in this phase, both innate and adaptive 
immunity are involved. In this context, cells of the 1st immunity response wave including: 
Natural killer cells (NK), Natural killer T cells (NKT) and  T cells are alerted by new source 
of local “danger” such as pro-inflammatory cytokines produced by growing tumor cells, 
activated macrophages or the surrounding stromal cells. This cascade is followed by a positive 
feedback loop of an amplified cytokine production and immune cell recruitment that will 
produce additional pro-inflammatory cytokines, namely: IFN- and IL-12. NK cell tumor 
cytotoxicity through perforin, Fas-L and tumor necrosis factor receptor (TNFR) causes antigen 
release that will set off the adaptive immune system response. In fact, high levels of IFN- also 
exert direct anti-proliferative, anti-angiogenic and pro-apoptotic functions on tumor cells. 
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Hereby, NK cells will bridge innate and adoptive immunity through activation of dentritic cells 
(either in a contact dependent manner or indirectly by IFN- production). As mentioned earlier, 
the tumor microenvironment is also enriched of HSP and apoptotic cell fragments that harbor 
excessive amounts of tumor antigens. Activation of DCs triggers their maturation and migration 
towards the draining lymph nodes where they trigger adoptive immunity. This response ideally 
involves CD4+ Th cell induction that subsequently supports the activation of cytotoxic CD8+ 
CTLs via dentritic cell exerted cross-presentation of tumor antigens. CD8+ CTLs and CD4+ Th 
following activation and clonal expansion will infiltrate the tumor site. Accordingly, CD8+ 
CTLs detect specifically antigen-expressing tumor cells and respond with cell cytotoxicity 
and/or IFN- secretion that in turn can activate macrophages, DCs, NK cells. In this context, 
CD4+ Th produce IL-2 that, together with host cell production of IL-15, helps to maintain the 
function and viability of the tumor-specific CD8+  T cells. 
Equilibrium  
Tumor elimination phase is not always fully successful in complete tumor clearance, in such 
cases the tumor cells and the effector cells of the immune system enter into a dynamic 
equilibrium, wherein the immune functions against the tumor cells are sufficient to avoid the 
tumor out-growth, but not sufficient for tumor annihilation, in other words tumor destruction 
and growth are matched. This conserved tumor bed gives rise to many genetically unstable and 
mutative emerging tumor cells. During the equilibrium phase, the immune-mediated selective 
pressure favors generation (sculpts) of a new population of tumor clones with reduced 
immunogenicity, compared to the parental population. Main factors for survival of such 
cancerous cells from the elimination phase can derive from the heterogeneity and high genetic 
instability of these cells that enable them to resist or escape the host's immune responses. 
The various effector molecules of the immune system have different degree of influence in 
imposing the selection pressure. In fact, Koebel has identified a subset of animals treated with 
low dose of 3’-methylcholanthrene (MCA) that develop tumors, which do not progress. These 
tumors remain stable for months but the transient suppression of the adaptive immune system 
(by antibody-mediated depletion of IFN- and T cells) induces rapid tumor growth, indicating 
that these stable tumors were held in check by adaptive immunity 345. This renders the 
equilibrium phase distinct from elimination phase that is based on both innate and adaptive 
immunity.  
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Equilibrium is believed to be the longest phase in the process of immunoediting. It has been 
estimated that it can take up to 20 years from the first contact with a carcinogen to clinically 
detected manifestation of malignant disease during which, most of the time, the tumor exists in 
an occult state in equilibrium phase. Solid organ transplantation has caused tumor transmission 
from a donor treated for melanoma 16 years earlier and considered tumor free. Indeed the 
pharmacologic suppression of the immune systems of transplant recipients facilitated the rapid 
and progressive outgrowth of occult tumors that had previously been maintained in the 
equilibrium phase by the donor's competent immune system. 
A recent controversial work in a murine model of spontaneous melanoma, tumor cells were 
found to disseminate early in the development of the primary tumor and remain dormant 
depending on the tissue were they were localized. Dormant cells from lung showed low 
proliferation rate in comparison to primary tumors, which was partly mediated by cytostatic 
CD8+ T cells. Therefore, immune strategies that favor the dormancy of disseminated cells are 
proposed to control the development of metastasis 346. 
The end result of the equilibrium phase is variants that are more aggressive compared to the 
original tumor cells as they are less immunogenic and eventually cannot be killed by immune 
cells anymore and thus grow out leading to malignant disease.  
Escape  
When tumor cells are equipped with mutations that protect them from immune system they go 
towards the last step in the immunoediting process which is termed: escape phase. This escape 
from immune recognition is mainly achieved through three mechanisms: first, lack of 
recognition that can be due to loss or alteration of molecules important in recognition such as 
loss of MHC molecules, second, an alteration of activation processes and third,  induction of 
immune dysfunction.  
 
 Mechanisms of tumor escape 
In response to selective pressure of immune system, tumors developed various strategies to 
hide from immune cell elimination process. One strategy shared by many tumor cells is down-
regulation or loss of MHC class I expression or of molecules that are involved in antigen 
processing and presentation such as TAP or low molecular-mass proteins (LMPs). Loss of 
MHC I in melanoma have been associated with disease progression347,348.  Melanoma cells are 
also able to express MHC II, but the costimulating molecules CD80 and CD86 are often absent, 
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for this reason they induce tolerogenic responses349. An additional escape strategy is the ectopic 
expression of HLA-G, a nonclassic MHC-I molecule, that can protect melanoma cells against 
natural killer (NK)-cells350.  
Moreover, to avoid CTL cytotoxicity tumor cells351 can over-express anti-apoptotic molecules 
such as (Bcl-2) and perforin/granzymes inhibitors (PI-9)352,353. Down-regulation or epigenetic 
changes of death receptors and caspases 354 or over-expression of FLIP (caspase-8 like 
inhibitory protein)355are also linked to reduced efficacy of CTL-mediated tumor eradication.  
In addition, many tumors, in particular melanoma can skew the immune system towards a more 
immunosuppressed state that protects them from immune response. Tumors can produce 
elements that prohibit maturation, differentiation and function of APC and effector cells. IDO 
(Indoleamine 2,3-dioxygenase) expression in melanoma blocks proliferation of CD8+ cells and 
promotes apoptosis of CD4+ cells at the tumor site 356. CD95L expression and secretion by 
melanoma cells is proposed to induce apoptosis in CD95 expressing tumor-specific T cells357 
358 359, although this expression and its function has been questioned by other studies 360,361.   
Tumors are also able to recruit and stimulate Tregs under the influence of certain, yet unknown 
factors that exert inhibitory effect on CTL cytotoxicity362 363. Recently, it has been proposed 
that expression and secretion of the antioxidant protein thioredoxin in melanoma increases 
recruitment and function of Tregs364. Moreover, in tumor-microenvironment presence of IL-6, 
IL-10, TGF, NOS2 (nitric oxide synthase 2) not only induces the generation of tolerogenic 
APCs but also causes immune-suppressive effects. Inflammatory-cytokines can induce over-
expression of immune-modulatory molecules such as PD-L1 and PD-L2 that can diminish the 
antigen-receptor signaling by binding to the receptors on T and B lymphocytes365,366. Such 
pattern of expression of PD-L1 has recently been linked to a worse prognosis in melanoma366 
367. 
4) Anti tumor immunotherapy for melanoma patients 
Assessment of changes in tumor burden is fundamental for clinical evaluation of cancer 
therapeutics and both tumor shrinkage (objective response) and disease progression are 
important endpoints in clinical trials. Since the introduction of response evaluation criteria in 
solid tumors (RECIST) in 2000 and the revised RECIST 1 in 2009, many investigators, 
industry and government authorities have adopted these criteria in assessment of treatment 
outcomes. RECIST is based on radiological measurements of lesion size and can be 
summarized as: complete response (CR) – disappearance of all tumor foci; partial response 
(PR) – a reduction of at least 30 % in tumor diameters; stable disease (SD) – neither partial 
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response nor progressive disease; and progressive disease (PD) - at least a 20% increase in the 
sum of all tumor dimensions from the smallest tumor size or the apparence of a new tumor 
lesion. The term objective response refers to either CR or PR. 
 Surgery and chemotherapy 
Melanoma that is confined to the skin or lymph nodes corresponds to the early detected disease 
and is primarily treated by surgery. Some of these patients, particularly those with thin and 
nonulcerated lesions are cured by surgery only. Melanoma is notoriously resistant to 
chemotherapy and single-agent chemotherapy results in limited (< 25%) response rates368,369. 
Dacarbazine is the only chemotherapeutic drug approved by the US food and drug 
administration for treatment of melanoma. It induces produced response rates between 7 and 25 
%, with median duration of 5 to 6 months and complete responses in < 5% of the patients. In 
order to improve response rates, combinatorial chemotherapies have been tested in clinical 
studies. The most effective multi agent combinations have included dacarbazine and other 
classes of chemotherapy agents (platinum compounds or alkaloids) and have been associated 
with 14 -37 % response rates. The most effective multidrug studies have included cisplatin, 
vinblastine and dacarbazine and have produced response rates of 40% with median duration of 
9 months and a median survival of 12 months370-372. 
I have described above the interplay between Immune cells and, more importantly CTLs, with 
tumor cells. During the last decade many advances have been made in the understanding of 
cancer immunology that helped to make progresses in the amelioration of immune responses in 
cancer either by direct targeting of immune cells or by utilization of immune-modulatory drugs. 
All in all, these findings helped to build up the very promising field of immunotherapy of 
cancer that aims at stimulation, restoring, management and even completion of patient’s own 
immune system for tumor control and annihilation. In this section I will introduce different 
relevant avenues of experimental anti-tumor immunotherapy with a focus on melanoma 
immunotherapy. 
 
 Cytokines  
Interleukin (IL-2) 
IL-2 has been shown to have anti-tumor activity both in vitro and in vivo373 374. Treatment of 
metastatic melanoma patients with high doses of IL-2 as single agent demonstrated 7% 
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complete remission (CR) and 10% partial remission (PR)375. 8 year follow up of 270 patients 
under such treatment supported moderate beneficial outcome of IL-2 treatment as patient’s CR 
median duration was estimated 59 months370. However, limited results in parallel with toxic 
side effects of high dose IL-2, restricts its general applicability. Combination of this treatment 
with chemotherapy had no statically significant response improvement 376,377. 
Interferon (IFN) 
IFNs are pleiotropic cytokines that induce synthesis of many proteins via activating the JAK-
STAT pathway (cellular signaling pathway coupled to cytokine receptor). There are two types 
of IFNs based on their recognizing receptors. Type I, that binding to IFN- receptors contains 
IFN-, andwhile type II includes IFN-and binds to IFN-receptorWhereas Different 
IFNs may recognize different receptors and activate different pathways; they have some 
overlapping effects, particularly in their anti-proliferatory activity378. 
IFN treatment has been thoroughly evaluated and it is now the only approved adjuvant therapy 
for melanoma patients (at stage / of the disease) since it can significantly improve disease 
free survival and, in some cases, overall survival320. However IFN usage associates with a lot of 
side effects (including autoimmunity and thyroid dysfunction) and must be monitored carefully 
379. 
Yet, in addition to the systemic application of IL-2 and IFN-α local application of IL-2 and 
TNF-α have been reported to induce beneficial effects for patients with soft-tissue sarcomas or 
melanoma380.  
 Vaccine-based strategies  
Several clinical cancer vaccination trials have been conducted, in particular with irradiated 
whole-tumor cells mixed with bacterial adjuvants that showed limited but significant effects in 
melanoma treatment 381,382.  
More recently, with comprehensive molecular understanding of melanoma progression and 
immune recognition, the attention has turned towards specific melanoma antigens. The role of a 
variety of tumor-associated antigens (differentiation, cancer testis and viral antigens) in 
enhancement of anti-tumor responses has been investigated both in animal models and in 
clinical trials. 
These antigen-based vaccines are divided into four categories: 
1) Plasmid DNA-based vaccines, delivering the gene encoding the antigen 
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2) Recombinant viral and bacterial vaccines 
3) Peptide or protein based vaccines, delivering antigen mixed with adjuvants 
4) Antigen-loaded DC vaccines 
DNA vaccines have the advantage of expressing the antigen over time as the expression relies 
on the cell ability to transcribe the gene from the delivered episomes. One example of this kind 
is Allovectin-7 that is designed to express allogeneic MHC class I antigen upon intralesional 
administration. However, this vaccine failed in providing encouraging results in phase of 
clinical trials383. Viral vaccines are currently under investigation but they appear to be difficult 
to be employed in clinical use due to the generation of neutralizing antibodies. Peptide or 
protein based vaccines are designed to have a better binding to MHC molecules or to induce an 
enhanced T cell response384. A mixed newly emerging vaccine is MelQbG10. It contains an 
immunogenic virus-like nanoparticle to which the melanoma tumor antigen (MART-1) and 
immunomodulatory oligonucleotides for TLR-9 triggering are covalently coupled. This vaccine 
can be efficiently drained into LN for uptake and processing by DCs and macrophages. This 
treatment in phase II clinical trial showed quantitative and qualitative different T cell 
responses385. 
One important example of approved antigen-loaded DC vaccines is Sipuleucel-T against 
prostate cancer, in which mononuclear cells are collected from the peripheral blood of prostate 
cancer patients and cultured with prostate antigens and then coupled with GM-CSF before 
administration in patients386. 
 Immune-targeted agents  
Anti – CTLA-4 
As discussed earlier activated T cells play an important role in tumor eradication while cancer 
cells develop strategies to escape from immune system through local and regional immune-
suppressive mechanisms. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a potent 
attenuator of immune responses expressed on many immune cells including CD4+ and CD8+ T 
cells. It is the CD28 homologue and competes with CD28 for binding to their mutual ligand 
(B7-family proteins) on APCs. CTLA-4 binding to its receptor will inhibit T cell activity. 
Blocking this receptor enhanced T cell responses both in vitro and in vivo and supports T cell 
proliferation of tumor specific T cells387. Ipilimumab is a fully human monoclonal antibody that 
binds to and blocks CTLA-4. Of note, in a large randomized trial ipilimumab was found to be 
the first treatment in 30 years to give a survival benefit in metastatic melanoma patients 388,389. 
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This treatment also requires specific managements as it’s also associated with many immune-
related disorders. It is a toxic therapy for many patients, and the response rate is relatively low, 
but its efficacy further asserts that the immune system can be coerced into yielding significant 
benefits for patients with melanoma. Combination therapies associating anti-CTLA-4 with 
other blocking agents are still under investigation390. 
Anti – PD-1 
PD-1 is an inhibitory receptor on T cells that upon, interaction with PD-1 ligand on the tumor 
cells prevents activation of T cells by recruiting SHP-2 (a tyrosine phosphatase) that in turns 
inhibits ZAP-70 signaling. One of tumor escape strategies from immunological surveillance is 
the over expression of PD-1 ligand. Treatment with anti-PD-1 antibody in patients showed 
objective response rate in 41% in melanoma patients391. 
 One of the main features of this treatment is that it targets the effector phase of the immune 
response. Combining this treatment with treatments acting in the T cell activation phase can 
provide favorable results in patients’ protection. Indeed, a major problem in immune response 
against cancer is that T cells are mainly ineffective within the tumor microenvironment due to 
the strong inhibitory milieu. This hypothesis was confirmed in a mouse model392. 
Since this ligand is not expressed (or expressed minimally) by normal tissue, abrogation of PD-
1 and PD-1 ligand interaction might have as less side effects in terms of auto-immnity365,366. 
 Adoptive T cell transfer  
Immunotherapy strategies have also focused on a personalized treatment that in melanoma 
patients it has shown some success. Compared to the previously introduced methods adoptive 
cell therapy (ACT) is not relying on activating endogenous immune cells but rather supplies 
exogenously autologous or allogeneic effectors in high numbers. 50% of the patients who 
received high-dose infusions of ex vivo expanded and activated TIL showed an objective 
clinical response with 10% obtaining complete remissin393. 
This method was developed in the lab of SA.Rosenberg in 1988 and is subdivided in three 
strategies: 
1)  To obtain TILs from melanoma biopsies and expand them ex vivo. The expanded TILs 
are then transfused back into the patients. 
2) To obtain lymphocytes from patient’s peripheral blood, to modify them to express 
chimeric antigen receptors (CAR). To amplify them ex vivo and transfuse them back in 
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patients. CARs are chimeric molecules that are composed of an extracellular single 
chain antibody targeting a tumor antigen and an intracellular signaling domain394 
3) To obtain lymphocytes from patient’s peripheral blood, modifying them for expression 
engineered TCR that recognize melanoma associated antigen with very high affinity. 
This is followed by amplifying them ex vivo and by their transfusion back in patients. 
In all three protocols the patients is immune-suppressed to gain stronger clinical response395,396.  
The first protocol has less risk but the main difficulty of is that in most cases it is impossible to 
isolate TILs from melanoma samples. It is also very time consuming and expensive as it is a 
kind of individualized therapy.  
Strategy two is independent of melanoma antigen presenting machinery. This is an important 
aspect when considering that one escape mechanism is down-regulation of MHC class I.  CARs 
will recognize antigen through the antibody portion of the molecule and the signaling domain 
will activate the T cells. The method is still under preclinical investigations. 
The third strategy gives the opportunity of having sufficient amount of tumor specific T cells. 
However, this method is limited to a certain antigens in the context of restricted MHC 
molecules and can favor immunoediting based escape of cancer cells. 
 
 NK cell-based therapy  
For immunotherapy, activated autologous or allergenic NK cells from peripheral blood, stem 
cells or induced from pluripotent stem cells are also used. In this context, some NK cell lines 
that were genetically modified to secrete activating cytokines or to express chimeric antigen 
receptors, have been tested397.  
The use of NK cell lines as allergenic NK cell source has several advantages. They can be 
easily maintained and expanded in vitro permitting large-scale production of NK cells. Further, 
they allow the use of one NK cell product for various application or patients thus eliminating 
deviations of donor-to-donor variability. Of note, the NK-92 line was found to be safe and 
potentially exhibits beneficial effects in malignant melanoma and advanced lung cancer 
patients. Thus, so far it is the only cell line that was FDA approved for tumor therapy. 
Importantly, due to their virtual complete lack of KIR molecules NK-92 are potent mediators of 
allo-reactivity.  
 
 
 87 
 
 BRAF inhibitor 
Vemurafenib is an inhibitor of mutated forms of BRAF, present in around half of metastatic 
melanomas. Half the patients treated with vemurafenib benefited from objective responses, and 
early analysis suggests a 3 month improvement in progression-free survival398.  It would be 
interesting to define whether BRAF inhibitors may synergize with different strategies of 
immunotherapy. 
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II- Aim of the study 
Background:  
Several lines of evidence indicate that an endogenous immune response against cancer develops 
in some patients. Tumor-specific CTL expand at relatively high frequency in cancer patients and 
tumor-infiltrating lymphocytes (TILs), can be isolated and expanded in vitro from a variety of 
human cancers. Some TILs have specific cytolytic activity for fresh autologous cancer cells. 
Yet, the effector function of these naturally occurring CTL is often insufficient to achieve 
clinical remission285,344,356,399. These data indicate that local specific immune responses may 
develop within tumors. Furthermore, tumor-associated antigen (TAA)-specific T cells have been 
detected in some tumor-infiltrated lymph nodes. These data lend strong support to the premise 
that the immune system can recognize and respond to endogenous cancer cells but is unable to 
eradicate it. Moreover, Therapeutic approaches based on adoptive transfer of ex vivo expanded 
tumor antigen-specific CTL emerged as a promising therapeutic strategies, in particular in 
melanoma395,399. However, these approaches still suffer limited efficacy and need to be 
improved before reaching high clinical benefits.  
In this respect the main paradigm is to understand why efficient CTLs do not directly translate 
into an efficient status of immune surveillance against tumors. 
Working Hypothesis and aim:  
We assume that an important factor contributing to the limited efficacy of CTL is the 
unfavorable balance between, the global efficacy of CTL-mediated cytotoxicity and the intrinsic 
tumor resistance to CTL attack. Thus, we believe that a closer look at the molecular events 
occurring at the CTL/melanoma IS could allow a better understanding of the mechanisms 
determining the outcome of the CTL/melanoma interaction. While, so far main efforts of the 
research community has been given to potentiating immune responses, we feel it is necessary to 
extend our focus from the induction of an anti-tumor immune response towards the complexities 
of CTL/tumor interaction.  
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The aim of our project is therefore to shed light on the molecular and cellular mechanisms 
taking place at the IS formed between CTL and melanoma target cells and to define whether 
they may influence melanoma resistance. This project is conducted on isolated human cells and 
in future will be followed by in vivo experiments in mice and later on by examining patients’ 
biopsies.  
Our current research aims at identifying the molecular mechanisms allowing remarkable 
prolonged resistance of melanoma cells following initial CTL activation and lethal hit delivery. 
 
Our experimental plan has been divided along the following three main lines:  
I) Analysis of CTL attack/melanoma cell resistance at the single cell level: time-lapse 
monitoring of CTL/tumor cell dynamic interactions by applying new molecular probes and 
imaging techniques. 
II) Identification of possible synaptic defects in lethal hit transmission at the 
CTL/melanoma cell contact site: investigate the IS from the tumor cell “point of view” in 
order to dissect early molecular steps of tumor cell resistance to CTL attack.  
III) Define molecular mechanisms of tumor “self-defense” at the immunological synapse: 
attempt to define molecular pathways that might be targeted to improve melanoma cell 
susceptibility to CTL attack. 
 
Targeting these synaptic self-defense mechanisms of melanoma cells could be a complementary 
approach to current strategies to stimulate the immune system to enhance tumor-specific CTL 
responses and could therefore provide a real clinical benefit. 
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III- Results 
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Abstract 
Human melanoma cells express various tumor antigens that are recognized by CD8+ cytotoxic 
T lymphocytes (CTL) and elicit tumor-specific responses in vivo. However, natural and 
therapeutically enhanced CTL responses in melanoma patients are of limited efficacy. The 
mechanisms underlying CTL effector phase failure when facing melanomas are still largely 
elusive.  
Here we show that, upon conjugation with CTL, human melanoma cells undergo an active late 
endosome/lysosome trafficking, which is intensified at the lytic synapse and is paralleled by 
chatepsin-mediated perforin degradation and deficient granzyme B penetration. Abortion of 
SNAP-23-dependent lysosomal trafficking, pH perturbation or impairment of lysosomal 
proteolytic activity restores susceptibility to CTL attack.  
Inside the arsenal of melanoma cell strategies to escape immune surveillance, we disclose a 
self-defense mechanism based on exacerbated lysosome secretion and perforin degradation at 
the lytic synapse. Interfering with this synaptic self-defense mechanism might be instrumental 
to potentiate CTL-mediated therapies in melanoma patients.  
Introduction  
CD8+ cytotoxic T lymphocytes (CTL) are major cellular effectors of the anti-tumor immune 
response144,199. They are, therefore, key components of therapeutic protocols aiming at 
potentiating immune response against cancer400. Clinical trials based on the induction of antigen-
specific CTL responses against tumor cells have been reported in various types of cancer. Among 
those, melanoma is the most studied tumor type in terms of immune reactivity and experimental 
immunotherapy401,402. In melanoma patients, several strategies are currently being evaluated, 
including vaccination with dendritic cells carrying tumor antigens, adoptive transfer of tumor-
specific CTL and treatment with immune-checkpoint inhibitors356,402-405. These strategies are 
mostly focused on strengthening CTL activation and effector function rather than on weakening 
tumor cell resistance to CTL attack. Although promising, those strategies are of limited efficacy 
and often present severe side effects405. Approaches aiming at dampening tumor cell resistance 
might therefore synergize with current therapeutic protocols and offer major benefits to patients. 
A key pathway used by human CTL to kill their target cells is based on perforin/granzyme-
mediated lethal hit delivery. Within minutes or seconds after productive TCR engagement, the 
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secretion of pore-forming protein perforin, granzyme B, and other proteases stored in CTL 
cytoplasmic granules (named lytic granules) takes place at the CTL/target cell lytic 
synapse107,192,237,239,406,407. Perforin-mediated penetration of granzyme B into target cells triggers 
an apoptotic cascade leading to target cell death227,408. Although CTL are equipped with other 
mechanisms of cytotoxicity, the perforin/granzyme pathway is key for human CTL and NK cell 
effector function, as indicated by the immunodeficiency status and the alteration of immune 
homeostasis in patients with genetic mutations of perforin or of molecules implicated in lytic 
granule docking and fusion to plasma membrane188,409. In spite of the major interest in 
potentiating CTL responses in melanoma patients, the molecular dynamics of perforin-mediated 
lethal hit delivery in this context remains to be elucidated. In particular, while it is well know that 
melanoma cells possess resistance mechanisms downstream of early pro-apoptotic granzyme B 
activity352,353, whether melanoma cells are endowed with mechanisms interfering with the early 
steps of perforin-mediated pore formation at the lytic synapse is presently elusive.  
In this work, we attempted to answer this outstanding question by monitoring the melanoma cell 
side of the lytic synapse during the encounter with cognate CTL, under conditions in which 
lethal hit delivery by CTL is efficiently triggered. Our results show that melanoma cells rapidly 
respond to CTL at the lytic synapse by a secretory burst of lysosome/late endosomes (LLE). 
Importantly, this leads to cathepsin-mediated degradation of perforin. Inhibition of this 
melanoma response by different means impairs melanoma cell resistance to perforin-mediated 
cytotoxicity. Our results reveal a previously unknown mechanism of perforin pathway 
inactivation, which might strongly contribute to melanoma cell immune resistance. They can 
inspire new therapeutic approaches that might be complementary to the immuno-modulatory 
strategies being currently used for the treatment of melanoma patients. 
Results 
Lethal hit deficiency at the CTL/melanoma cell lytic synapse 
We have previously shown that human CTL interacting in vitro with antigen-pulsed melanoma 
cells are efficiently triggered to lytic granule secretion, yet melanoma cells can resist for 
prolonged time to CTL-mediated cytoxicity231. To dissect the molecular mechanisms of 
melanoma cell resistance to CTL attack at the lytic synapse, we used, as cellular model, 
melanoma cells that were either pulsed with strong antigenic ligands (peptides of the human 
cytomegalovirus protein pp65) or left unpulsed prior to conjugation with cognate CTL. This 
strategy was chosen to focus on the melanoma cell side of the lytic synapse in conditions in 
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which optimal CTL activation was ensured. Virus specific CTL are indeed fully activated to 
lethal hit delivery when interacting with peptide-pulsed melanoma cells231.  
As target cells we employed the metastatic melanoma cell line D10 that we have previously 
characterized for its sustained resistance to CTL-mediated cytotoxicity231 and JY cells, an EBV-
transformed B cell line largely employed as a conventional target cell for human CTL410. D10 
cells have been recently characterized for their high clonogenic capacity and for their capacity 
to grow in spheroids411. 
To investigate whether melanoma cells might impair early steps of CTL mediated cytotoxicity, 
we assessed, in a first approach, perforin staining on target cell surface following short time 
interaction with CTL. As shown in Fig. 1a and Supplementary Fig. 1, melanoma cells 
exhibited a limited perforin staining when compared to conventional target cells, although CTL 
were similarly activated to lethal hit delivery during interaction with the two different target 
cell types, as revealed by the increase of surface CD107a expression (Fig. 1b and 
Supplementary Fig. 2). Under these experimental conditions melanoma cells exhibited 
resistance to CTL-mediated cytotoxicity when compared to conventional target cells, in line 
with our previously reported data (Fig.1c, and reference231). Deficient perforin staining was 
also observed in five additional metastatic melanoma cell lines (Supplementary Fig. 3).  
To better characterize this phenomenon, we investigated whether the observed defective 
staining of perforin on melanoma cell surface would translate into an impaired pore formation. 
To this end, the efficacy and time kinetics of lethal hit delivery to individual melanoma cells 
were studied by time-lapse confocal laser scanning microscopy. Propidium Iodide (PI) was 
added at high concentration to the culture medium to monitor lethal hit transmission based on 
the entry of this probe via the pores formed upon perforin binding on target cell surface412. 
CTL/melanoma cell conjugates from four independent experiments were analyzed to define the 
intensity of PI staining and the time elapsed between the initial CTL/target cell contact and the 
appearance of the PI staining at the target cell synaptic area. Results were compared with those 
obtained with conventional target cells. This analysis showed that the initial entry of PI was 
delayed in melanoma cells when compared to conventional target cells (Fig. 1d and 1e and 
Supplementary Movie 1 and 2). Moreover, melanoma cells exhibited an overall lower PI 
staining (Fig. 1d and 1f and Supplementary Movie 1 and 2).  
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In a third approach aiming at defining whether a defective transmission of lytic enzymes might 
occur at the CTL/melanoma cell synapse, we visualized granzyme B (GrzB) staining in target 
cells 15 minutes after conjugation with CTL using confocal laser scanning microscopy. This 
analysis showed that following interaction with CTL, while GrzB staining was significantly 
detected in a large fraction of sensitive target cells (~73%), only a small fraction of melanoma 
cells were detected GrzB+ (~8%) (Fig. 2a). Defective GrzB penetration in melanoma cells, 
when compared to sensitive target cells, was also measured by FACS analysis in fixed and 
permeabilized CTL/target cell conjugates (Fig. 2b and 2c). This analysis allowed us to show 
that GrzB release by CTL is similarly triggered following interaction with melanoma cells as 
compared to conventional target cells, thus ruling out the possibility that defective GrzB 
transfer would result from defective CTL activation (Fig. 2b and 2c). 
Taken together, the above results point out a deficient lethal hit delivery at the CTL/melanoma 
cell lytic synapse characterized by altered perforin pore formation and GrzB internalization.  
 
High-rate LLE vesicle trafficking in melanoma cells  
 
It is well established that LLE play a key role in cell membrane repair following physical, 
chemical and biological assaults413,414. We thus investigated the dynamics of melanoma late 
LLE as compared to those of conventional target cells susceptible to CTL-mediated 
cytotoxicity.  FACS analysis showed that melanoma cells exhibited higher constitutive CD107a 
and CD63 surface expression when compared to conventional target cells, suggesting that 
melanoma cells might exhibit a constitutively active secretion of LLE vesicles (Fig. 3a). We 
therefore attempted to monitor the constitutive exocytosis and recycling of LLE on melanoma 
cell surface using time-lapse microscopy. 
To do so, we took advantage of a method we recently set up to visualize real-time granule 
exocytosis by human mast cells based on the addition of avidin-sulforhodamine (Av-SRho) to 
culture medium, which binds to the serglycin- proteoglycans exposed on cell surface upon 
granule exocytosis415. Although serglycin-proteoglycan is best known as a hematopoietic cell 
granule proteoglycan, it is also expressed in human endothelial cells and in some metastatic 
tumors416,417.  Accordingly, our data show that it is expressed by both conventional target cells 
and melanoma cells (Supplementary Fig. 4). We thus monitored, by time-lapse microscopy 
the constitutive exocytosis of LLE vesicles in melanoma cells by adding Av-SRho to the culture 
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medium. This analysis revealed a constitutive exposure of lysosomal vesicles on melanoma cell 
surface. In comparison, the conventional target cells failed to display detectable constitutive 
exposure of lysosomal vesicles on their surface (Fig. 3b, Supplementary Movies 3 and 4). 
In parallel experiments, overnight incubation of melanoma cells with Av-SRho resulted in its 
up-take. Intracellular Av-SRho partially co-localized with CD107a and CD63 within 
intracellular vesicles, validating the use of Av-SRho as a tool to study melanoma LLE exposure 
(Fig. 3c). 
Taken together, the above results reveal that melanoma cells exhibit a constitutive high-rate 
LLE vesicle exocytosis at the cell surface. 
 
Melanoma cell LLE vesicles exocytosis towards attacking CTL  
 
We next investigated whether vesicular trafficking in melanoma cells might be exacerbated at 
lytic synapses formed with cognate CTL. In a first approach, we investigated, by confocal 
microscopy the localization of CD63+ intracellular vesicles in fixed and permeabilized 
CTL/melanoma cell conjugates. As shown in Fig. 3d, peptide-pulsed melanoma cells engaged 
in cognate interactions with CTL, displayed a significant enrichment of CD63 towards the lytic 
synapse. Such enrichment was not observed in non-cognate interactions (unpulsed melanoma 
cells).  Morphological data were quantified by drawing two equal regions, one on the 
melanoma cell side of the lytic synapse and the other on the opposite side of the cell (see 
scheme in Fig. 3e). Three-dimensional (3-D) measurements of the CD63 fluorescence intensity 
in the cell volume defined by the regions were performed (see material and methods). This 
analysis provided quantitative evidence of an antigen-dependent enrichment of melanoma cell 
CD63+ endosomal compartment at the synaptic area in a significant number of CTL/melanoma 
cell conjugates (Fig. 3f).  
To monitor the dynamics of the LLE in melanoma cells facing the attack of cognate CTL, we 
expressed CD107a/GFP in melanoma cells. CD107a/GFP+ intracellular vesicles were 
visualized by time-lapse microscopy using a spinning-disk confocal microscope. Upon contact 
with CTL, peptide-pulsed melanoma cells displayed a rapid re-localization of the 
CD107a/GFP+ compartment as measured by an accumulation of GFP fluorescence intensity at 
the synaptic area during the first minutes after conjugation with CTL (Fig. 4a and 4b and 
Supplementary Movie 5). In order to monitor CTL lytic granule polarization towards target 
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cells with the dynamics of melanoma LLE upon cognate cell-cell interaction in T 
cell/melanoma cell conjugates, we took advantage of the observation that pre-treatment of CTL 
with either Av-SRho or Av-Alexa488 allows to stain lytic granules (as shown by Av-SRho and 
perforin co-localization in fixed and permeabilized CTL, Supplementary Fig. 5). We could 
therefore monitor CTL lytic granule dynamics (as detected by the polarization of Av-SRho 
loaded lytic granules) together with melanoma cell LLE polarization by time-lapse microscopy 
as indicated in Fig. 4a.  
Having observed that melanoma cells rapidly re-locate their LLE toward the contact site 
formed with cognate CTL, we asked whether the high-rate of constitutive lysosomal secretion 
observed in melanoma cells might be further enhanced upon contact with cognate CTL. We 
thus visualized the exposure of lysosomal vesicles on peptide-pulsed melanoma cell surface 
during interaction with CTL by adding Av-SRho to the culture medium. As shown in Fig. 4c 
and 4d and Supplementary Movie 6, melanoma cells exhibited an increased staining with Av-
SRho during the first 10 minutes after contact with CTL. In contrast, unpulsed melanoma cells 
did not undergo detectable increase of Av-SRho binding upon contact with CTL 
(Supplementary Movie 7). We also monitored CTL lytic granule polarization towards target 
cells in parallel with the secretory burst of melanoma LLE upon cognate cell-cell interaction. 
Dynamics of CTL lytic granules was visualized by monitoring the polarization of Av-Alexa488 
loaded lytic granules whereas melanoma cell LLE exposure was detected by the addition of Av-
SRho to the culture medium. This analysis extended the above results by showing that the 
melanoma cell LLE exocytosis occurs following CTL lytic granule re-polarization 
(Supplementary Movie 8). 
To quantify this phenomenon in a large number of melanoma cells we analyzed fixed 
CTL/melanoma cell conjugates after 5 minutes co-culture in the presence of Av-SRho. As 
shown in Fig. 4e in unpulsed conditions perforin+ lytic granules of CTL did not polarize 
towards melanoma cells and melanoma cell exhibited non-polarized basal level of Av-SRho 
binding. Conversely, when melanoma cells were previously pulsed with the antigenic peptide, 
CTL polarized their lytic granules towards melanoma cells and melanoma cells exhibited a 
strong Av-SRho binding that was enriched at the synaptic area. Morphological data were 
quantified by drawing two equal regions, one on the melanoma cell side of the lytic synapse 
and the other on the opposite side of the cell (as indicated in Fig. 3f). 3-D measurements of the 
Av-SRho fluorescence intensity in the cell volume defined by the regions showed an increase 
of Av-SRho staining in the synaptic volume in the majority of peptide pulsed melanoma cells 
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(Fig. 4f). It should be noted that conventional target cells exhibited a barely detectable 
exposure of LLE vesicle when interacting with cognate CTL in the presence of Av-SRho 
(Supplementary Movie 9 and 10).  
Taken together, the above results show that melanoma cells respond to CTL attack by adjusting 
the direction of their vesicular trafficking towards the lytic synapse and by enhancing global 
late-endosomal vesicle exocytosis on the cell surface. 
 
Melanoma cells degrade perforin from CTL granules  
Having observed that melanoma cells activate a late-endosomal vesicle exocytosis process 
towards cognate CTL, we asked whether this mechanism might neutralize CTL-mediated 
cytotoxicity by degrading critical lytic molecules. We investigated the possibility that perforin 
might be degraded by melanoma cells since this enzyme has been previously reported to be 
substrate of lysosomal hydrolyses cathepsin B (CatB)222,223, and since human and mouse 
melanoma cells are known to express high levels of cathepsin B418. In line with this hypothesis, 
the level of exposure of the CatB on melanoma cell surface upon CTL attack was significantly 
higher than that on conventional target cell surface (Supplementary Fig. 6). 
In a first approach, we employed FACS analysis to test whether CatB might inhibit perforin 
lytic activity. Perforin-sensitive Jurkat cells were incubated with purified human perforin either 
in the absence or in the presence of CatB or in the presence of CatB together with its inhibitor 
CA074. Incubation of Jurkat cells with purified perforin resulted in a strong cell 
permeabilization (as detected by PI entry) that was inhibited by CatB. Perforin lytic function 
was recovered in the presence of CA074 (Fig. 5a and 5b).  
In a second approach, we investigated cathepsin-mediated degradation of perforin contained in 
CTL lytic granules by Western blot analysis. Incubation of lytic granule extracts with CatB 
resulted in perforin degradation. This degradation was inhibited by the addition of CA074 (Fig. 
5c and Supplementary Fig. 7). Interestingly, dose-dependent lytic granule perforin 
degradation was also observed when lytic granule extracts were co-incubated with melanoma 
cell lysates (Fig. 5d and Supplementary Fig. 7). 
In a further approach, we incubated CTL lytic granule lysates with Jurkat cells in the presence 
of a purified vesicular fraction of melanoma cells. This analysis showed that melanoma cell 
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vesicular fraction was able to inhibit the lytic activity of CTL granules. Lytic activity was 
recovered in the presence of CA074 (Fig. 5e and f).  
Taken together the above results show that melanoma cells are endowed of an intrinsic capacity 
to degrade perforin. 
 
SNAP-23 silencing in melanoma cells enhances cytotoxicity  
In order to establish whether a mechanistic link might exist between the polarized LLE 
exocytosis of melanoma cells and the defective perforin-mediated cytotoxicity, we devised 
strategies to interfere with melanoma cell lysosomal compartment dynamics and function. The 
expression of SNAP-23, a SNARE molecule known to mediate lysosomal vesicle 
exocytosis419,420 was silenced in melanoma cells by transfection of a specific shRNA. This 
treatment resulted in the reduction of SNAP-23 expression in melanoma cells of 60-70%, as 
detected by polymerase chain reaction and by antibody staining (Supplementary Fig. 8). We 
tested whether the reduced SNAP-23 expression would interfere with the dynamics and 
secretion of LLE compartments in melanoma cells. The dynamics of CD107a/GFP+ 
intracellular vesicles in cells treated with SNAP-23 shRNA was profoundly altered. Indeed, the 
rapid re-localization of the CD107a/GFP+ compartment towards the CTL was abrogated and no 
enrichment of the GFP fluorescence intensity at the synaptic area could be measured (Fig. 6a 
and 6b and Supplementary Movie 11).  
Accordingly, when we monitored the exposure of LLE vesicles (as detected by the addition of 
Av-SRho to the culture medium) on the surface of melanoma cells with reduced SNAP-23 
expression, a profound inhibition of endosomal vesicle exocytosis was observed, as detected by 
a lower Av-SRho uptake (Fig. 6c and 6d and Supplementary Movie 12). Transfection of 
melanoma cells with control shRNA did not affect CD107a/GFP+ vesicle synaptic enrichment 
nor LLE exocytosis (Fig. 6a–d and Supplementary Movies 13, 14 and 15). 
We next investigated the impact of SNAP-23 silencing on melanoma cell resistance to CTL 
attack. As shown in Fig. 6e and 6f, reducing the expression of SNAP-23 resulted in increased 
susceptibility to CTL-mediated cytotoxicity.  
Taken together, these results establish a mechanistic link between active lysosomal secretion in 
melanoma cells and defective perforin-mediated cytotoxicity. 
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 Enhanced cytotoxicity by perturbing lysosome function 
Having observed that interfering with LLE trafficking in melanoma cells weakened their 
resistance to perforin-mediated cytotoxicity, we investigated whether alteration of melanoma 
cell lysosome function would also increase their sensitivity to CTL attack. In a first approach, 
we perturbed melanoma cell LLE function by using drugs altering the pH of those 
compartments. Melanoma cells were pretreated with 40µM monensin, a carboxylic ionophore 
specific for monovalent cations that elevates vacuolar pH421. This treatment resulted in a 
profound alteration of melanoma cell LLE compartment as detected by impaired staining with 
the pH-dependent probe Lyso-Tracker Red (Fig. 7a). Monensin was thoroughly washed before 
co-culture with CTL. Monensin-treated melanoma cells exhibited enhanced cytotoxicity when 
compared to the untreated counterpart (Fig. 7b). Under the same experimental conditions, CTL 
activation was not affected, as detected by CD107a exposure on their surface (Fig. 7c).  
Enhancement of CTL-mediated cytotoxicity following monensin treatment was confirmed in 
eight additional melanoma cell lines (Supplementary Fig. 9).  
In further experiments, the impact of bafilomycin A1 and concanamycin A (two additional 
drugs altering acidic endosomal compartment pH422) was investigated. As shown in 
Supplementary Fig. 10, pre-treatment of melanoma cells with these drugs followed by 
washing before conjugation with CTL, significantly enhanced cytotoxicity.  
In a second approach, we pre-treated melanoma cells with inhibitors of proteolytic enzymes. 
Pre-treatment of melanoma cells with E64d, a protease inhibitor targeting a limited number of 
protelytic enzymes including cathepsins (see material and methods) or specific inhibitor of 
cathepsins (CI3), followed by extensive washing before conjugation with CTL, significantly 
increased cytotoxicity (Fig. 7d and 7e).  
These results supported our finding that perforin can be degraded by melanoma cathepsins and 
further illustrated that the LLE pathway might serve as an important defense mechanism 
against CTL-mediated cytotoxicity in melanoma cells.  
Finally, we investigated if it was possible to visualize, by confocal microscopy, synaptic quanta 
of perforin on melanoma cell surface. We stained therefore CTL/melanoma cell conjugates with 
anti-perforin antibodies followed by secondary antibodies labeled with QDots. This approach 
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allowed us to detect synaptic perforin and to quantify the amount of early exocytosed perforin 
bound to the melanoma cell side of the synapse. We performed 3-D confocal microscopy in 
conditions in which melanoma cells were either untreated or pre-treated with monensin and 
conjugated for 5 minutes with CTL. As shown in Fig. 7f and Supplementary Movie 16, 
perforin staining was barely detectable on untreated melanoma cells. Conversely, synaptic 
perforin quanta were detected on the surface of melanoma cells that had been pre-treated with 
monensin (Fig. 7f and Supplementary Movie 17). Measurement of perforin staining on a 
significant number of CTL/melanoma cell conjugates showed a significant increase in synaptic 
perforin staining in monensin treated melanoma cells (Fig. 7g and 7h).   
To further visualize this phenomenon, we performed 3-D reconstruction of images in which 
CTL/melanoma cell conjugates were stained with antibodies directed against CD107a and 
perforin. The 3-D images further show that in monensin-treated melanoma cells, perforin 
quanta decorate the synaptic side of the melanoma cell surface (Supplementary Movies 18-
20). 
Taken together, the above results illustrate that perforin, once released by CTL at the synaptic 
cleft, is rapidly destroyed by melanoma cells via a mechanism dependent on LLE proteolytic 
potential. 
 
Discussion 
In the present work, we investigated the dynamics of interaction between CTL and melanoma 
cells. We reveal a novel mechanism of melanoma cell defense from CTL attack, based on 
targeted trafficking of late LLE vesicles towards the synaptic area and on LLE burst exocytosis. 
This self-defense mechanism leads to synaptic degradation of perforin and failure in pore 
formation.  
In this study, we took advantage of our previous observation that virus specific CTL are fully 
activated to lethal hit delivery when interacting with peptide-pulsed melanoma cells231. Using 
this cellular model we could therefore focus on melanoma cell mechanisms of resistance, with 
no concern for CTL activation. The fact that human CTL can be efficiently triggered to lethal 
hit delivery when interacting with peptide-pulsed melanoma cells (that might exhibit variable 
levels of HLA molecules) is not surprising. Others and we, indeed, put forth the notion that 
CTL are exquisitely sensitive to antigenic stimulation and exhibit saturating cytotoxicity 
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responses when interacting with target cells displaying on their surface an extremely low 
number of specific peptide-MHC complexes40,107,410,423 .  
Our results shed new light on the role played by lysosomal proteolytic enzymes in the 
regulation of CTL function. The interplay between cathepsins and various components of the 
CTL lytic cascade has been thoroughly investigated. It is well established that cathepsins 
contained within CTL lytic granules are instrumental for maturation of pro-caspases into 
caspases and for the efficient induction of target cell apoptosis 424,425. Moreover, CTL granule 
CatB has been reported to restrain perforin function by degrading perforin bound on the CTL 
surface. This mechanism has been proposed to be instrumental in the protection of CTL from 
suicide or fratricide killing223. However, this function of CatB is controversial since it has been 
reported that in CatB knockout mice CTL can survive their own lytic granule secretion222.  
While the functional role of cathepsins contained in lytic granules has been studied, whether 
and how proteolytic enzymes released by target cells at the lytic synapse might enhance or 
dampen the efficacy of lethal hit delivery remains to be elucidated. We provide here 
experimental support to the hypothesis that perforin can indeed be a substrate of cathepsins and 
that perforin proteolysis is instrumental for the survival of melanoma target cells. 
Our results are in apparent contrast with previous data showing that purified perforin is a 
relatively poor substrate for CatB in vitro222. A possible explanation of this apparent 
discrepancy might be that several proteolytic enzymes contained in melanoma LLE and in lytic 
granules themselves might concur to perforin degradation. An alternative explanation is that 
cathepsins might activate additional proteolytic enzymes contained in melanoma cell lysosomes 
that would be responsible for perforin degradation.  
An interesting question raised by our work concerns where perforin degradation actually 
occurs in CTL/melanoma cell conjugates.   
Our results are compatible with two scenarios. First, degradation might occur extracellularly on 
the melanoma cell side of the lytic synapse. Accordingly, melanoma cell lysosome secretion 
might allow synapse acidification thus creating a synaptic microenvironment facilitating 
hydrolases function. Such a scenario has been previously described for lysosomal exposure at 
the B cell synapse for antigen extraction and processing225. A second scenario also compatible 
with our data is that perforin degradation might rapidly occur intracellularly upon endocytosis.  
We favor the hypothesis that perforin is degraded at the cell surface, since in our hands, 
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perforin quanta at the lytic synapse are barely visible in untreated melanoma cells while they 
are detected on the cell surface following alteration of lysosomal pH (Fig. 7 and Movies 16-
20). 
Taken together, our results underline the role played by the endosomal compartment of target 
cells in regulating the process of perforin-mediated cytotoxicity. It has been reported that 
perforin triggers in target cells an early endosomal compartment-based reparation mechanism 
that regulates cell death by favoring the induction of apoptosis as opposed to necrosis245,254. 
Here we extend this notion, by showing that, in CTL-resistant target cells, such as melanoma 
cells, the process of cell death is aborted by lysosomal proteases-mediated perforin degradation.  
We also show that upon interaction with cognate CTL, melanoma cell LLE vesicles are 
enriched at the lytic synapse. These results indicate that melanoma cells are capable of 
dedicated lysosomal polarization responses to face CTL lytic assault. The molecular 
mechanisms triggering such dedicated responses are presently elusive. We speculate that they 
might be triggered by localized calcium entry due to perforin-mediated pore formation at the 
synaptic area252. 
An interesting aspect of our research is that we describe an important constitutive trafficking of 
lysosomal vesicles at the melanoma cell plasma membrane that is enhanced following contact 
with cognate CTL. Together, these results indicate that active lysosomal secretion might have 
been developed by melanoma cells as part of an immunoediting process occurring under the 
selective pressure of the immune system and might therefore serve to escape from CTL-
mediated immune surveillance in vivo426.  
It is tempting to speculate that LLE-mediated defense of target cells from CTL attack is not a 
prerogative of melanoma cells but is shared by other tumor cells. A previous study reported a 
correlation between the resistance to natural killer cell–mediated killing and reduced perforin 
staining in a human leukemia cell line, however the molecular mechanisms of impaired 
perforin staining were not investigated427. Further research is required to define whether LLE 
secretion might be a general defense mechanism against the perforin/caspase pathway in 
cytotoxicity resistant cells. A first indication in favor of this possibility comes from our results 
showing that conventional target cells expressing high levels of CD63 and CD107a are more 
resistant to CTL-mediated cytotoxicity than their CD63lowCD107alow counterpart 
(Supplementary Fig. 11).  
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A number of studies have demonstrated that anti-apoptotic pathways and other escape 
mechanisms, operate in cancer cells to mediate resistance to CTL or NK cell attack352,353,428-430. 
Our observation of an early defect in lethal hit delivery does not exclude that additional 
downstream pathways might operate in melanoma cells to generate resistance to CTL mediated 
cytotoxicity. However, in our study, we show that the suppression of lysosome-based early 
defense mechanisms enhances cytotoxicity, indicating that this might be a relevant mechanism 
of defense among others.  
It is well know that in melanoma patients the up-regulation of PD-L1 in response to 
inflammatory mediators released by infiltrating T lymphocytes and by other cells of the 
microenvironment plays a crucial role in reducing ongoing immune responses365,431,432. It is 
tempting to speculate that LLE secretory burst might work as an early “innate” mechanism of 
defense at the beginning of immune cell attack to give time to melanoma cells to deploy late 
“adaptive” defense mechanisms against infiltrating lymphocytes, including PD-L1 up-
regulation. During late phases of the response, immune checkpoint receptors would serve as 
key mechanisms of melanoma cell escape from immune surveillance. Upon patient treatment 
with antibodies directed against immune checkpoint molecules, the LLE secretory burst might 
regain a primary role in melanoma cell defense from immune cell attack. 
All in all, our results are compatible with a model in which LLE vesicle secretion at the lytic 
synapse by melanoma cells is a fundamental early molecular mechanism of cell resistance to 
CTL attack that acts during the first few minutes after the encounter with CTL and is per se 
sufficient to confer strong resistance to CTL attack. Nevertheless, this resistance mechanism is 
potentially complementary to other additional mechanisms of resistance that individual 
melanoma cells might develop, including up-regulation of PD-L1 and resistance to apoptosis 
induction.  
 
Various strategies are currently employed to potentiate CTL-mediated immune responses in 
melanoma patients with the goal of impairing tumor progressions. However, current clinical 
results are overall unsatisfactory356,405. Although melanoma vaccines using peptides emulsified 
in incomplete Freund’s adjuvant, irradiated whole cells (either untreated or genetically 
modified to release immuno-stimulating factors), cell lysates or autologous dendritic cells 
carrying melanoma antigens are currently being assessed, clinical benefits have been obtained 
only on a small number of patients356,405. Therapies based on adoptive transfer of autologous in 
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vitro expanded TILs are promising and can elicit clinical responses lasting for years in a 
fraction of treated patients, however these procedures are expensive and require lymphocyte 
depleting regimens that can expose patients to severe adverse effects356,402,403,405. Finally, 
therapies based on monoclonal antibodies targeting the CTLA-4/CD80-CD86 or the PD-1/PD-
L1 axis are certainly very promising356,405,433 however they need to be optimized to establish the 
best compromise between clinical benefits and adverse effects.  
Our results point out a new possible therapeutic path worth following in order to tackle 
melanoma resistance to immune-surveillance from a new angle.  Targeting lysosomal 
proteases-mediated defense of melanoma cells at the lytic synapse can be indeed 
complementary to any current immuno-stimulating strategy and can therefore provide a real 
clinical benefit. Protease inhibitors have been previously tested in the therapy of melanomas as 
well as of other tumors in an attempt to interfere with tumor invasion and metastasis434. It is 
tempting to speculate that the use of protease inhibitors might be re-considered in order to 
associate them to therapeutic strategies aiming at potentiating CTL responses. 
In conclusion, our results underscore a previously unknown potential Achilles’ heel of 
melanoma cells in respect to CTL mediated cytotoxicity that might be exploited in clinical 
trials. They can inspire the pioneering of new therapeutic strategies to enhance CTL-mediated 
activity in melanoma patients by targeting the melanoma cell side of the immunological 
synapse. 
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Methods 
Cell lines, culture and transfection conditions 
Human CD8+ T cell lines were purified from healthy donor blood samples using the 
RosetteSep™ Human CD8+ T Cell Enrichment Cocktail (StemCell Technologies). For cloning, 
HLA-A2–restricted CD8+ T cells specific for the NLVPMVATV peptide or the VLAELVKQI 
peptide of the CMV protein pp65 were single cell sorted into 96-U-bottom plates using a BD 
FACSAria II cell sorter using tetramer staining. Cells were cultured in RPMI 1640 medium 
supplemented with 8% human AB serum (PAA), minimum essential amino acids, HEPES and 
sodium pyruvate (Invitrogen), 100 IU/ml human rIL-2 and 50ng/ml human rIL-15. CD8+ T cell 
clones were stimulated in complete RPMI/HS medium containing 1µg/ml PHA with 1×106/ml 
35Gy irradiated allogeneic peripheral blood mononuclear cells (PBMC isolated on Ficoll Paque 
Gradient from buffy coats of healthy donors) and 1×105/ml 70Gy irradiated EBV-transformed 
B cells. Re-stimulation of clones was performed every 2 weeks. Blood samples were collected 
and processed following standard ethical procedures (Helsinki protocol), after obtaining written 
informed consent from each donor and approval for this study by the local ethical committee 
(Comité de Protection des Personnes Sud-Ouest et Outremer II). 
The following HLA-A2+ cell lines were used as target cells: EBV-transformed B cells (JY); 
HBL and D10 cells (isolated from metastatic melanoma patients, kindly provided by Dr. G. 
Spagnoli, Basel, Switzerland); M17, M44 and M113 melanoma lines (isolated from metastatic 
melanoma patients, kindly provided by Dr. F. Jotereau, Nantes, France), EB81-MEL.B, 
LB3110-MEL and LB2259-MEL.A (isolated from metastatic melanoma patients, kindly 
provided by Dr. P. Coulie & N. V. Baren, Brussels, Belgium); ME275 (isolated from metastatic 
melanoma patients, kindly provided by Dr. Daniel Speiser Ludwig Institute for Cancer 
Research Lausanne, Switzerland). The human acute T cell leukemia cell line Jurkat was from 
the ATCC collection. Transfection of 1×106 melanoma D10 cells with 4µg plasmids coding for 
shRNA targeting SNAP-23 or a non-targeting shRNA plasmid (Sigma,SNAP-23: 
GTACCGGGAAACTCATTGACAGCTAAAGCTCGAGCTTTAGCTGTCAATGAGTTTCTT
TTTTG and Control: no specific target) were performed using TransIT-X2 dynamic delivery 
system (Mirus), according to the manufacturers’ recommendations.  
The medium was replaced 8 hours after transfection. Alternatively, 1×105 melanoma D10 cells 
were transduced with 10 MOI lentiviral vector carrying the same plasmids over 6 hours in 
RPMI-1640 containing 5% FCS and polybrene (4μg/ml). Transfected cells were selected by 
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culturing them in the presence of 2µg/ml puromycin for 7 days. Puromycin was added 48 hours 
after transfection. Target cells were cultured in complete RPMI 1640 supplemented with 10% 
FCS. Transfection efficiency was evaluated by PCR and flow cytometry. 
 
FACS analysis  
The following mAbs were used:  Alexa Fluor 488 or Alexa Fluor 647 anti-human perforin 
antibody (clone dG9; BioLegend), PE-Cy7 mouse anti-human CD107a (cloneH4A3; BD 
Biosciences), Pacific Blue anti-human CD8 antibody (clone RPA-T8; BioLegend) and FITC 
mouse anti-human CD63 (cloneH5C6; BD Biosciences).  
To distinguish CTL from target cells in the analysis, CTL were loaded with 1μM CellTracker™ 
Green CMFDA (5-Chloromethylfluorescein Diacetate, (Molecular Probes, Invitrogen) in RPMI 
for 15 minutes at 37°C, prior conjugation with target cells. Alternatively, cells were not loaded 
with 0.1µM CMFDA before conjugation instead CD8+ cells were identified by a staining with 
Pacific Blue anti-human CD8 antibody. Target cells were co-cultured with T cells in RPMI, 5% 
FCS/HEPES at 2 CTL versus 1 target cell ratio. At different time points, CTL/target cell co-
culture cells were washed in ice-cold PBS containing 0.5mM EDTA. Nonspecific binding was 
prevented by 15 minutes incubation with 1% PBS containing 1% FCS which was used 
throughout the procedure as staining and washing buffer. Cells were stained with either specific 
antibodies or corresponding isotype controls. For cathepsin B expression on target cell surface 
cells were stained with a goat anti-human cathepsin B (sc-6493; Santa Cruz) followed by an 
Alexa Fluor 647 donkey anti-goat Ab (Invitrogen). Staining was performed on ice at 4°C for 30 
minutes. Samples were acquired using a FACScalibur or LSR II (Becton and Dickinson). 
Results were analyzed using the FlowJo Pro software (Tree Star, Inc.). 
 
Cytotoxicity assay  
Target cells were left unpulsed or pulsed with 10µM antigenic peptide during 2 hours at 
37°C/5% CO2, washed three times and subsequently transferred to a 96 well U-bottom plate at 
25×103 cells/100μl RPMI, 5% FCS/HEPES. CTL were previously stained with 0.1μM CMFDA 
for 15 minutes at 37°C/5% CO2, washed and added to the target cells at 2 CTL versus 1 target 
cell ratio (unless indicated) in 100μl RPMI, 5% FCS/HEPES. Cells were pelleted for 1 minute, 
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1500 rpm, and incubated at 37°C/5% CO2 for 4 hours. In some experiments target cells were 
pre-treated with either 40µM monensin or 1µM bafylomycin A1 or 1µM concanamycin A and 
thoroughly washed before conjugation with CTL. In additional experiments, melanoma cells 
were pretreated for 16 hours with 10µM E64d (inhibitor of calpain, cathepsin B, H and L; 
Sigma) or 10µM Cathepsin inhibitor III (cathepsin B, H and L inhibitor; Merck-Millipore) in 
serum free medium. During the last 2 hours, cells were either unpulsed or pulsed with antigenic 
peptide. Cells were thoroughly washed before conjugation with CTL. Before FACS analysis, 
0.25µg 7-Aminoactinomycin D (7-AAD; BD Biosciences) was added to each sample in order 
to measure the percentage of death targets. For the present study, a 4 hour 7-ADD uptake 
cytotoxicity assay has the advantage, over other possible tests, used to measure melanoma cell 
survival and growth (such as colony formation assays), since it allows to measure cell death 
during a time window compatible with perforin-mediated cytotoxicity. 
 
Time-lapse microscopy monitoring of perforin pore formation 
Target cells were pulsed with 10µM peptide, washed and seeded at 1.5x105 cells/well on poly-
D-lysine coated 8-well chambered slides (Ibidi, Munich, Germany) 5 minutes prior to imaging. 
Chambered slides were mounted on a heated stage within a temperature-controlled chamber 
maintained at 37°C, and constant CO2 concentrations (5 %). At the beginning of recording 
2x105 CTL, labeled with either 1µM CMFDA or with 5µM TubulinTracker™ Green 
(Molecular Probes, loading was performed for 30 minutes at 37°C/5% CO2) were added to 
chambered slides in the presence of 200µM Propidium Iodide. Images of CTL/target cell 
conjugates were acquired for 1 hour using either a Zeiss LSM 510 or a Zeiss LSM 710 
microscope (Zoom factor 63X). 
 
Intracellular staining  
Target cells were either unpulsed or pulsed with 10μM antigenic peptide for 2 hours at 37 °C in 
RPMI 5% FCS/HEPES and washed three times (in some experiments cells were pretreated 
with 40µM monensin for 2 hours). Conjugates of 2 CTL versus 1 target cell were then formed 
by 1 minute centrifugation at 1500 rpm. Upon 5 or 15 minutes of co-incubation at 37°C, cells 
were fixed with 3% paraformaldehyde, permeabilized with 0.1% saponin (in PBS/3% 
BSA/HEPES), and stained with the following primary antibodies: anti-human perforin mAb 
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(clone δG9; BD Pharminogen), anti-human CD63 mAb (ab1318; Abcam), anti-human GrzB 
mAb (clone G11; Santa Cruz Biotechnology), anti-human Serglycin mAb (ab76512; Abcam) 
anti-human CD107a rabbit Ab (ab24170; Abcam) and anti-human SNAP-23 (Ab4114; Abcam). 
Primary Abs were followed by goat anti-mouse isotype-specific Ab or goat anti-rabbit Ab 
labeled with Alexa 488, Alexa 555, Alexa 647, Alexa 700 or goat anti-Mouse IgG conjugate 
(H+L) labeled with either QDot 525 or QDot 585 (Molecular Probes). In some experiments 
target cells are identified by Cell Tracker Blue (life technologies) staining. The samples were 
mounted in 90% glycerol-PBS containing 2.5% DABCO (Fluka) and examined using either a 
LSM 710 (Zeiss) or SP8 (Leica) confocal microscope over a 63× Plan-Apochromat objective 
(1.4 oil). Electronic zoom 4 on LSM710 and 5 on SP8. Z-Stack images of optical sections were 
acquired throughout the cell volume. Alternatively, GrzB staining was evaluated by FACS 
analysis as described above.  
 
Image quantification 
Images were scored by evaluating, for each experimental condition, at least 45 CTL/target cell 
conjugates in randomly selected fields from at least three independent experiments. GrzB 
staining was evaluated by scoring the percentage of positive target cells. To quantify the 
polarization of CD63+ vesicles towards the immunological synapse or synaptic enrichment of 
Av-SRho staining, unprocessed images were analyzed by dividing each target cell into three 
equal regions. Fluorescence was measured using the ROI statistics tool of the ImageJ software 
on image projections in two equally defined volumes (one at the synaptic area and the other at 
the distal area). In order to exclude CD63 or Av-SRho staining of CTL a region was carefully 
drawn on the melanoma cell side of the lytic synapse. Results were reported as the fold increase 
of the corresponding staining integrated fluorescence intensity at the synaptic region divided by 
the same fluorescence intensity measured at the distal region (see schemes drawn in Fig. 3). For 
quantification of perforin on melanoma cells, the lytic synapse was divided into two equal 
volumes, one on the CTL and one on the melanoma cell side. Total perforin fluorescence 
intensity at the lytic synapse of both volumes was acquired on image projections of 
CTL/melanoma conjugates. Perforin on melanoma cells was quantified as the percentage of 
perforin fluorescence intensity (FI) at the defined melanoma cell volume (red box) divided by 
the totality of perforin fluorescence intensity (FI, black box) at the lytic synapse (% of perforin 
FI = (perforin Fl on melanoma cell/Total perforin Fl) × 100; see schemes drawn in Fig. 7) using 
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the ImageJ software. The above-described measurements were confirmed by analyzing 
fluorescence intensity in melanoma cells z-stack projections using the Region Measurements of 
the Metamorph software (Universal Imaging). In further experiments z-stack images of CTL 
interacting with melanoma cells were reconstructed and analyzed using the Surface tool of the 
Imaris software. 
 
Monitoring melanoma cell LLE trafficking and secretion 
To quantify lysosomal localization at the lytic synapse, wild type D10 cells or SNAP-23 
silenced D10 cells were infected with 40 particles per cell of baculovirus coding for CD107a-
GFP (Cell Light Lysosomes; Invitrogen) overnight. Cells were either unpulsed or pulsed with 
10µM peptide and monitored during interaction with CMFDA or Av-SRho loaded CTL. Time 
lapse video microscopy was performed for 1 hour using a Nikon inverted spinning disk 
confocal microscope equipped with a back-thinned charge-coupled device (CCD) camera 
(Evolve; Photometrics, Tucson, AZ, 512 X 512 pixels), equipped with a temperature-controlled 
chamber maintained at 37°C, and constant CO2 concentration (5%), allowing acquisition of 
multi-position images using an NA1.3/40X oil-immersion objective piloted by the Metamorph7 
software. The images were processed using ImageJ. CD107a-GFP integrated fluorescence 
intensity at the lytic synapse was quantified for several conjugates and reported as fold increase 
over the initial intensity at time 0 of conjugate formation. 
To measure the exposure of the lysosomal compartments of melanoma cells, peptide-pulsed 
wild type D10 or SNAP-23 silenced D10 cells were seeded into poly-D-lysine coated 
chambered slides in 100฀l medium containing 8µg/ml Av-SRho- Av-SRho (red) uptake in the 
presence or absence of CMFDA or Avidin-Alexa488 loaded CTL was monitored for 1 hour 
using a Nikon inverted spinning disk confocal microscope. 
 
Measurement of perforin lytic activity  
Human purified perforin (Enzo Life) permabilizing activity was determined by 1 hour 
incubation of 1x106 Jurkat cells with 125ng of perforin following manufactures recommended 
conditions. Perforin was pre-treated or not for 2 hours at 37°C with 500ng/ml purified human 
liver cathepsin B (CatB, Merck-Millipore), or CatB that was previously co-incubated with 
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10µM CA074 (Merck-Millipore) for 30 minutes at 37°C. Cell permeabilization was measured 
in the presence of 25µg/ml Propidium iodide (PI) by FACS analysis. In some experiments, lytic 
granule lysates were pre-treated or not with melanoma cell vesicular fraction lysates for 2 hours 
at 37°C. Melanoma cell vesicular fraction lysates were previously co-incubated or not with 10 
µM CA074 (Merck-Millipore) for 30 minutes at 37°C before being incubated with lytic granule 
lysates. Intracellular vesicles isolation from melanoma cells was performed following a 
published protocol435, that we previously employed for lytic granule isolation with minor 
modifications (see below). 
 
 Western blot analysis of perforin cleavage  
Granule isolation was performed following a published protocol435 with minor modifications. 
Briefly, CD8+ T cells were washed three times with ice cold PBS and reconstituted in 
2×107cells/ml of relaxation buffer: 130mM KCl; 5mM NaCl; 2mM MgCl2; 1mM disodium-
ATP/10mM Hepes pH 7.4. Cells were disrupted by N2 cavitation at 400p.s.i and the cell 
suspension was collected in the presence of 4mM EGTA. The cell lysate was separated into a 
post-nuclear supernatant (SN1) and a pellet (P1) by centrifugation at 800×g for 10 minutes at 
4°C. SN1 was submitted to another centrifugation step at 20.000×g for 30 minutes at 4°C, 
which resulted in a cytosolic supernatant (SN2) and a total vesicular extract enriched in the 
pellet P2. For melanoma cell lysates, 5×106 cells were diluted in cytobuster for protein extract 
following manufacture protocol (Merck-Millipore). The supernatant was harvested by 
centrifugation. Aliquots of 500ng of total protein from lytic granule (LG) extract lysates were 
either treated with 500ng/ml CatB or an increasing concentration of melanoma cell lysate (0.5, 
1and 3µg/ml total protein) for 2 hours at 37°C, then mixed with SDS sample buffer. Reduced 
10% SDS gels were run and blotted onto a nitrocellulose membrane. After blocking with 3% 
nonfat dry milk in TBST for 1 hour, the membranes were incubated with 10μg/ml anti-perforin 
(clone H-315; Santa Cruz Biotechnology) mAb overnight at 4°C, followed by 2 hours of 
incubation with an HRP-anti–rabbit IgG (SouthernBiotech). The blots were developed using 
ECL (GE Healthcare). Western Blot images were acquired using a ChemiDoc™ MP System 
(Biorad). In some experiments CatB was pre-treated with 10µM CA074 for 30 minutes at 37°C 
before addition of the mixture on LG lysates. Band intensity was quantified using ImageJ 
software as raw intensity over non-treated LG lysate.  
 
 111 
 
 cDNA synthesis, polymerase chain reaction 
RNA isolation was performed using the RNeasy Mini Kit (Roche Life sciences), and RNA 
concentration was assessed using the NanoDrop 1000 (Thermo Scientific) system RNA was 
converted to complementary DNA (cDNA) using the Applied Biosystems High Capacity cDNA 
Reverse Transcription Kit (Life Technologies). The gene expression of SNAP-23 
(Hs001870775_m1) was evaluated by real time quantitative PCR (RT qPCR) using TaqMan 
gene expression assays (Applied Biosystems) according to the indicated protocol, using a 
LightCycler® 480 System (Roche Life sciences). All reactions were performed in triplicates 
and relative gene expression levels were evaluated using the comparative CT (threshold cycle) 
method (2-deltaCT). GAPDH (Hs03929097_g1) was used as endogenous controls for 
normalization. 
 
 Statistical analysis 
 Unpaired Student’s t-test using the GraphPad Prism software (version 6; 
GraphPad) was used to determine the statistical significance of differences 
between the groups.  
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Figures and Figure Legends 
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Fig.1. Defective lethal hit delivery at the CTL/melanoma cell synapse. a) Time kinetics of 
perforin staining on the surface of conventional target cells (JY) and melanoma cells (D10) 
following conjugation with CTL. Target cells were either unpulsed or pulsed with 10µM 
antigenic peptide. The MFI (Median Fluorescence Intensity) of perforin staining is indicated. b) 
Efficient activation of CTL to lethal hit delivery following encounter with peptide-pulsed 
melanoma cells. Target cells either pulsed or not with antigenic peptide were conjugated for 1 
hour with CTL. Cells were stained for CD107a extracellular exposure at 4°C.  c) Measurement 
of target cell killing. Cytotoxicity was evaluated by FACS analysis in target cells either pulsed 
or not with antigenic peptide following 4 hour incubation with CTL. Cytotoxicity is expressed 
as fold increase over corresponding basal death. d) Sequences of snapshots depicting either JY 
or D10 cells pulsed with the antigenic peptide interacting with tubulin tracker green-labeled 
CTL. 200µM PI was added to culture medium at time 0. Perforin pore formation on target cells 
was detected by PI internalization (red). Typical conjugates with the JY and D10 target cells are 
shown. Supplementary Movie 1 and 2 show the entire time-lapse recording. Bars, 5µm.  e) 
Time required for detection of initial PI entry in target cells in JY or D10/CTL conjugates as 
detected by 1 hour time-lapse confocal microscopy. Red bars represent the mean time. f) 
Measurement of the cytosolic PI intensity in target cells at the end of the time-lapse video 
recording in CTL/target cell conjugates. Red bars represent the mean PI fluorescence intensity.  
Analysis in e and f was performed only on cells exhibiting detectable PI entry. In a, results are 
representative of 3 independent experiments. In b and c results are expressed as mean ± SEM 
of 3 independent experiments (b) and 4 independent experiments (c). In e and f data are from 
40 conjugates for each cell type. Data are from 3 independent experiments. Unpaired Student’s 
t-test using the GraphPad Prism software (version 6; GraphPad) was used to determine the 
statistical significance of differences between the groups. ***P < 0.001, **P<0.01. 
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Fig. 2. Defective granzyme B penetration in melanoma cells. a) Visualization of GrzB 
staining in CTL/target cell conjugates by confocal laser scanning microscopy. Target cells were 
previously pulsed with 10µM peptide. Cells were stained with anti-tubulin (green) and anti 
GrzB (red). Target cells were identified by loading them with Cell Tracker Blue before 
conjugation (cyan). Percentage of GrzB+ target cells in peptide pulsed JY and D10 cells are 
indicated. Sixty conjugates from three independent experiments were scored. Bars, 5µm. 
Results are expressed as mean ± SEM of 3 independent experiments. Unpaired Student’s t-test 
using the GraphPad Prism software was used to determine the statistical significance of 
differences between the groups.  ***P < 0.001. b) Left panels: time kinetics of GrzB staining in 
conventional target cells (JY) and melanoma cells (D10), either unpulsed or pulsed with 10µM 
peptide concentration, following conjugation with CTL. Right panels: Time course of GrzB 
loss in CTL following interaction with target cells. Target cells were either unpulsed or pulsed 
with the antigenic peptide. The median fluorescence intensity of GrzB staining is indicated. 
Results are from one representative experiment out of three. c) Pooled results from three 
independent experiments showing the time-dependent loss of GrzB by CTL interacting with JY 
cells (black dotted lines) or with D10 cells (red dotted lines) and GrzB uptake by JY cells 
(black plain lines) or by D10 cells (red plain lines). MFI= Median Fluorescence Intensity. 
Results are expressed as mean ± SEM of 3 independent experiments. 
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Fig. 3. Melanoma cells exhibit a high rate vesicular trafficking and enrich LLE vesicles at 
the lytic synapse during conjugation with CTL. a) Extracellular staining for CD107a and 
CD63 on JY and D10 cell surface as detected by FACS analysis. Results are shown as median 
fluorescence intensity (MFI) fold increase over isotype control. Results are expressed as mean 
± SEM of 5 independent experiments. b) Basal lysosomal endo/exocytosis was quantified via 
Av-SRho uptake by JY (upper panel) or D10 cells (lower panel) in the presence of 8µg/ml Av-
SRho in the culture medium. Panels show Av-SRho fluorescence intensity in cells during 2 
hour acquisition, as measured by time-lapse confocal microscopy. Graphs show 6 cells 
representative of the two cell types from 3 independent experiments. c) Av-SRho accumulates 
in melanoma cells lysosomal compartment. Melanoma cells were incubated in the presence of 
8µg/ml of Av-SRho (red) overnight. Cells were fixed, permeabilized and stained for CD107a 
(blue) and CD63 (green). d) Melanoma cells either unpulsed or pulsed with 10µM antigenic 
peptide were conjugated with peptide-specific CTL for 5 minutes at 37°C. Cells were then 
fixed, permeabilized and stained for CD63 (green and pseudo-color) and perforin (Cyan). Bars, 
5µm. e) Scheme depicting the gating strategy used to measure CD63 fluorescence intensity in 
melanoma cells in a cell volume corresponding to the synaptic area and in an equal volume 
drawn at the opposite side of the cell. f) Re-localization of lysosomal compartments was 
quantified by measuring the CD63 fluorescence intensity fold increase at the lytic synapse in 
melanoma cells (as indicated in the scheme). 45 and 60 conjugates (for unpulsed and peptide 
pulsed cells respectively) formed by only 1 melanoma cell and 1 CTL were scored. Data are 
from 3 independent experiments. Bars indicate mean values. Unpaired Student’s t-test using the 
GraphPad Prism software was used to determine the statistical significance of differences 
between the groups. **P<0.01.  
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Fig. 4. Recruitment of melanoma cell lysosomal compartment to the lytic synapse. a) and 
b) Melanoma cells expressing CD107a-GFP and pulsed with 10µM antigenic peptide were 
monitored during interaction with CTL using a spinning-disk confocal microscope. a) Snap 
shots depicting the CD107a-GFP+ LLE localization before conjugation and after conjugation. 
The pseudo color scale indicates molecular enrichment. Snapshots are from Supplementary 
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Movie 5. b) Quantification of CD107a fluorescence intensity (FI) fold increase. Fluorescence 
intensity either before or 5 minutes after cell-cell conjugation in 13 melanoma cells conjugated 
with CTL was measured at the lytic synapse and normalized over fluorescence intensity 
measured in the region of interest at time 0. Data are from five independent experiments. c) and 
d) Peptide-pulsed melanoma cells were monitored during interaction with CTL in the presence 
of 8µg/ml Av-SRho by spinning-disk confocal microscopy. c) Sequences of snap shots 
depicting enhanced LLE vesicle exposure in peptide pulsed melanoma cells during conjugation 
with CMFDA loaded CTL (green). Lysosomal exposure is detected via Av-SRho uptake 
(pseudo color scale intensity). Snapshots are from Supplementary Movie 6. d) Measurement of 
Av-SRho fluorescence intensity fold increase in peptide pulsed melanoma cells during 
conjugation with CTL. Intensities were scored from 14 conjugates in nine independent 
experiments and normalized over Av-SRho fluorescence intensity of the cell of interest at time 
0. Data are expressed as mean ± SEM of the scored cells. e) Melanoma cells either pulsed or 
not with antigenic peptide were conjugated with peptide-specific CTL for 5 minutes at 37°C in 
the presence of Av-SRho. Cells were fixed, permeabilized and stained for perforin (green). f) 
Exposure of LLE vesicles was quantified by measuring the Av-SRho fluorescence intensity fold 
increase at the lytic synapse in melanoma cells (as indicated in the scheme in Fig. 3e). 61 and 
60 conjugates (for unpulsed and peptide pulsed cells respectively) formed by 1 melanoma cell 
and 1 CTL were scored. Data are from 3 independent experiments. Bars indicate mean values. 
Bars, 5µm. Unpaired Student’s t-test using the GraphPad Prism software was used to determine 
the statistical significance of differences between the groups. ***P<0.001. 
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Fig. 5. Perforin degradation by cathepsin and melanoma cell extracts. a) and b)  
Measurement of perforin lytic activity on Jurkat cells. Jurkat cells were incubated with purified 
human perforin either in the absence or in the presence of CatB or of CatB plus CA074 for 1 
hour. PI entry in cells was measured by flow cytometry.  a) Plots show results from one 
representative experiment; b) data are expressed as mean ± SEM of four independent 
experiments. c) and d) Degradation of perforin in isolated CTL lytic granules. c) Western Blot 
analysis of lytic granule perforin either untreated or incubated with CatB or with CatB plus 
CA074. d) Western Blot analysis of lytic granule perforin either untreated or incubated with 
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increasing concentrations of melanoma cell lysates (+ 0.5µg/ml; ++ 1µg/ml; +++ 3µg/ml). 
Results are from one representative experiment out of three. Numbers indicate band intensity 
fold increase. 
e) and f) Jurkat cells were incubated for 1 hour with purified human lytic granules lysate either 
in the absence or in the presence of melanoma cell vesicular fraction lysates or of melanoma 
cell vesicular fraction lysates plus CA074 for 1 hour. PI entry in cells was measured by flow 
cytometry. Data are from 3 independent experiments. Bars indicate mean values. Unpaired 
Student’s t-test using the GraphPad Prism software was used to determine the statistical 
significance of differences between the groups. ***P<0.001, **P<0.01. LG = lytic granules; 
VF = vesicular fraction. 
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Fig. 6. Interference with melanoma cell vesicular trafficking enhances their susceptibility 
to perforin-mediated cytotoxicity. a) Upper panel: Sequence of snap shots depicting dynamics 
of CD107a/GFP+ intracellular vesicles (pseudo color scale intensity) in control shRNA 
transfected 10µM peptide-pulsed melanoma cell during conjugation with CTL. Snapshots are 
from Supplementary Movie 13. Lower panel: Sequence of snap shots depicting dynamics of 
CD107a/GFP+ intracellular vesicles (pseudo color scale intensity) in SNAP-23 silenced 
peptide-pulsed melanoma cell during its conjugation with a CTL. Snapshots are from 
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Supplementary Movie 11. CTL lytic granules are stained in red. b) Quantification of CD107a 
fluorescence intensity (FI) fold increase at the lytic synapse of 8 SNAP-23 silenced peptide-
pulsed melanoma cells conjugated with CTL either before or 5 minutes after cell-cell 
conjugation. Data are from two independent experiments. c) Upper panel: sequence of snap 
shots depicting LLE vesicle exocytosis of control shRNA transfected peptide-pulsed melanoma 
cells interacting with CMFDA loaded CTL (green). Lysosomal exposure is detected via Av-
SRho binding (pseudo color scale intensity). Snapshots are from Supplementary Movie 14. 
Lower panel: sequence of snap shots depicting LLE vesicle exocytosis of a SNAP-23 silenced 
peptide-pulsed melanoma cell interacting with CMFDA loaded CTL (green). Lysosomal 
exposure is detected via Av-SRho binding (pseudo color scale intensity). Snapshots are from 
Supplementary Movie 12.  d) Measurement of Av-SRho fluorescence intensity fold increase in 
SNAP-23 silenced peptide pulsed melanoma cells during conjugation with CTL. Intensities 
were scored from 8 conjugates in three independent experiments. Data are expressed as mean ± 
SEM of the scored cells. e) and f) Cytotoxicity was evaluated in melanoma cells either 
transduced with control non-targeting shRNA (shCtr) or with shRNA targeting SNAP-23 
(shSNAP-23) following 4 hour incubation with CTL. Melanoma cells were either unpulsed or 
peptide pulsed and cytotoxicity was quantified by measuring 7-AAD uptake by FACS analysis. 
e) A representative experiment is shown; f) pooled data from three independent experiments. 
Cytotoxicity is expressed as fold increase over corresponding basal death in transduced cells. 
Bars, 5µm. Unpaired Student’s t-test using the GraphPad Prism software was used to determine 
the statistical significance of differences between the groups. ***P<0.001. 
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Fig. 7.  Impairment of melanoma cell lysosome function enhances their susceptibility to 
perforin mediated cytotoxicity. a) Cells were either untreated or treated for 2 hours with 
40µM monensin, washed and stained with lysotracker red. Panels show typical snap shots of 
treated and untreated melanoma cells. b) Cytotoxicity was evaluated by FACS analysis in 
melanoma cells following 4 hour incubation with CTL. Melanoma cells either pre-treated or 
not with 40µM monensin for 2 hours before conjugation were either unpulsed or pulsed with 
10µM antigenic peptide. Cytotoxicity is expressed as % of positive 7-AAD cells. c) Efficient 
activation of CTL to lethal hit delivery after encountering melanoma cells treated or not with 
monensin. Target cells, either pretreated or not with 40µM monensin were conjugated for 1 
hour with specific CTL. Cells were surface stained for CD107a. d) and e) Cytotoxicity was 
evaluated in melanoma cells following 4 hour incubation with CTL. Melanoma cells were 
either untreated or treated with E64d or CI3 protease inhibitors. Melanoma cells were either 
unpulsed or peptide pulsed and cytotoxicity was quantified by measuring 7-AAD uptake by 
FACS analysis. d) A representative experiment is shown; e) pooled data from three independent 
experiments. Cytotoxicity is expressed as % of positive 7-AAD cells. f) Perforin quanta (green) 
at the lytic synapse after 5 minutes conjugation with CTL of peptide-pulsed melanoma cells 
(either untreated or pre-treated with 40µM monensin). g) Scheme depicting the fluorescence 
intensity quantification strategy for perforin deposits at the lytic synapse of melanoma cell/CTL 
conjugates. h) Quantification of percentage of perforin fluorescence intensity on melanoma cell 
side of the lytic synapse in peptide-pulsed melanoma cells either pre-treated or not with 40µM 
monensin. Red bars indicate mean values of measured fluorescence. 54 and 55 conjugates (for 
untreated and monensin-treated cells respectively) formed by 1 melanoma cell and 1 CTL were 
scored. Data are from 3 independent experiments.  In b, c and e results are expressed as mean ± 
SEM of 3 independent experiments. Bars, 5µm. Unpaired Student’s t-test using the GraphPad 
Prism software was used to determine the statistical significance of differences between the 
groups. ***P<0.001, **P<0.01, nsP>0.05. 
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Supplementary Figure 1. Limited perforin staining on melanoma cells. Perforin staining on the 
surface of conventional target cells (JY) and melanoma cells (D10) following conjugation with CTL. 
Target cells were either unpulsed or pulsed with10µm antigenic peptide. The fold increase of median 
fluorescence intensity of the entire cell population over the isotype control is shown. Results are 
expressed as mean ± SEM of 6 independent experiments. Unpaired Student’s t-test using the GraphPad 
Prism software (version 6; GraphPad) was used to determine the statistical significance of differences 
between the groups. **P<0.01. 
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Supplementary Figure 2. Expression of CD107a on the surface of CTL following interaction with 
melanoma cells or with conventional target cells. The gating strategy and typical results of CD107a 
up-regulation on the surface of CTL interacting for 1 hour with either JY cells or with D10 cells either 
unpulsed or pulsed with 10µM peptide concentration is shown. Data are from one representative 
experiment out of three. 
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Supplementary Figure 3. Perforin staining on several melanoma cell lines. D10, HBL, M17, M44, 
M113, LB22 and JY cells were either unpulsed or pulsed with 10µM antigenic peptide. Cells were 
conjugated with CTL for 1 hour. Cells were assessed for perforin staining on their surface and analyzed 
by FACS. Data are from one representative experiment out of two. 
                                   
Supplementary Figure 4. Serglycin expression in target cells. Typical plots of intracellular staining for 
serglycin in D10 and JY cells are shown. Results are from one representative experiment out of two 
performed in triplicates. 
 
                               
                          
 
Supplementary Figure 5. Av-SRho staining in CTL can be used as a marker of lytic granules. CTL 
were cultured in the presence of 8µg/ml of Av-SRho (red) overnight. Cells were fixed, permeabilized 
and stained for perforin (green). 
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Supplementary Figure 6. Cathepsin B exposure on the surface of target cells upon interaction with 
CTL.  JY cells and D10 cells either unpulsed or pulsed with 10µM peptide were conjugated for 15 
minutes with CTL and stained for surface expression of cathepsisn B. The fold increase of median 
fluorescence intensity of the entire cell population over the secondary antibody is shown. Results are 
expressed as mean ± SEM of 3 independent experiments. Unpaired Student’s t-test using the GraphPad 
Prism software (version 6; GraphPad) was used to determine the statistical significance of differences 
between the groups. **P<0.01; *P<0.05. 
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Supplementary Figure 7. Uncropped Western Blots related to Figure 5. The original Western Blots 
for results shown in Figure 5c and 5d are shown in panel a and b respectively.  
 
 
                       
                  
Supplementary Figure 8. Reduction of SNAP-23 expression in melanoma cells transfected with 
SNAP-23 shRNA. a) Reduced SNAP-23 gene expression as detected by RT-PCR.  b)  Reduced SNAP-
23 protein expression as detectd by FACS analysis using an anti-SNAP-23 antibody. Results are from 
one representative experiment out of two performed in triplicates. 
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Supplementary Figure 9. Treatment with monensin enhances CTL-mediated cytotoxicity in nine 
melanoma cell lines. Melanoma either untreated (NT) or pretreated for 2 hours with monensin (Mon) 
were conjugated with specific CTL for 4 hours. Cells were either unpulsed of pulsed with 10µM 
antigenic peptide. Cytotoxicity is reported as fold increase over basal cell death. Results are expressed 
as mean ± SEM of 3 independent experiments. Two-Way Anova test using the GraphPad Prism software 
(version 6; GraphPad) was used to determine the statistical significance of differences between the 
groups. ***P<0.001; **P<0.01. 
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Supplementary Figure 10. Treatment of melanoma cells with bafilomycin A1 or concanamycin A 
enhances CTL-mediated cytotoxicity. Melanoma cells either untreated or pretreated for 2 hours with 
bafilomycin A1 (BFA) or concanamycin A (CMA) were conjugated with specific CTL for 4 hours. Cells 
were either unpulsed of pulsed with 10µM antigenic peptide. Cytotoxicity is reported as fold increase 
over basal cell death. Results are expressed as mean ± SEM of 3 independent experiments. Unpaired 
Student’s t-test using the GraphPad Prism software (version 6; GraphPad) was used to determine the 
statistical significance of differences between the groups. ***P<0.001; **P<0.01. 
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Supplementary Figure 11. The resistance of conventional target cells to CTL-mediated cytotoxicity 
correlates with the level of CD63 surface expression. a) JY cells previously sorted on the level of 
expression of CD63 were pulsed or not with antigenic peptide and co-incubated with CTL for 4 hours. 
Cytotoxicity was evaluated by FACS analysis using 7-AAD uptake and is reported as fold increase over 
basal cell death. b) To evaluate the level of LLE markers expression by cells used in a), the intracellular 
expression of CD107a and CD63 of sorted cells was measured by FACS analysis. Numbers indicate 
median fluorescent intensity (MFI). Data are from one representative experiment out of two. 
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Supplementary movie legends: 
Movie 1. The video shows the interaction between a peptide pulsed JY cell and tubulin tracker 
green loaded CTL for 1 hour in the presence of PI (red). Cells were inspected using a confocal 
laser-scanning microscope (LSM 510; zoom factor 63X) to monitor PI entry. Recording time is 
indicated in minutes in upper left corner.  
 
Movie 2. The video shows the interaction between a peptide pulsed D10 cell and tubulin 
tracker green loaded CTL for 1 hour in the presence of PI (red). Cells were inspected using a 
confocal laser-scanning microscope (LSM 510; zoom factor 63X) to monitor PI entry. 
Recording time is indicated in minutes in upper left corner.  
 
Movie 3. JY cells were seeded in chambered wells in the presence of 8µg/ml Av-SRho (pseudo 
color) and monitored for 2 hours using a confocal spinning disk microscope to visualize 
constitutive vesicular exocytosis. A typical cell is shown; data are representative of three 
independent experiments.  
 
Movie  4. D10 cells were seeded in chambered wells in the presence of 8µg/ml Av-SRho 
(pseudo color) and monitored for 2 hours using a confocal spinning disk microscope to 
visualize constitutive vesicular exocytosis. Three typical cells are shown; data are 
representative of three independent experiments.  
 
Movie 5. The video shows interaction between a peptide pulsed D10 cell expressing CD107a-
GFP (pseudo color) and two CTL (previously loaded with Av-SRho, red). Cells were inspected 
using confocal spinning disk microscope. Recording time is indicated in minutes in upper left 
corner.  
 
Movie 6. The video shows interaction between a peptide pulsed D10 cell interacting with a 
CTL (previously loaded with CMFDA, green) in the presence of 8µg/ml Av-SRho (pseudo 
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color). Cells were inspected using confocal spinning disk microscope. Recording time is 
indicated in minutes in upper left corner.  
 
Movie 7. The video shows interaction between unpulsed D10 cells interacting with CTL 
(previously loaded with CMFDA, green) in the presence of 8µg/ml Av-SRho (pseudo color). 
Cells were inspected using confocal spinning disk microscope. Recording time is indicated in 
minutes in upper left corner.  
 
Movie 8. The video shows a peptide pulsed D10 cell interacting with a CTL (that was 
previously loaded with Av-Alexa488, green) in the presence of 8µg/ml Av-SRho (red). Cells 
were inspected using a confocal spinning disk microscope. Recording time is indicated in 
minutes in upper left corner. 
 
Movie 9 and 10. The videos show interactions between peptide pulsed JY cells with a CTL 
(previously loaded with CMFDA, green) in the presence of 8µg/ml Av-SRho (pseudo color). 
Cells were inspected using confocal spinning disk microscope. Recording time is indicated in 
minutes in upper left corner.  
 
Movie 11. The video shows interactions between SNAP-23 silenced peptide-pulsed D10 cells 
expressing CD107a-GFP (pseudo color) and a CTL (previously loaded with Av-SRho, red). 
Cells were inspected using confocal spinning disk microscope. Recording time is indicated in 
minutes in upper left corner. 
 
Movie 12.  The video shows interactions between SNAP-23 silenced peptide-pulsed D10 cells 
interacting with CTL (previously loaded with CMFDA, green) in the presence of 8µg/ml Av-
SRho (pseudo color). Cells were inspected using confocal spinning disk microscope. Recording 
time is indicated in minutes in upper left corner. 
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Movie 13. The video shows interactions between control shRNA transfected peptide-pulsed 
D10 cells expressing CD107a-GFP (pseudo color) and a CTL (previously loaded with Av-
SRho, red). Cells were inspected using confocal spinning disk microscope. Recording time is 
indicated in minutes in upper left corner. 
 
Movie 14. The video shows interactions between control shRNA transfected peptide-pulsed 
D10 cells interacting with CTL (previously loaded with CMFDA, green) in the presence of 
8µg/ml Av-SRho (pseudo color). Cells were inspected using confocal spinning disk 
microscope. Recording time is indicated in minutes in upper left corner. 
 
Movie 15. The video shows interactions between control shRNA transfected peptide-pulsed D10 
interacting with CTL (previously loaded with Av-SRho, red) in the presence of 8µg/ml Av-
Alexa488 (pseudo color). Cells were inspected using confocal spinning disk microscope. 
Recording time is indicated in minutes in upper left corner. 
 
Movie 16 and 17. Movies show 3-D reconstructions of conjugates formed between CTL 
conjugated for 5 minutes with melanoma cells either untreated (Movie 16) or treated with 
monensin (Movie 17). Cells were stained for perforin (green). 
 
Movie 18-20. Movies show 3-D reconstructions of conjugates formed between CTL conjugated 
for 5 minutes with melanoma cells either untreated (Movie 18) or pretreated with monensin 
(Movie 19 and 20). Cells were stained for perforin and CD107a (blue) The 3-D reconstructed 
images were processed using the Imaris software to show in green the perforin co-localizing with 
CD107a (mostly found intracellularly in CTL only), and in red the perforin not colocalizing with 
CD107a (detected extracellularly in conjugates in which melanoma cells were previously treated 
with monensin). 
 
Movie 21. The videos show interactions between peptide pulsed JY cells (preloaded with Fluo-
4) with CTLs (previously loaded with CMFDA (green) and Lysotracker red). Cells were 
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inspected using confocal microscope. Recording time is indicated in minutes in upper left 
corner.  
 
Movie 21. The videos show interactions between peptide pulsed JY cells (preloaded with Fluo-
4) with monensin pretreated CTLs (previously loaded with CMFDA (green) and Lysotracker 
red). Cells were inspected using confocal microscope. Recording time is indicated in minutes in 
upper left corner.  
Movie 23. The videos show interactions between peptide pulsed D10 cells with CTLs 
(previously loaded with Tubulin tracker (green) in the presence of 8µg/ml Av-SRho (pseudo 
color). Cells were inspected using confocal microscope. Recording time is indicated in minutes 
in upper left corner.  
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IV- Related questions 
Q.1) Is LLE exposure on melanoma cells a direct response to perforin action or is it 
related to cell-cell contact? 
Having observed that specific interaction of CTL and melanoma cells induce LLE exposure, we 
were interested to know whether such self-defense response was triggered by cognate cell-cell 
contact or it was related to direct perforin action on melanoma cell surface. 
 
A) LLE exposure from melanoma cell requires formation of a “lytic” synapse. 
 
A.1 Technical approach for IS and LS dissociation. 
We set up a method to dissociate stimulatory and lytic synapses (Refer to introduction chapter 
X; 156).  
It is well studied that intracellular organelles involved in endocytic and exocytic pathways are 
acidified through V-ATPase and that the internal acidification plays an important role in these 
pathways 436. Monensin, is a monocarboxylic ionophore that exchanges Na+/K+ with proton and 
consequently neutralize the acidic pH of endocytic vesicles437-439. Moreover, it has been 
previously shown that monensin pretreatment inhibits NK cytotoxicity440. Later on, the 
importance of acidic environment of CTL lytic granules for their perforin mediated cytotoxicity 
was reported using CMA (a specific inhibitor of V-ATPase that is known to impair vesicular 
pH;441).Therefore we tested the effect of monensin pre-treatment on CTL cytotoxicity and 
synapse formation. 
 
A.1.1 Monensin impairs CTL cytotoxicity. 
In a first approach, we examined the effect of monensin treatment on cytotoxic responses of 
CTL encountering either unpulsed or peptide-pulsed conventional target cells. CTLs were 
pretreated with 40µM monensin for 2 hours and were thoroughly washed before conjugation 
with target cells. Cytotoxicity of CTL clones was evaluated in a classical 4 hours killing assay 
using 7-AAD. As shown in Figure IV-1a pretreatment of CTLs with monensin significantly 
reduced their cytotoxic activity.  
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A-1-2) Monensin does not alter activation induced CTL cytokine production and lytic granule 
exposure. 
The observation of such strong inhibition of CTL-mediated cytotoxicity prompted us to 
investigate whether pre-treatment with monensin would affect CTL responses to antigenic 
stimulation. We observed that, neither IFN- production nor CD107a exposure was altered upon 
CTL pretreatment with monensin (Figure IV-1b and IV-1c). These results indicate that, 
although CTL cytotoxicity is strongly impaired, monensin treatment does not substantially 
influence CTL activation in response to recognition of specific targets.  
 
       
 
                                                                                                                           
Figure IV-1. Monensin CTL pre-treatment inhibits cytotoxicity of CTL but does not alter CTL activation. a) Measurement of target cell 
killing. Cytotoxicity was evaluated by FACS analysis in target cells either pulsed or not with antigenic peptide following 4 hour incubation 
with CTL (CTLs were either untreated or pre-pretreated with 40µM monensin for 2h in 37°C, the drug was thoroughly washed before 
conjugation with target cells). Percentage of specific cytotoxicity is shown. b) Efficient degranulation of untreated and monensin pre-treated 
CTLs following encounter with peptide-pulsed target cells. Target cells either unpulsed or pulsed with antigenic peptide were conjugated for 1 
hour with CTL. Cells were stained for CD107a extracellular exposure at 4°C. c) Efficient IFN- production in untreated and monensin treated 
CTLs. Target cells either unpulsed or pulsed with antigenic peptide were conjugated for 4 hours with CTL. Cells were stained for IFN- 
secretion. Results are expressed as mean ± SEM of 7 independent experiments. ***P < 0.001, nsP>0.05 
 
A-1-3) Monensin does not alter CTL polarization response at the IS. 
We next investigated the polarization of tubulin cytoskeleton of monensin pretreated or 
untreated CTLs toward the IS formed with target cells. CTLs were co-cultured for 5 minutes 
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with peptide pulsed conventional target cells, fixed, permeabilized, and stained for α-tubulin 
and phosphotyrosine (pTyr). CTLs interacting with pulsed conventional target cells 
(independently of monensin treatment), indeed formed a signal inducing immunological 
synapse and polarized their secretory machinery toward target cells, as detected by pTyr 
staining at the CTL/target cell contact site and reorientation of the MTOC beneath the synaptic 
area respectively (Figure IV-2a and IV-2b). 
Measurement of the distances between the center of the IS and the T cell MTOC in a large number of 
conjugates showed that the CTL MTOC polarization toward target cells occurred to a similar extent 
regardless of monensin pretreatment of CTLs (Figure IV-2b). The approach used for the measurement of 
the T cell MTOC distance from the IS was previously described159.  
 
 
A-1-4) Monensin treatment induce perforin conformational change via pH perturbation. 
Having observed similar reorientation of microtubules of monensin treated and untreated CTLs 
toward target cells, we studied the content and integrity of lytic granules of CTLs under these 
conditions and during interaction with target cells. Monensin pretreated or untreated CTLs were 
co-cultured with peptide pulsed target cells. After fixation, permeabilization, and staining, lytic 
granule status was evaluated. As shown in Figure IV-2c, lytic granule polarization at the IS was 
similar as detected by CD107a enrichment towards target cells (Figure IV-2c and IV-2d). 
However, in CTLs pretreated with monensin we could not detect granzyme B penetration in 
target cell cytosol indicating that monensin treatment inhibited perforin-mediated granzyme B 
penetration (i.e. perforin pore formation) in target cells (Figure 2c and 2e). Under the same 
condition we failed to detect perforin staining using anti-perforin antibody clone dG. 
Interestingly, using another antibody for perforin detection (clone pf80) revealed perforin 
staining in these conjugates (Figure IV-2f), indicating that perforin is still present in CTL but 
under a different conformational status not detectable by the dG9 antibody.  
Moreover, to confirm pH perturbation in CTLs by pretreatment with monensin, we investigated 
CTL/target cells conjugates using video microscopy. CTLs were pretreated or not for 2 hours with 
monensin, and their lytic granules were stained with lyso-tracker red (a pH dependent dye). As it is 
shown in Figure IV-2g lyso-tracker red failed to stain (or barely stained) the lytic granules of monensin 
pretreated CTLs, validating the pH perturbation action exerted the drug. Moreover, in agreement with 
the above results, independently of monensin pretreatment, both CTLs were capable or recognizing their 
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target cells and repolarize their MTOC towards the IS as detected by tubulin tracker staining (green) 
(Figure IV-2g). 
All in all, the above results show that the acidic environment is essential for keeping the proper 
conformational state of perforin in the lytic granules before delivery to the synapse. It is tempting to 
speculate that such conformation is necessary to allow perforin to acquire an active form that is able to 
bind and polymerize on the surface of target cell. 
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Figure IV-2.Monensin alters perforin conformation without impairing T cell polarization responses at the IS. a) Peptide-pulsed target cells 
were conjugated for 5 minutes with CTLs (either untreated or pretreated with monensin). Cells were fixed, permeabilized, and stained for α-
tubulin (blue) and pTyr (green). Bars, 5µm. b) Synaptic re-localization of MTOC was quantified by measuring the distances between the center 
of the IS and the T cell MTOC (as shown by red line in the scheme) using ImageJ software. Bars indicate mean values. Unpaired Student’s t-
test using the GraphPad Prism software (version 6; GraphPad) was used to determine the statistical significance of differences between the 
groups.  C) Under similar conditions cells were stained for CD107a (green), α-tubule (blue) and granzyme B (red). Target cells’ were identified 
by loading them with Cell Tracker Blue before conjugation (cyan). d) Percentage of CD107a polarized CTLs (untreated or monensin treated) in 
conjugate with peptide pulsed target cells are indicated. e) Percentage of granzyme B positive (GrzB+) peptide pulsed target cells are in 
conjugate with either untreated or monensin treated CTLs are indicated. f) Similarly to a and c, cells were stained for perforin (red) using two 
different clones of anti-human perforin antibody (Right panel: dG9; Left panel: pf80). g) CTLs were stained with tubulin tracker green and 
lysotracker red (pH dependent) and conjugated with peptide pulse target cells. Snap shots are from supplementary movie 21 and 22. In a, d 
and e 60 conjugates were scored. Data are from three independent experiments. 
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A.2) Melanoma cells interacting with monensin treated CTLs do not expose their LLE 
compartments. 
 
Using the above described technique, we have investigated whether monensin treated CTLs 
(containing non functional perforin molecules) could trigger LLE secretory burst in melanoma 
cell. Using time-lapse video microscopy we studied conjugates between monensin-pretreated 
CTLs and peptide pulsed melanoma cells for 1hour in the presence of Avi-SRho (for LLE 
exposure). As shown in figure IV-3, specific recognition of target cell results in formation of an 
effective IS between the two cells that as detected by polarization of CTL MTOC towards 
melanoma cells (Figure IV-3 and supplementary Movie 23). Melanoma cells did not expose 
their LLE compartments (since we did not detect any Avi-SRho staining), probably as a 
consequence of the absence of a functional perforin in CTL (compare to Figure 4 and 
Supplementary Movie 6 and 15). 
 
                
 
Figure IV-3.: Melanoma cells do not expose their LLE compartments during interaction with monensin pre-treated CTLs. Sequences of 
snap shots depicting monensin treated CTLs (loaded with tubulin tracker green) and peptide pulse melanoma cells in the presence Av-SRho. No 
lysosomal exposure was detected via Av-SRho staining (pseudo color scale intensity). Snapshots are from supplementary movie 23. 
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B) LLE exposure on melanoma cells is triggered by perforin binding. 
 
B.1) Melanoma cells expose their LLE compartments in the presence of purified perforin. 
 
To confirm the relationship between LLE secretory burst and perforin binding on melanoma 
cell surface, we thus monitored, by time-lapse microscopy the exocytosis of LLE vesicles in 
melanoma cells by adding purified perforin to the medium in the presence of Av-SRho. This 
analysis revealed that perforin addition enhanced exposure of lysosomal vesicles on melanoma 
cell surface that was paralleled by a rapid [Ca+2]i increase when compared to constitutive LLE 
exposure on melanoma cells (no perforin in culture medium).  
 
                             
 
Figure IV-4. Purified perforin induces LLE exposure in melanoma cells. Upper panels: LLE exocytosis was visualized via Av-SRho uptake 
by melanoma cells in the presence of either PBS or 125ng purified perforin (prf) in the culture medium. Lower panels: Detection of [Ca+2]i 
increase in melanoma cells loaded with Fluo-4 AM (in pseudo color scale).  
 
We are presently finalizing the above results that we are planning to submit in the future 
in a short paper aiming at better characterize the link between CTL lytic activity and 
melanoma cell defense. 
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Q.4) Are there other molecules implicated in vesicular trafficking of melanoma cells 
involved in their self defense mechanism? 
Given the importance of vesicular trafficking in melanoma cell self defense against CTL attack, 
it is important to identify other effector molecules that are contributing to this self defense 
mechanism. Using a large panel of shRNA plasmids targeting various key elements of 
melanoma vesicular trafficking, we evaluated their influence in melanoma cell resistance to 
CTL attack. To this aim, CTLs were conjugated with peptide pulsed melanoma cells and 
cytotoxicity was assessed in a 4 hours classical killing assay. As shown in figure IV-5, 
downregulation of CD107a, VAMP-7 as well as SNAP-23 expressions in melanoma cells 
enhanced their susceptibility to CTL attack. Further investigations may identify other 
molecules implicated solely in melanoma cells LLE trafficking. 
                                                     
Figure IV-5. Interference with melanoma cell vesicular trafficking enhances their susceptibility to perforin-mediated cytotoxicity. 
Cytotoxicity was evaluated in peptide pulsed melanoma cells either transduced with control non-targeting shRNA (shCtr) or with shRNA 
targeting SNAP-23 (shSNAP-23), CD107a (sh CD107a) or VAMP-7 (sh VAMP-7) following 4 hour incubation with CTL. Cytotoxicity was 
quantified by measuring 7-AAD uptake by FACS analysis and is expressed as fold increase over corresponding basal death in transduced cells. 
Unpaired Student’s t-test using the GraphPad Prism software (version 6; GraphPad) was used to determine the statistical significance of 
differences between the groups. ***P<0.001; *P<0.05. 
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V- Discussion and Perspective: 
 
The interest of our experimental model: 
 
In this study we have investigated the molecular crosstalk occurring during early 
CTL/melanoma cell interaction. To this aim, we set up a cellular model allowing in vitro 
evaluation of the response that human metastatic melanoma cell lines might provide when 
encountering fully activated antigen specific CTL clones.  In vitro experiments using human 
cells have the advantage to allow a detailed observation of cell contact site as well as to enable 
precise quantification of molecular expression and localization in parallel to their interactions 
by employing reagents and readouts that can be directly transferred to clinical research and 
practice. In other words, such studies provide high resolution outcomes that are thoroughly 
reproducible and consistent. However, this approach has the obvious limitation of simplifying 
the scenario of a physiological immune response based on multiple and heterogeneous cellular 
interactions (detailed in chapter “Cancer biology and tumor immunology”). 
The Objective of this thesis was to focus mainly on the melanoma cell side of the lytic synapse, 
and study the responses of individual melanoma cells to CTL attack outside the context of 
tumor microenvironment that may influence T cell activity. Given the complexity of CTL/tumor 
cell interaction, we focused on a system in which CTLs would be capable of, first, recognizing 
melanoma cells as specific targets and, second, being fully activated upon contact with 
melanoma cells. We thus used T clones specific for viral antigen that we previously 
characterized for their extremely high efficacy in responding to peptide-pulsed melanoma cells. 
The use of cells pulsed with antigenic peptide is a useful method to bypass the necessity for 
antigen processing and exposure on the cell surface and is a method that is largely used in the 
laboratory of Dr. Valitutti since his initial work at the Basel Institute in the laboratory of Dr. 
Lanzavecchia7,442 . 
As discussed in the introduction, activation of CTLs is a very efficient phenomenon with high 
degree of sensitivity and rapidity that is initiated upon recognition of as few as 2-3 pMHC 
complexes at the cell-cell interface. TCR-mediated signaling is followed by a lethal hit delivery 
that occurs extremely rapid 159,238,247 443and that has an extraordinary low threshold (pico/nano 
molar concentration of specific peptide used for pulsing). The efficacy of cytotoxic activity of 
CTLs is reinforced by their rapidly detachment and recycling behavior that endows them with 
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simultaneous/serial killing capacity 159,293. In our cellular model we used a saturating 
concentration of an antigenic peptide from CMV pp65 protein that, during the 2 hours of 
incubation, is loaded into the MHC class I molecules of target cells, due to its high affinity for 
the peptide groove of the HLA-A2 molecules442,444. Thus, in our system target cells are 
displaying on their surface high densities of specific pMHC recognized by our CTL clones. It’s 
generally accepted that one key processes of cancer cells escape from immune surveillance is 
MHC class I molecules downregulation 351,445. Nevertheless, results I obtained during my 
research show that although HLA-A2 expression by melanoma cells is relatively low, under 
optimal pulsing conditions with antigenic peptide they can efficiently stimulate CTL to lethal hit 
delivery and to IFN- production (Supplementary figure 12 and 13). My observations are in 
agreement with previously published data by members of Valitutti’s team who investigated in 
details the extent of CTL responses (in terms of MTOC polarization, lytic granule exposure, 
perforin discharge and [Ca+2]i increase) during interaction with melanoma cells as compared to 
conventional target cells. They showed that melanoma cells nullify the rapidity and sensitivity 
of CTL responses and concluded that melanoma cell annihilation requires multiple hits during a 
longer cell/cell interaction time231. My results extend this view by revealing one key molecular 
mechanism of such a sustained resistance of melanoma cells to the attack of fully activated 
CTL. Thus, the use of an “artificial system” to fully activate CTL against melanoma cells 
allowed us to identify a previously non-described melanoma self defense barrier that CTLs 
should overcome. 
 
A limitation of our study was that we had limited access to melanoma cells at different stages of 
differentiation, to be able to conclude whether the observed defense mechanism might be 
related to a defined stage of melanoma cell differentiation 446.   
Moreover we still do not know whether the abundant lysosomal reserve and the capacity of 
intense LLE vesicle exposure in response to perforin action is an intrinsic characteristic of 
melanocytes or if it evolved during tumorigenesis in melanoma patients. To address this 
question it would be important to compare response of untransformed HLA-A2+ melanocytes 
and melanoma cells to CTL attack. The team is currently setting up procedure to obtain human 
untransformed melanocytes. Although we did not directly answer to this question, several lines 
of evidence support a tumor-related acquisition of such a behavior. First, there is a high level of 
CD63+ exosomes in the serum of patients at the late stage of melanoma 447. Second, other teams 
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have published that non-metastatic melanoma cells are less resistant to CTL cytotoxicity when 
compared to metastatic melanoma cells 448;449. Third, several molecules involved in the 
regulation of vesicular trafficking  or belonging to LLE are disregulated during melanoma 
tumorgenesis450 451-453.  
It is also interesting to speculate whether our described self-defense mechanism is a general cell 
defense mechanism or is only related to melanoma. Our preliminary data indicates that even 
conventional target cells expressing on their surface high level of lysosomal markers show 
higher resistance to cytotoxicity when compared to low level expressing conventional target 
cells (Supplementary Figure 11). In addition, cells with abundant secretory potentials such as 
CTL, NK and mast cells, have been reported by others and us to be more resistant to perforin 
mediated cytotoxicity (222,223,454 and R. Khazen unpublished observation). 
 
Detailed investigation of intercellular communication: 
1) Lethal hit delivery by CTL and its reception by target cells: 
One interesting aspect of our work is that we contribute to ameliorate the concept of lethal hit 
delivery by CTL and consequent lethal molecules uptake by target cells.  
In this context, several studies have been conducted (detailed in chapter “effector function of 
CTLs” of the introduction, page 53-59) to study perforin-mediate granzyme B delivery to target 
cells. CTL lethal hit delivery is a finely regulated process in which small quanta of toxic 
molecules, triggers membrane repair mechanism in target cells that modulates target cell destiny 
towards apoptosis rather than necrosis, thus target cells actively participate in determining their 
own fate during cell-mediated death. This target cell participation is mediated by mechanisms of 
plasma membrane resealing. Currently, the perforin mode of action is controversial. It is not 
established whether perforin pore formation takes place on cell surface186,247 or it rather 
functions within newly internalized endosomes227,245,254.  
In our study we add to the present knowledge. We applied time-lapse microscopy and flow 
cytometry analysis to investigate spatiotemporal response of melanoma cells to lethal hit 
delivery in comparison to conventional targets both at single cell level and at whole population 
level. We show that majority of melanoma cells are resistant to perforin mediated cytotoxicity 
as they exhibit limited and delayed membrane perforation (paper Figure 1) under condition in 
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which they are receiving several lethal hits as indicated by [Ca+2]i increase in their cytosol (
231 
and R.Khazen data not shown). Interestingly, my preliminary results indicates that [Ca+2]i was 
not delayed in melanoma cells encountering CTL when compared to conventional targets cells, 
indicating that lethal molecules efficiently achieve melanoma cell membrane. However, the 
duration of the [Ca+2]i differed between the two cell types. Conventional target cells exhibited a 
transient [Ca+2]i that was followed by their rapid death while a majority of melanoma cells 
exhibited a sustained and repetitive pattern of [Ca+2]i. Rapid [Ca
+2]i in target cells subjected to 
CTL attack158,159,455 or treated with purified Perforin 456 has been previously reported. Our 
previous and recent data differentiate [Ca+2]i pattern in sensitive and resistant target cells. The 
sustained calcium signaling in melanoma cells might influence melanoma cell gene expression 
and even trigger secondary self defense mechanism that needs to be elucidated.  
 
2) The parameter time in the dynamics of CTL/melanoma cell interaction. 
The time parameter in CTL cytotoxicity has been previously investigated. Previous studies 
reported that a prolonged time is required for tumor cell annihilation both in vitro and in vivo 
110,231,288. A preliminary observation I made during my thesis is that CTL polarize for prolonged 
time their lytic compartment towards melanoma cells (>1h) while CTL polarization towards 
conventional target cells appears to be more dynamic and transient. Indeed I observed that 
CTLs in contact with conventional target cells tend to rapidly relocate their lytic granules 
towards different targets. In addition, CTLs treated with drugs affecting lysosomal pH stayed 
attached to their targets for a prolonged time with no cytotoxicity. This preliminary observation 
is in agreement with data recently reported by J. Trapani and co-workers who showed that the 
absence of either perforin or granzymes dramatically increases synapse dwell time. They 
proposed that the signal for synapse breakage is generated in a caspase-dependent fashion and is 
mediated by target cell. Our preliminary observations together with these recently published 
data points out a dynamic communication between CTL and their target cells and raise the 
possibility that target cell death per se provides signals for CTL killing termination.  
Together, these findings points out that CTL/target cell interaction might be viewed as a 
platform for information exchange between the two cells that are mutually regulating signaling 
and function processes of each other. On one hand, to optimize the outcome of cytotoxicity in 
terms of inducing apoptosis rather than necrosis254 and on the other hand to economize CTL 
lethal potential for their multiple/serial killing activity293. Via this bidirectional exchange of 
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information, CTLs send small quanta of toxic molecules repetitively that will be translated into 
death signals in target cells until a threshold reached. Once the threshold is reached, target cells 
send, still undetermined, signals for cytotoxicity termination. This mechanism might be 
favorable to the efficacy of CTL multiple killing capacity, but might become detrimental in 
conditions in which melanoma cells resist for prolonged time, since repetitive lytic granule 
release might conduct CTL to waste of their lytic potential. 
 
3) Melanoma cell synaptic defense against CTL attack 
A central finding of my study is that that the LLE compartment enrichment and exposure at the 
synaptic area accounts for melanoma cell self defense to perforin mediated CTL attack, since 
impairment of vesicular trafficking (fusion and docking to the plasma membrane) and pH 
perturbation enhanced perforin binding on the surface of melanoma cells (paper Figure 6 and 7 
and supplementary movies 6, 12,14 and 15).  
This observation can be explained by two possibilities. First, such a synaptic oriented intense 
lysosomal exposure will cause the localization and clustering of several heavily glycosylated 
lysosomal molecules at LS that can create a shield at the site of perforin release that might 
reduce the possibility of perforin binding (“space related hypothesis”). In line with this 
hypothesis, Cohen et al recently proposed that increased exposure of CD107a during 
degranulation of NK cells might be involved in their protection from self-annihilation. During 
my thesis work I observed that silencing of CD107a expression reduce melanoma cell resistance 
to CTL attack (refer to chapter: Related questions, Q4), a finding in agreement with the “space 
related hypothesis”.  
Second, the exposure on melanoma cell surface of lysosome resident perforin inhibitory 
molecule(s) upon vesicular exocytosis at LS would block or cleave perforin molecule 
(“cleavage related hypothesis”). Of note, In the process of forming membrane channels, 
perforin goes through an intermediate membrane-associated stage in which it is highly 
susceptible to proteolysis before polymerization into a more resistant pore-forming 
complex224,457,458. In our submitted article, we proposed that cathepsin B exposure on the 
surface of melanoma cells, in response to perforin might contribute to proteolytic cleavage of 
perforin at the lytic synapse. Such extracellular activity of membrane bound cathepsin B has 
been reported for extracellular matrix degradation during tumor metastasis in melanoma, or for 
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antigen extraction and processing by B cells225. This protease was not (or minimally) expressed 
on melanoma cell surface at steady state, but rapidly detectable on the surface of melanoma 
cells after interaction with CTL. The presence of both molecules in the synaptic cleft and the 
acidic environment of the lytic synapse by analogy to what has been described in B cells225 
might favor cathepsin B mediated proteolytic cleavage of perforin monomers.  
Both scenarios can take place simultaneously, we do not have enough proof to eliminate one of 
them since our current data supports both hypothesis. To further dissect the specific ongoing 
molecular interactions at the interface between CTL and melanoma cells, it would be helpful to 
investigate with super resolution microscopy: 1) If SNAP-23 and VAMP-7 molecules play a 
role in focalizing CD107a clustering at the synaptic area and if perforin is trapped in such 
compartments, rapidly endocytosed and degrades inside the melanoma cell polarized lysosomes 
that are rich in lytic enzymes. 2) The localization of Cathepsin B and perforin at LS and the 
kinetic of their exposure, insertion and cleavage. 
Moreover, while we have shown rapid exposure of LLE cathepsin B on melanoma cell surface 
and proved that it can indeed block perforin pore formation, we did not quantify the activity of 
cathepsin B and specificity of such cleavage. Furthermore, such cleavage can be also mediated 
by other proteolytic enzymes resident in the lysosomes. Further experimental support is 
required. 
 
An alternative not mutually exclusive mechanism that may contribute to melanoma cell defense 
is that since melanoma cells are highly efficient in exosome release 447, one can imagine that 
lethal molecules are prohibited from target cell entry by a rapid uptake and  release in the 
medium, quantify the content of perforin and granzyme in the released vesicles of extracellular 
medium of short duration CTL/melanoma interaction can give hints on the existence of such a 
phenomenon.  
Another possibility to explain limited perforin binding could be expression of additional 
inhibitory molecules. Fraser et al. reported complete blockade of perforin activity by 
Calreticulin at 2.2 x 10-7 M, they proposed that calreticulin indirectly prevents perforin 
polymerization by stabilizing the membrane. In 1991 Matsudka identified a perforin inhibitor 
protein (ApoB100) that not only inhibits the membrane binding activity of perforin but also the 
pore insertion activity of membrane-bound perforin459. In our model, melanoma cells did not 
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over express these molecules at their surface when compared to conventional target cells231. 
However, we cannot exclude the exposure of such inhibitors on the melanoma cells surface 
during CTL attack. These inhibitors might therefore contribute to melanoma self-protection by 
mechanisms complementary to cathepsin B-mediated cell protection. 
 
4) How CTL resist to their own perforin? 
CTLs are well known to resist to perforin action. CTLs resist to lysis not only when attacked by 
other killer cells, but also when soluble effector proteins are used 224,460,461. In 1980s several 
articles reported resistance of CTL clones to perforin mediated cytotoxicity when they served 
as target cells and described the CTL “self-sparing concept”460-463. It is noteworthy that in all of 
these articles some clear examples of lysis, even rare, were shown. In the 1990s, additional 
fratricidal processes among CTL clones were described464-466. Therefore CTLs are in principle 
able to kill other CTLs, and such mechanism can be sometime of great importance, for instance 
in viral infection of CTLs223.  
One study reported that perforin binding to CTL membranes was defective when compared to 
binding to sensitive targets cell membranes467, whereas another study could not detect a 
correlation between perforin binding and susceptibility to lysis, but provided evidence for a 
different conformation of membrane-bound perforin on CTLs probably mediated by cleavage 
of an inhibitory molecule present on CTL membrane224.  
All in all, published data indicate that CTL are not completely refractory to cytotoxicity and 
that they might need local self-defense mechanisms to avoid self-annihilation. In 2002 Henkart 
and co-workers provided evidence that upon degranulation CTLs expose Cathepsin B on their 
surface. Cathepsin B stays bound to the membrane and is proteolyticaly active223. Exposed 
Cathepsin B is capable of membrane bound perforin cleavage at its susceptible intermediate 
stage before polymerization into the resistant pore-forming complex. In agreement with this 
finding, our results also suggest that cathepsin B might be indeed a valuable self defense 
mechanism. Further research would be require to demonstrate this phenomenon in our cellular 
model and I am presently investigating whether, in agreement with Henkart’s findings, 
treatment of T cell with cathepsin inhibitor might render them more prone to self-annihilation. 
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5) Vesicular trafficking in melanoncytes/melanoma cells. 
Our cytotoxicity assays also suggested a various range of importance of several key elements of 
vesicular transport (Myosin Va, Bloc1) or vesicular fusion (SNAP23, VAMP7) in protecting 
melanoma cells against perforin mediated cytotoxicity (refer to chapter “Related questions”: 
Q4). Among those mechanisms SNAP-23 silencing had the highest impact on breaking 
melanoma cell resistance barrier, pointing out the crucial role of this molecule in melanoma 
lysosomal secretion.  
These observations can be explained by two possibilities.  
First, it is possible that the role played by SNAP-23 in lysosomal secretion in melanoma cells, 
is not redundant with other homologues of this molecule. Predominant expression of SNAP-23 
was observed in melanocytes335. The relationship between the levels of SNAP-23 expression 
and tumorigenesis in melanoma cells is presently unknown. Also, whether other tSNARE 
molecules such as SNAP-25 and SNAP-24 can play a functional role although they are 
expressed to a much lower level remain to be elucidated. 
Second, SNAP-23 might be the core component of the vesicular trafficking complexes in 
melanoma cells. Several studies aimed at describing melanocytes/melanoma secretory 
pathways (as detailed in the introduction) and reported the necessity of formation of molecular 
complexes between v and t SNAREs for secretion. One can imagine that such complexes are 
solely formed in the presence of SNAP-23. According to this view, staining of CTL/melanoma 
conjugates for different molecules involved in several steps of vesicular fusion may provide 
information on the possible co-localization of these molecules in each cell type, either in the 
presence or in the absence of SANP-23. The enrichment of these complexes towards the 
synaptic area, as well as, possible differences of vesicular trafficking in melanoma cell versus 
melanocytes should be also investigated.  
 
Furthermore, we have tried to describe more in details molecular mechanism of LLE based self-
defense during CTL/melanoma interaction. We have shown that conjugation of melanoma cells 
with CTLs harboring non functional form of perforin molecules did not initiate LLE secretory 
burst whereas incubation of purified perforin with melanoma cells induced LLE exposure on 
melanoma cells (refer to chapter “Related questions”: Q1 and Q2). Thus, we concluded that 
such polarized LLE secretory burst is a specific response to initial perforin binding on 
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melanoma cell membrane. Moreover we observed that LLE secretory burst was not 
accompanied by a polarization of MTOC in melanoma cells, indicating that a complete re-
polarization of tubulin is not necessary159 (data not shown). However, it is yet to define whether 
microtubule integrity is required for LLE dynamics in melanoma cells. In addition, studying the 
exact signaling pathway responsible for LLE recruitment in melanoma cells can provide 
molecular targets for turning off this auto-defense mechanism. Accordingly, synaptotagmin 
(Syt) VII413,468, dysferlin 469,470, and apoptosis-linked gene-2 (ALG-2)471,472, are reported to be 
involved in plasma membrane resealing. Depending on injury size and the type of injury, 
multiple sources of Ca2+ may be recruited to trigger and orchestrate repair processes 473. 
 
6) Heterogeneity of response to CTL attack 
Intratumoral heterogeneity is one of the obstacles of current therapies474,475. Targeted 
immunotherapies, while targeting a specific subset of melanoma cells, might indirectly apply a 
selection pressure that gives rise to a population resistant to such a treatment, thus treatments 
which appeared to be beneficial in the beginning could be followed by recurrence of a form of 
disease no longer susceptible to the given treatment.  Using a propidium iodide pore formation 
assay I observed a heterogeneity of response among melanoma cells and we categorized them in 
3 sub groups termed (paper Figure 1): sensitive, persistent and resistant among which 80% of 
the cells (persistent and resistant) showed a delayed and limited perforin-mediated pore 
formation (while the other 20% were easily killed by CTLs). The absence of PI staining in a 
large fraction of cells might be explained by the fact that melanoma cells rapidly ignite a LLE 
secretion defense mechanism that does not allow the stable formation of pores in plasma 
membrane. Hence, our described strategy of melanoma cell resistance reversion might be of 
great interest for the future melanoma immunotherapy treatments since they might aim to the 
large fraction of resistant cells. 
 
7) In vivo confirmation of LLE secretion-based melanoma cell resistance to CTL attack  
It is now well described how cancer cell interaction with the tumor microenvironment may 
influence their gene expression as well as their function476, therefore tumor microenvironment 
is a critical determinant of the response of cancer cells to therapeutic agents. To verify my 
finding in a model better mimicking in vivo immune responses we are starting to use 
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humanized mice. Humanized mice models provide a powerful tool in pre-clinical testing of 
various in vitro finding, by creating a scenario mimicking, as close as possible, the features of 
the tumor micro-environmental context477. Humanized mice are immunodeficient mice 
engrafted with human hematopoietic cells (either stem cells or PBMCs) or tissues, or mice that 
transgenically express human genes 478. Several research teams tried to establish a proper 
model by using strains that are often used as recipients of human xenografts such as Severe 
Combined Immunodeficiency (SCID) mice that being immunodepressed can accept xenografts.  
Improved tumor engraftment rates have been reported in the NOD-scid strain, where 
introduction of the scid mutation into the non-obese diabetic (NOD) background results in 
reduced macrophage and NK function, as well as, an absence of complement-dependent 
hemolytic activity 479,480. Recently, two additional immune-deficient strains have been 
described: NOD-scid β2mnull, and NOD-scid IL2Rnull (477). The NOD-scid IL2Rnull strain 
(NSG) greatly increased engraftment of human tissue; HSCs and PBMCs compared with all 
previously developed immunodeficient humanized mouse models. IL-2R -chain leads to 
severe impairments in T and B cell development and function, and completely prevents NK-
cell development. Features of such strains are summarized in table below. 
                               
                                         (Modified from Christianson, S. W. et al. 1997 and Lapidot, T.2001) 
 
Up to now our observations were limited to in vitro studies. Observation of the same trend of 
response to CTL attack in several highly metastatic melanoma cell lines (Supplementary figure 
9) prompted us to establish in vivo experiments for studying the relevance of such defense 
mechanism in mice. In particular it is interesting to study the potential role that LLE secretory 
burst might play during tumor progression in vivo.  
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Intracutaneous injection of Melan A (an immune dominant antigenic peptide) expressing tumor 
cell lines in NSG mice provides an experimental model in which one can study tumor nodule 
attack by Melan A specific T cell clones.  In this model several aspects of melanoma vesicular 
trafficking can be studied: a) The impact that silencing of molecules implicated in vesicular 
transport and/or vesicular docking and fusion to plasma membrane might have on melanoma 
cell resistance to CTL-mediated cytotoxicity. b) Which kind of Cathepsin B inhibitor 
pretreatment and at what concentration and duration can enhance CTL tumor annihilation? c) 
The impact of lysosome pH altering drugs such as chloroquine, monensin, etc. can be 
evaluated. 
For such a study our team has established collaboration with the team of Dr. J.E Sarry at the 
CRCT in Toulouse. 
 
8) Human tissues a vital source of information 
 
Currently, the gold standard for melanoma diagnosis is the histopathological assessment of 
tissue sections stained with haematoxylin and eosin, combined with knowledge of the clinical 
context of the lesion and the patient. Immunohistochemical staining is an important and 
frequently used adjunct to the histopathological diagnosis of melanoma. For example, 
immunohistochemistry using the S100 marker can more clearly delineate ‘subtle’ melanoma 
cells present in the epidermis or help to identify rare subtypes of disease, such as desmoplastic 
melanoma481. Yet there is no diagnostic biomarker that can allow prediction in the early stages 
of the melanoma disease progression. In this manner, improved diagnostic and prognostic 
biomarkers are of increasing importance in the treatment of melanoma. Tumor biomarkers 
might help to identify patients with early-stage melanoma who are likely to develop advanced 
disease and would benefit from additional therapies. Analysis of tissue specimens provides 
important information of mutations and modification of melanoma cell compartments during 
tumor development that can guide future researches towards improved immunotherapy 
strategies. 
Concerning our in vitro findings, it is interesting to investigate how abundance of LLE vesicle 
expression may correlate with tumor aggressiveness. Staining human tissue samples of 
different stages for lysosomal compartment markers such as LAMP-1 and LAMP-3 as well as 
vesicular docking and fusion proteins such as SNAP23 or VAMP-7, may provide some new 
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prognostic markers that may also be related to patient responsiveness to various 
immunotherapy strategies. 
Moreover, such experimental approach might not only reveal useful biomarkers, but might also 
provide key information on how melanoma cell secretory alteration may influence the 
recruitment of immune cells and the profile of response (type, positioning, activation state and 
reciprocal distance/interaction among infiltrated immune cells) in melanoma microenvironment 
and help us better correlate ongoing immune responses to disease progression. 
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VI- Conclusion  
In the last decades many studies were conducted to better understand the biochemical nature of 
tumor antigens and to identify cellular and molecular mechanisms leading to activation of 
innate and adaptive immune cells. Obtained results have been of paramount importance in the 
progress of tumor immunology. Studies on the intricate network of interactions between tumor 
and immune cells have revealed novel regulatory signals, including cell surface inhibitory 
receptors and costimulatory molecules, intracellular regulatory pathways, immunosuppressive 
cytokines and pro-apoptotic mediators, which may operate in concert to orchestrate tumor-
immune escape351.  
Enforcing effector function of innate and adaptive immune cells, manipulation of their 
subsequent interaction with tumors as well as tumor intrinsic self protection mechanism, either 
alone or in combination, could be exploited for therapeutic purposes in cancer patients. 
In this respect our data suggest an early synaptic level of melanoma cell resistance to CTL 
attack, in which melanoma cell hijacked LLE machinery as a tool of protection. This 
mechanism is based on targeted trafficking of LLE vesicles towards the synaptic area and on 
LLE burst exocytosis. This self-defense mechanism leads to synaptic degradation of perforin 
and failure in pore formation due to exposure of proteolytic activity of cathepsin B enzyme. A 
better understanding of this phenomenon would open the possibility of enhancing CTL activity 
via alteration of cancer cell resistance and it can pave the road to immunotherapy strategies 
aiming at ameliorating CTL potential. 
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Abstract 
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Human melanoma cells express various tumor antigens that are recognized by CD8+ cytotoxic 
T lymphocytes (CTL) and elicit tumor-specific responses in vivo. However, natural and 
therapeutically enhanced CTL responses in melanoma patients are of limited efficacy. The 
mechanisms underlying the failure of CTL effector phase against melanomas are still largely 
elusive. Our hypothesis is that the limited efficacy of CTL in their fight against tumors is the 
result of an unfavorable balance between CTL ability to kill tumors and an intrinsic tumor 
resistance to CTL cytolytic activity.  
During my thesis I focused on the molecular dynamics occurring at the lytic synapse in order to 
identify possible “early response-mechanism” of melanoma cells to CTL attack. 
Using a combination of cutting edge microscopy approaches and molecular tools, I showed that 
upon conjugation with CTL, human melanoma cells undergo an exacerbated late 
endosome/lysosome trafficking, which is intensified at the lytic synapse and is paralleled by 
cathepsin-mediated perforin degradation and deficient granzyme B penetration. Abortion of 
SNAP-23-dependent lysosomal trafficking, pH perturbation or impairment of lysosomal 
proteolytic activity restores susceptibility to CTL attack.  
Our results reveal an unprecedented strategy of melanoma cell “self-defense” at the 
immunologic synapse based on a lysosome secretory burst and perforin degradation at the lytic 
synapse. Interfering with this synaptic self-defense strategy might be instrumental to potentiate 
CTL-mediated therapies in melanoma patients.  
 
